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Abstract 
Amyotrophic Lateral Sclerosis (ALS) is a lethal motor neuron disorder, characterized 
by selective and progressive degeneration of both upper and lower motor neurons. Currently 
the only available drug for the treatment of ALS is Riluzole, which exerts little overall 
effects. Therefore ALS is currently an untreatable disease. A small proportion (5%) of 
patients develop the hereditary form of the disease known as familial ALS (FALS), 40% of 
which are associated with G4C2 hexanucleotide repeat expansion in the C9orf72 gene and 
20% with mutations in the SOD1 (copper/zinc superoxide dismutase-1) gene. In addition, 
recently a mutation has been identified at position R199W in the DAO gene, accounting for 
less than 1% of FALS cases. The DAO gene encodes D-amino acid oxidase (DAO) protein, a 
peroxisomal flavin adenine dinucleotide (FAD)-dependent oxidase involved in degradation of 
D-amino acids. There have been reports indicating that DAO protein plays a crucial role in 
regulation of D-serine (a D-amino acid involved in neuronal signalling) in the central nervous 
system. 
The focus of this thesis was to investigate and establish the role of both mutant 
(DAOR199W) and wild type DAO proteins (DAOWT) in ALS pathology in terms of disease 
onset, disease progression and survival in a well-known model of ALS, the high copy number 
SOD1G93A mouse, through two large cohort survival studies. Thus, for the first survival study 
(cross of DAOR199W and SOD1G93A) we hypothesized that overexpression of the mutant allele 
exacerbates the ALS-like phenotypes, resulting in an earlier onset, accelerated progression 
and shorter lifespan in the double transgenic animals. Our data from this study showed that 
DAOR199W expression does not modify disease onset, progression and survival in the 
DAOR199W/SOD1G93A animals compared to their SOD1G93A littermates. 
The second survival study (cross of DAOWT and SOD1G93A) was designed based on reports of 
elevated levels of the D-serine in the spinal cord of ALS patients. Considering the high 
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abundance of D-serine in the central nervous system and its ability to induce excitotoxicity, 
we hypothesized overexpression of the DAOWT enzyme results in a more rapid break down of 
D-serine, ameliorating the SOD1G93A phenotype by delaying disease onset, slowing down 
disease progression and prolonging survival in the double transgenics. Our results from this 
survival study indicate that overexpression of DAOWT at the cellular level does not effect 
disease onset but significantly delays the onset of neurological symptoms, slows down 
progression and prolongs survival in both sexes in the SOD1G93A/DAOWT animals, compared 
to their SOD1G93A littermates.  
In a separate approach we aimed to investigate the affect of two different murine IGF-
I isoforms (IGF-IA and MGF), in in vivo models of ALS by means of an efficient method of 
gene delivery, electroporation of recombinant plasmid vectors. For this investigation we 
hypothesized treating SOD1G93A animals with IGF-I, results in slower disease progression 
and prolonged survival. Both vectors were successfully cloned, expressed in cell culture 
followed by in vivo electroporation. However there was insufficient time to test their 
therapeutic potential in the SOD1G93A mouse.  
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1.1. Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease or adult 
motor neuron disease, is one of the most common neurodegenerative disorders with the 
worldwide incidence of 1 to 2 per 100,000 individuals where males are affected more 
frequently than females (Cozzolino et al., 2008, Robberecht and Philips, 2013). 
ALS was first described in 1869 by the French neurologist Jean-Martin Charcot, and 
today is defined as a lethal motor neuron disease, characterized by selective and progressive 
degeneration of both upper and lower motor neurons in the spinal cord, brainstem and 
cerebral cortex (Charcot and Joffory, 1869, Cozzolino et al., 2008, Andersen and Al-Chalabi, 
2011, Robberecht and Philips, 2013). Except for juvenile forms, the majority of ALS cases 
have a late onset commencing in middle adulthood with the clinical signs ranging from 
muscle weakness, atrophy, inability to speak or swallow, and progressive paralysis; with 
death usually occurring within three to five years after diagnosis due to respiratory failure 
(Cozzolino et al., 2008, Wijesekera and Leigh, 2009). Interestingly however, motor neurons 
controlling the eye movement and bladder are unaffected in ALS (Cozzolino et al., 2008).   
Although the underlying molecular mechanisms leading to the pathogenesis of ALS is 
yet to be elucidated, growing evidence indicates that ALS is a multifactorial disorder. It is 
therefore thought that a combination of impaired cellular pathways including genetic factors, 
oxidative stress, neuroinflammation, excitotoxicity, protein misfolding and aggregation, 
mitochondrial dysfunction, cytoskeletal abnormalities and defective axonal transport may 
contribute towards the pathogenesis of ALS (Cozzolino et al., 2008, Robberecht and Philips, 
2013). 
Furthermore, recent studies raised suspicions regarding the possible role that various 
environmental factors may play in triggering the development of ALS such as exposure to 
neurotoxins, electromagnetic fields, agricultural chemicals and formaldehyde, excessive 
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exercise, repeated head injury, cigarette smoking (this seems to affect female smokers only) 
and epigenetic modifications (Khabbazian et al., 2002, Horner et al., 2003, Li and Sung, 
2003, Weisskopf et al., 2004, Chio et al., 2005, Doi et al., 2006, Qureshi et al., 2006, Chen et 
al., 2007, Chio et al., 2009, Weisskopf et al., 2009, Trojsi et al., 2013). However, little is 
known about the relative risk of environmental factors and their possible contribution towards 
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1.2. The Genetics of ALS 
ALS is classified into two categories, familial (FALS) defining the hereditary form of 
the disease that very often is inherited in an autosomal dominant manner affecting 
approximately 5% of the ALS cases, and patients with no family history of the disease, 
therefore categorized as sporadic (SALS) (Cozzolino et al., 2008,  Byrne et al., 2011, 
Robberecht and Philips, 2013). Miss-classification however occurs due to incomplete family 
history, non‐paternity and incomplete penetrance (Andersen and Al-Chalabi, 2011).  
The first gene discovered to be associated with FALS, affecting approximately 20% 
of the FALS cases, was the SOD1 gene encoding the protein copper/zinc superoxide 
dismutase-1 (SOD1) (Rosen et al., 1993, Robberecht and Philips, 2013). 
The human SOD1 gene is located on chromosome 21, encoding the SOD1 protein. 
SOD1 is a member of the SOD family that is ubiquitously expressed. The 32kDa 
homodimeric enzyme consists of two monomers each with a binding site for one zinc ion and 
one copper ion, that is highly abundant in the cytoplasmic matrix (Rakhit and Chakrabartty, 
2006). Under normal conditions, SOD1 operates by breaking down toxic free radical products 
(highly toxic by-products of the respiratory process by mitochondria) to hydrogen peroxide 
and molecular oxygen, preventing further production of reactive oxygen species (ROS) and 
detoxifying the cellular environment (Dion et al., 2009). Two other proteins have also been 
identified that belong to the SOD protein family, namely SOD2 and SOD3. The former is an 
intracellular protein found in the mitochondria, encoded by chromosome 6; whereas the latter 
is present in the extracellular space whose gene is localized on chromosome 4 (Zelko et al., 
2002).  
While the link between mutations in the SOD1 protein and ALS is very well 
established, there are no reports indicating the involvement of the other two SOD proteins in 
ALS. To date more than 160 different SOD1 mutations have been identified with no obvious 
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mutational hotspots in the protein, all (except for one) inherited in a dominant manner 
resulting in an ALS phenotype (Cozzolino et al., 2008, Andersen and Al-Chalabi, 2011, 
Robberecht and Philips, 2013). Mounting evidence suggests that the harmful effect of SOD1 
mutations is not due to loss of function. This hypothesis has been supported by various lines 
of evidence including a study with transgenic mice overexpressing the human mutant form of 
the SOD1 gene, which showed that overexpression of the faulty gene leads to development of 
motor neuron disease (Gurney et al., 1994). 
Other studies showed that transgenic mice overexpressing the wild type form of the 
human SOD1 protein developed neurodegenerative characteristics such as axonal 
degeneration, loss of spinal motor neurons late in their lifespan (2 years of age), and 
mitochondrial vacuolization in the axons of the spinal cord and brain stem (Jaarsma et al., 
2000), and upon peripheral nerve injury these animals displayed impaired regeneration 
(Kotulska et al., 2006). 
In a separate investigation researchers observed that the Sod1 knock-out mouse grows 
normally (Reaume et al., 1996) but develops an age-related chronic peripheral hindlimb 
axonopathy consequently resulting in significant locomotor deficits (Flood et al., 1999). By 
two months of age a reduction in the number of functional motor axons was observed which 
continued to decrease slowly but significantly throughout the animal’s lifespan (Shefner et 
al., 1999). It was further demonstrated that despite the changes in the number of functional 
motor axons, the number of motor neuron cell bodies were unchanged (Flood et al., 1999, 
Shefner et al., 1999). These data therefore suggested that the “SOD1 enzyme is crucial for the 
maintenance of normal neuromuscular junctions (NMJ) (a type of synapse existing between 
skeletal muscle fibers and motor neurons) by hindlimb motor neurons” (Flood et al., 1999).  
In the light of these observations, scientists therefore proposed that in ALS the 
mutated form of the SOD1 protein misfolds and acquires one or more toxic properties related 
	   25 
to production of aggregates, which in turn leads to a gain of function feature (Dion et al., 
2009). Accumulation of these aggregates is detrimental at the cellular level, interfering with 
cellular components and pathways leading to the impairment or inactivation of these vital 
processes, which will consequently result in activation of the apoptotic cascade (Estevez et 
al., 1999, Cleveland and Rothstein, 2001, Pasinelli and Brown, 2006). In addition, it was 
previously hypothesized that in SALS, where an initial SOD1 mutation is absent, oxidation 
may result in misfolding of the wild type SOD1 enzyme, creating a modified protein 
featuring binding abnormalities and toxic properties similar to those identified in the mutated 
SOD1 proteins (Ezzi et al., 2007).  
While a small proportion of FALS cases initiate from SOD1 mutations 
(approximately 20%), a new study revealed that the GGGGCC (G4C2) hexanucleotide repeat 
expansion in the C9orf72 (chromosome 9 open reading frame 72) gene is associated with 
40% of the FALS and 7% of the SALS cases and has therefore been recognized as the most 
common ALS related pathogenic mutation (DeJesus-Hernandez et al., 2011, Renton et al., 
2011, Gijselinck et al., 2012). The function of the encoded protein product and the length of 
the pathologically expanded repeat are currently undefined. However, a recent review by 
Cruts and colleagues (2013) has concluded that except for the Han Chinese population where 
the G4C2 repeats do not exceed 15 units in the healthy individuals (Tsai et al., 2012), the 
repeat size in the normal population ranges from 2 to 24 (DeJesus-Hernandez et al., 2011, 
Renton et al., 2011, Gijselinck et al., 2012, van der Zee et al., 2013). The pathogenic 
expanded allele is thought to generally exceed ±60 repeats in the affected individuals, making 
it difficult for the standard repeat-primed PCR technology to detect the exact number of 
repeated units (Cruts et al., 2013). This newly discovered mutation, the resulting protein 
product and its role in ALS are currently a matter of numerous investigations. 
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The remainders of ALS cases therefore arise from mutations in other genes. 
Mutations in TARDBP gene (trans-activation response element DNA-binding protein) 
encoding TDP-43 is associated with both SALS and FALS accounting for approximately 5% 
of ALS cases (Sreedharan et al., 2008, Gitcho et al., 2008, Yokoseki et al., 2008, Van Deerlin 
et al., 2008, Kabashi et al., 2008, Valdmanis et al., 2009). TDP-43 has been identified as a 
DNA/RNA binding protein involved in a variety of pathways including pre-mRNA splicing, 
translational regulation and transcriptional repression (Polymenidou et al., 2011, Tollervey et 
al., 2011).  
Another rare mutation also affecting approximately 5% of the ALS patients occurs in 
a gene known as FUS (fused in sarcoma) encoding another RNA binding protein which is 
also linked to 1% of SALS and 4% of FALS (Kwiatkowski et al., 2009, Vance et al., 2009). 
FUS protein is known to be involved in processes such as regulation of gene transcription and 
pre-mRNA maturation (Delva et al., 2004).  
Among mutations in other proteins such as Angiogenin (Greenway et al., 2006), 
Ubiquitin 2 (Deng et al., 2011), and Vesicle-associated membrane protein-associated protein 
B and C (VAPB) (Nishimura et al., 2004), accounting for less than 1% of the FALS cases, a 
new mutation was discovered in the D-amino acid oxidase protein (DAO) associated with 
FALS and an autosomal dominant inheritance pattern was observed in at least one family 
(Mitchell et al., 2010).  
The human DAO gene is mapped to chromosome 12q24 (Fukui and Miyake, 1992) 
and encodes a 39.4kDa flavin adenine dinucleotide (FAD)-dependent oxidase protein known 
as DAO. DAO enzyme is responsible for catalyzing the oxidative deamination of D-amino 
acids. The first step of the process involves oxidization of the D-amino acids into imino acid 
and concomitant reduction of FAD, followed by oxidization of the reduced FAD, release of 
hydrogen peroxide, and non-enzymatic hydrolysis of the imino acid to generating the 
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corresponding 2-oxoacids (α-keto acids) and ammonia (Krebs, 1935, Pilone Simonetta et al., 
1989). While the expression pattern of DAO varies between species, it is present in high 
levels in the mammalian kidney and liver (although DAO is absent in mouse liver) (Konno et 
al., 1997), where it acts by degrading a selection of substrates including hydrophobic, polar, 
basic and neutral D-amino acids to their corresponding keto-acids (Pilone Simonetta et al., 
1989, Curti et al., 1992, Pilone, 2000, Pollegioni et al., 2007a, Pollegioni et al., 2007b). 
Furthermore, DAO has been found in the mammalian central nervous system (CNS), where it 
has been shown to be present in high levels in both glial (Sacchi et al., 2008, Sacchi et al., 
2011) and neuronal cells (Popiolek et al., 2011), and it is particularly rich in Bergmann glial 
cells, hindbrain within facial nuclei and gigantocellular reticular, Purkinje cells of the 
cerebellum and gray matter of the spinal cord including the motor neurons (Moreno et al., 
1999, Mitchell et al., 2010).  
A whole genome analysis using microsatellite markers carried out by Mitchell and 
colleagues (2010), in families with confirmed ALS phenotype and an unknown FALS 
mutation, demonstrated a missense mutation within the DAO gene in a three generational 
FALS kindred. The authors have shown that this mutation is responsible for transformation of 
C to T at codon 199, resulting in substitution of an arginine amino acid by tryptophan 
(R→W) at this position. Moreover, screening for the R199W mutation in a total of 1,002 
unrelated individuals with the aim of determining its prevalence in the general population, 
showed that no other individual carries this particular mutation (Mitchell et al., 2010).  
Arginine 199 is highly conserved both in mammals and lower organisms, and it is 
located near the FAD binding site (Mitchell et al., 2010). In addition, arginine 199 resides 
between residues Tyr228 and His307, that have been shown to play a crucial role in enzyme 
activity (Todone et al., 1997). Although the underlying mechanisms by which the R199W 
mutation brings about the ALS phenotype is yet to be established, in vitro studies 
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demonstrated that the mutated form of the DAO protein loses its enzymatic activity, promotes 
the formation of ubiquitin aggregates, and increases apoptosis in neuronal cells (Mitchell et 
al., 2010).  
Thus, DAOR199W has been qualified yet as another pathogenic mutation leading to 
ALS accounting for less than 1% of the reported cases (Mitchell et al., 2010).   
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1.3. ALS Pathogenesis 
Although the underlying primary mechanisms for the neurodegenerative 
characteristics and the consequent selective loss of motor neurons in ALS is not well 
understood, mounting evidence from patients and transgenic animal models highlighted 
various factors that may contribute towards ALS pathophysiology. These factors include 
protein aggregation, mitochondrial dysfunction, inflammation and toxic glial activation, 
oxidative stress, ER stress, excitotoxicity, and defects in axonal transport (Cozzolino et al., 
2008, Ilieva et al., 2009, Wijesekera and Leigh, 2009, Spalloni et al., 2013), some of which 
are discussed here.   
While severe loss of motor neurons has been shown to be the ultimate cause of death 
in both ALS patients and animal models of the disease, mounting evidence revealed that ALS 
pathogenesis is of a non-cell autonomous nature. This phenomenon refers to a toxic 
pathogenic process involving both the affected motor neurons, their neighbouring astrocytes 
and microglia cells (Ilieva et al., 2009). Evidence supporting this theory first emerged from a 
study carried out on chimeric mice, demonstrating that wild type non-neuronal cells exert a 
protective effect on their surrounding motor neurons expressing the mutated SOD1 protein 
(Clement et al., 2003). Following this observation, other studies using transgenic mouse 
models showed that neuron specific Cre-mediated excision of the mutated SOD1 gene 
resulted in reduced mutated SOD1 expression in motor neurons which in turn delayed disease 
onset (Boillee et al., 2006). Reducing mutated SOD1 expression, in either microglia (Boillee 
et al., 2006) or astrocytes (Yamanaka et al., 2008) also delayed disease progression. In line 
with these observations another investigation reported that astrocytes from both SALS and 
FALS patients and mutant SOD1G93A mouse model induce motor neuron death in vitro 
(Haidet-Phillips et al., 2011). 
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The non-cell autonomous nature of ALS brought another phenomenon into the light 
known as neuroinflammation. Although neuroinflammation is considered to be a 
consequence rather than a cause of ALS, its association with the neurodegenerative events in 
ALS has received a lot of attention over the years and is considered an important feature of 
ALS pathology. A study carried out by Mitchell and colleagues reported dysregulation of 
various inflammatory and anti-inflammatory cytokines in the cerebrospinal fluid (CSF) of 
ALS patients. Some of these factors include, IL-2 (responsible for stimulating growth and 
cytotoxicity of activated T lymphocytes (Grande et al., 2006)), IL-6 (a cytokine with 
inflammatory, anti-inflammatory and neutrotrophic properties (Sekizawa et al., 1998)), and 
IL-15 (an activator of microglia and a T lymphocyte chemoattractant (Huang et al., 2007)), 
(Mitchell et al., 2009). In addition, various post-mortem studies of ALS patients demonstrate 
loss of neurons in the brainstem, the ventral horn of the spinal cord and the motor nuclei, 
accompanied by microglia proliferation, astrocytosis, and the presence of lymphocytes 
(Kushner et al., 1991, Kawamata et al., 1992, Engelhardt et al., 1993, Nagy et al., 1994, 
Schiffer et al., 1996). Other studies reported widespread microgliosis in the brain of living 
ALS patients using PET imaging (Turner et al., 2004, Corcia et al., 2012). Similar results 
were also observed in the spinal cord of the animal models of ALS. Interestingly some of 
these studies demonstrated that activated microglia were present prior to the onset of the 
disease and continuously increased in number as the disease progressed until the animal 
reached the end-stage (Hall et al., 1998, Henkel et al. 2004, Alexianu et al. 2001).  
Activation of glial cells is characterized by a change in their morphology from a small cell 
body and thin processors to an enlarged cell body and thick processors, as well as a change in 
expression levels and type of markers. Activation of astrocytes is associated with 
upregulation of GFAP, production of nitric oxide, release of pro-inflammatory cytokines and 
growth factors, microglia activation on the other hand is accompanied by an increased 
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expression of IBA1, secretion of various neurotoxins and production of ROS (Keller et al., 
1999, Ridet et al., 1997, Lull and Block, 2010).  
Various investigations reported the presence of reactive astrocytes within various 
areas of the CNS in affected individuals including the cortical gray matter, the subcortical 
white matter and the primary motor area of the brain as well as the dorsal and ventral horn of 
the spinal cord (Kushner et al., 1991, Murayama et al., 1991, Nagy et al., 1994, Jossan et al., 
1994, Schiffer et al., 1996). While the exact mechanisms resulting in activation of astrocytes 
remains to be elucidated, some studies suggest that degenerating motor neurons secret 
fibroblast growth factor 1 (FGF-1) resulting in activation of astrocytes. Activation in turn 
elevates the oxidation levels and the production of pro-inflammatory/apoptotic factors 
including nerve growth factor (NGF) in these cells (Barbeito et al., 2004, Vargas et al., 2005, 
Marchetto et al., 2008, Díaz-Amarilla et al., 2011). Upon activation astrocytes exhibit 
features that are detrimental for motor neuron survival, including reduced production of 
neurotrophic factors and down regulation of the excitatory amino acid transporter 2 (EAAT2) 
glutamate transporter. Down regulations in the former mechanism results in eventual 
neuronal death and in the latter leads to impaired glutamate clearance, eventually leading to 
excitotoxicity and cell death (Rothstein et al., 1992, Bruijn et al., 1997, Cleveland and 
Rothstein, 2001, Howland et al., 2002).  
In an event of neuroinflammation one crucial role of astrocytes is to recruit microglia 
cells (Davalos et al., 2005). Activated microglia have been reported in the spinal cord ventral 
horn, the whole corticospinal tract, the brainstem motor nuclei, the motor cortex and the CSF 
of the affected individuals (Engelhardt et al., 1990, Kawamata et al., 1992, Banati et al., 
1995). In their activated state, microglia cells exhibit very distinct phenotypic features which 
depending on the stage of the disease and the rate at which the disease progress can be 
beneficial or detrimental towards the motor neuron cells. These characteristics are categorised 
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into classically activated microglia (M1) and the alternatively activated microglia (M2). The 
M1 group are cytotoxic and act by secreting ROS and pro-inflammatory cytokines (IL-1β, 
TNF-α, IL-6, IL-12 and IL-23), whereas the M2 category produce large amounts of 
neurotrophins (IGF-I and GDNF) and anti-inflammatory cytokines (IL-10, IL-4, IL-13 and 
TGF-β) and are therefore thought to be neuroprotective (Buechler et al., 2000, Tiemessen and 
Kuhn, 2007, Henkel et al., 2009, Gordon and Martinez 2010, Lewis et al., 2012). Studying 
the spinal cord from the mutant SOD1 animal models indicate that M2 microglia are present 
at early stages of the disease where the symptoms are gradually progressing, while the M1 
microglia are present at the late stage of the disease where the symptoms are accelerated and 
the animal is reaching the end stage (Beers et al., 2011).     
Activation and proliferation of microglia cells is accompanied by infiltration of T 
lymphocytes. Post mortem analysis of spinal cord and brain from the affected individuals has 
indicated the presence of these cells at the area of neurodegeneration (Engelhardt et al., 1993, 
Graves et al., 2004, Lewis et al., 2012). It has been demonstrated that there is an increased 
population of T lymphocytes in the lumbar region of the spinal cord of the mutant SOD1 
animals at presymptomatic stage, this number consisntently increase as the animal ages, 
reaching as high as 10 fold at the end stage of the disease. Futher analysis indicat that the 
population of cells present within the spinal cord were T helper cells expressing CD4+, 
whereas at the end stage of the disease 40% of the cells present in the affected area were 
cytotoxic T cells expressing CD8+ (Beers et al., 2008, Chiu et al., 2008). The CD4+ T helper 
cells have been shown to play a neuroprotective role in the SOD1 mouse model of the 
disease, by modulating the microglial activation and shifting the phenotype towards the M2 
microglia phenotype (Beers et al., 2008). Appearance of cytotoxic CD8+ T cells at the end 
stage of the disease however is aligned with a reduction in regulatory T cells CD25+ and 
CD4+CD25+ within the spinal cord of the mutant SOD1 mouse and the resultant shift in the 
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microglial phenotype to M1 and the consequent death of motor neurons. This could therefore 
be a reason why neuroprotective mechanisms enforced by CD4+ T helper cells eventualy fails 
(Beers et al., 2011).   
Another process that is thought to play a significant role in pathogenesis of ALS is 
excitotoxicity (Doble, 1999), an expression first described by Olney (1969) referring to 
excessive and prolonged stimulation of glutamate receptors resulting in significant calcium 
influx consequently leading to degeneration and eventual death of neurons (Olney, 1969). 
Glutamate-mediated toxicity and its association with ALS was first demonstrated in 1987 by 
Plaitakis and Caroscio and then by Rothstein and colleagues (1990). They reported a marked 
increase in glutamate levels in CSF and plasma of ALS patients (Plaitakis and Caroscio, 
1987, Rothstein et al., 1990). Interestingly, numerous studies further documented the loss of a 
glial glutamate transporter EAAT2 in both SOD1 mouse models and ALS patients (SALS 
and FALS), leading to an impaired/decreased glutamate clearance (Rothstein et al., 1995, 
Bruijn et al., 1997, Howland et al., 2002, Yang et al., 2009).  
In addition, mounting evidence indicates that motor neurons are particularly 
vulnerable to glutamate induced excitotoxicity (Van Den Bosch and Robberecht, 2000, Van 
Den Bosch et al., 2000, Vandenberghe et al., 2000a, Vandenberghe et al., 2000b). Some in 
vitro studies demonstrated that spinal cord organotypic motor neuron cultures were 
exceptionally vulnerable to both alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
receptor (AMPAR)-mediated excitotoxicity and increased levels of glutamate (Rothstein et 
al., 1993, Saroff et al., 2000). Other investigations also reported activation of the Ca2+-
permeable AMPAR promoted motor neuron death both in vitro (Van Den Bosch et al., 2000) 
and in vivo (Nakamura et al., 1994, Hirata et al., 1997, Corona and Tapia, 2004, Tovar et al., 
2007). The link between glutamate induced excitotoxicity and ALS was further confirmed 
when various studies documented that exposure of neuronal cultures to CSF from ALS 
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patients resulted in excitotoxicity, whereas this effect was blocked in the presence of 
glutamate receptor antagonists (Heath and Shaw, 2002, Cid et al., 2003, Sen et al., 2005). 
Based on the above evidence glutamate induced excitotoxicity has been established as 
a key player in pathogenesis of ALS.  
Moreover, one major pathological hallmark of ALS is the presence of mutant protein 
aggregates in the cytoplasm of the degenerating motor neurons and their surrounding 
oligodendrocytes (Blokhuis et al., 2013). While the specific roles of these aggregates in ALS 
pathogenesis is currently not well understood, three different types of aggregates have been 
reported in various ALS cases, including the predominant ubiquitinated aggregates, Bunina 
bodies and hyaline inclusions (Wood et al., 2003). According to Cozzolino et al., (2008) and 
Blokhuis et al., (2013), a selection of proteins have been shown to be associated with these 
aggregates such as TDP43 (Arai et al., 2006, Neumann et al., 2006), FUS (Kwiatkowski et 
al., 2009, Vance et al., 2009, Groen et al., 2010, Hewitt et al., 2010), ATXN2 (Nonhoff et al., 
2007, McCann et al., 2011), SOD1 (Shibata et al., 1996a, Shibata et al., 1996b, Bruijn et al., 
1998, Kato et al., 2001), intermediate filaments proteins (Lariviere and Julien, 2004), and 
kinases that are involved in the signal transduction pathways (Nakamura et al., 1997, 
Bendotti et al., 2004). The presence or absence of some of these proteins in the disease-
causing aggregates however is variable. While some of these proteins are present in the 
majority of ALS cases, such as TDP43, which has been identified in inclusions in both SALS 
and FALS except for FALS cases arising from SOD1 mutation (Mackenzie et al., 2007, Tan 
et al., 2007), others such as ATXN2 are limited to SALS only (Elden et al., 2010). Although 
the contribution of these pathogenic aggregates towards ALS pathogenesis remains elusive, 
researchers have hypothesized that the cellular protein homeostasis is disrupted in the 
presence of these inclusions or their complex oligomeric precursors, which in turn interferes 
with a number of mechanisms at the cellular level including mitochondrial function, 
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cytoskeletal architecture, and the intracellular transport system thus triggering cellular stress, 
leading to axon withdrawal and consequently cell death (Saxena and Caroni, 2011, Bendotti 
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1.4. ALS Progression 
The pattern of cell loss in ALS has been investigated by various groups, and an in 
depth study by Fischer and colleagues (2004) demonstrated that “before any loss of motor 
neurons, there is a severe loss of ventral root motor axons and significant denervation at 
corresponding NMJs” (Fischer et al., 2004).  
It appears that the formation and maintenance of NMJs is accomplished by multiple 
interactions between glial cells, skeletal muscle fibers, motor neurons, and Schwann cells 
(Wu et al., 2010). Motor neurons control the differentiation of the postsynaptic apparatus of 
the NMJ by secreting a combination of molecules, directly stimulating receptors on muscle 
cells or indirectly promoting glial function and differentiation (Wu et al., 2010). Schwann 
cells on the other hand may be involved in the maintenance of NMJs by guiding motor 
neuron growth and regeneration upon injury (Reddy et al., 2003). This therefore means that a 
fault in any of the cellular properties of these participating cells or their mechanisms may 
lead to eventual destruction and ultimate loss of NMJs, which seems to be the primary event 
resulting from the pathological changes in ALS. Loss of the postsynaptic apparatus is then 
followed by destruction of axons, ultimately leading to death of motor neuron cell bodies 
(Fischer et al., 2004).  
This sequence of events therefore describes a “dying back” pathophysiological pattern 
in ALS, where cell death and disease progression occur from distal in the periphery to 
proximal in the spinal cord (Fischer et al., 2004). This theory is in line with data collected 
from MRI examination of ALS patients where retrograde degeneration of  axons was 
observed (Eisen and Weber, 2001, Karlsborg et al., 2004).  
Fischer and collaborators also showed that in the SOD1G93A mutant mouse the motor 
neuron axons retract from the muscle at early stages of the disease in asymptomatic animals 
(Fischer et al., 2004). These observations have therefore led scientists to hypothesize that the 
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asymptomatic nature of ALS in humans, before its onset, is due to the fact that the denervated 
muscle fibers are constantly being replenished and reinnervated by the axon branches of the 
neighbouring surviving motor neurons. However, as the disease progresses, a large portion of 
motor neurons are destroyed and the few remaining ones are unable to compensate for the 
loss, hence the late appearance of the clinical symptoms (Williams et al., 2009).   
In the light of the above evidence, it has therefore been proposed that survival in ALS 
patients and animal models is primarily determined by the loss of contact between muscles 
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1.5. Animal Models 
With the aim of studying and understanding the underlying molecular and cellular 
mechanisms leading to the ALS phenotype in patients and in the hope of developing therapy 
or treatment for the affected individuals, various animal models have been developed 
including the wobbler mouse (displaying progressive degeneration of upper and lower motor 
neurons), the motor neuron degenerative (mnd) mouse, the progressive motor neuronopathy 
(pmn) mouse, transgenic mice overexpressing mutant neurofilaments, the transgenic SOD1 
mouse, FUS mouse and TDP-43 mouse each displaying specific range of symptoms and 
characteristics.  
Following the discovery of the SOD1 mutations and its association with ALS 
phenotype, a selection of mutant SOD1 transgenic animals were generated including the 
SOD1G37R, which develops ALS-like symptoms by 4 to 6 months of age followed by 
hindlimb paralysis (Wong et al., 1995). The SOD1G85R that displays very late onset of ALS 
phenotypes (at 8-10 months of age) leading to aggressive paralysis within 2 weeks of initial 
symptoms (Bruijn et al., 1997). The low copy number SOD1G93A and the high copy number 
SOD1G93A mouse.  
Currently the high copy number transgenic SOD1G93A mice represents the best 
available and the most studied model for ALS, as it develops severe motor neuron 
degeneration, closely resembling the human disease (Gurney et al., 1994). This particular 
model is discussed in detail in ‘3.0. Animal Models Chapter, section 3.2.1’. In brief, by ~30 
days of age, the animals develop aggregation of mutant SOD1 in muscles and motor neurons 
as well as mitochondrial abnormalities in various tissues (Gurney et al., 1994, Johnston et al., 
2000, Higgins et al., 2003, Turner et al., 2003). ALS-like symptoms become evident at ~90 
days, presented by weakness and fine tremors in the hindlimbs. Symptoms progressively 
worsen leading to severe paralysis at ~120 days (Gurney et al., 1994). Comparison of this 
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model to the low copy number SOD1G93A mouse indicates that transgene copy number has a 
direct influence on the clinical phenotype developed by these mutant animals (Alexander et 
al., 2004). The low copy number animals have been shown to display a substantial delay in 
disease onset and increased lifespan in comparison to the high copy SOD1G93A mouse strain. 
With this in mind and by considering the fact that the low copy number SOD1G93A animals 
can emerge while breeding high copy number SOD1G93A animals due to intra locus 
recombination events during meiosis (Gurney, 1997), Scott and colleagues (2008) concluded 
that in large cohort survival studies any animal that displays transgene copy numbers that are 
different to the rest of their cohort must be eliminated from the final experimental analyses as 
their presence may introduce errors into the results and manipulate interpretation of the data 
(Scott et al., 2008). 
In addition, following the recent discovery of the R199W mutation in the DAO gene 
leading to ALS phenotype in humans by Mitchell and colleagues (2010), two new lines of 
transgenic mice were developed in a collaboration between the de Belleroche and Wells 
groups (unpublished data), namely DAOR199W that expressed the mutant DAO protein and 
DAOWT which overexpressed the wild type form of the DAO protein both of which form the 
basis for this thesis and their characteristics are discussed in full details in the ‘3.0. Animal 
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1.6. Therapeutic Measures 
Currently the only drug available for the treatment of ALS is Riluzole, which acts by 
inhibiting the release of glutamate by inactivating voltage-dependent Na+ channels at the 
presynaptic terminals (Bensimon et al., 1994, Lacomblez et al., 1996). Riluzole slows down 
disease progression by activating a G-protein dependent signal transduction process. It is 
capable of blocking some of the postsynaptic effects of glutamate by inhibiting the N-methyl-
D-aspartate (NMDA) and AMPA receptors in a non-competitive manner (Doble, 1996, Albo 
et al., 2004). Whilst Riluzole has some therapeutic potential, it only prolongs survival by a 
few months, hence ALS remains an untreatable disease (Federici and Boulis, 2006).  
Given the devastating nature of ALS, its high frequency, and the severity of its 
symptoms, finding a novel therapeutic technique for ALS has been the target of numerous 
investigations with the aim of delaying the onset of the disease, slowing down its progression 
or reducing the severity of the symptoms and ultimately prolonging life or possibly curing the 
affected individuals.  
 Hence, over the years a large number of drugs have been examined on SOD1G93A 
animal models, targeting a range of mechanisms/pathways involved in the pathogenesis of 
ALS, details of many of the potentially therapeutic drugs used in ALS animal models has 
been summarized by Turner and Talbot (2008) spanning the years 1996-2007, and another 
review by Pandya and colleagues (2013) listed a number of new drugs that were tested for 
targeting ALS (Turner and Talbot, 2008, Pandya et al., 2013). A few of these tested drugs 
that generated a positive outcome in mouse experiments include, Ceftriaxone, an antibiotic 
classified under the anti-excitotoxic category that prevents glutamate neurotoxicity and was 
shown to delay neuronal loss and muscle weakness, as well as increasing survival (Rothstein 
et al., 2005); Edaravone, a protein clearing compound that prevents formation of protein 
aggregates, its also known to be anti-apoptosis, anti-oxidative stress, and its treatment slowed 
	   41 
symptom progression, loss of body mass and motor neuron degeneration (Ito et al., 2008); 
melatonin, an agent with anti-apoptotic, anti-oxidative stress, and anti-inflammatory 
properties with the ability to prevent excitotoxity, its treatment delayed disease onset and 
progression, decreased microglial activation and astrogliosis, as well as extending survival 
(Weishaupt et al., 2006, Wang et al., 2008, Wang et al., 2011, Zhang et al., 2013); Rasagiline, 
an antioxidant molecule that provides mitochondrial protection, its presence promoted 
improved motor performance and survival (Waibel et al., 2004); A9-THC, an anti-
inflammatory and anti-oxidative stress compound that also provides prevention against 
excitotoxity, treatment with this agent delayed disease progression and increased lifespan 
(Raman et al., 2004). While a large number of the tested agents generated promising results, 
introducing them into clinical trials did not yield any beneficial outcome and therefore none 
of the previously tested drugs progressed to an approved and official treatment for the ALS 
patients. Thus, the search for a novel therapeutic agent for the treatment of ALS with the aim 
of delaying disease onset, slowing down disease progression or possibly curing the affected 
individuals, continues.  
Another area that has received particular attention since the 1990s, is the delivery of 
neurotrophic factors (NTFs) such as brain-derived neurotrophic factor (BDNF), ciliary 
neurotrophic factor (CNTF), vascular endothelial growth factor (VEGF), and insulin-like 
growth factor 1 (IGF-I), to the site of injury. 
Neurotrophic factors are endogenous proteins, crucial for neuronal survival and 
differentiation throughout development, and maintenance of normal function in the adult 
nervous system (Azzouz, 2006). They are known to have potent neuroprotective properties 
such as prevention of axonal degeneration, neuronal atrophy, and cell death. And are 
therefore recognized as ideal candidates for treatment of motor neuron disorders, many of 
which have been tested on human subjects (Raoul and Aebischer, 2004).  
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 Due to their attractive properties, NTFs have been a subject of numerous 
investigations, with CNTF being the first NTF used for the treatment of ALS patients. 
Following the promising data generated in animal studies where CNTF was shown to 
increase motor neuron survival (Sendtner et al., 1990) and prolong survival (Sendtner et al., 
1992b), it was tested in two large-scale human clinical trials with the hope of treating ALS. 
Results of these studies however demonstrated that administration of CNTF did not yield any 
significant differences in treated individuals in comparison to the patients in the placebo 
group. It was further shown that CNTF administration resulted in undesirable side effects and 
even death in some cases (Miller et al., 1996) which disqualified this agent as a potential 
candidate drug for the treatment of ALS patients (Ekestern, 2004).  
Animal studies focusing on BDNF also generated promising results ranging from 
increased motor neuron survival (Sendtner et al., 1992a, Yan et al., 1992, Gimenez y Ribotta 
et al., 1997), innervation and motor function (Ikeda et al., 1995), as well as promoting 
neuroprotection (Bemelmans et al., 2006). However intrathecal injection of this NTF into 
ALS patients in clinical trials demonstrated no beneficial effects (Kalra et al., 2003, Beck et 
al., 2005).  
Similarly IGF-I clinical trials did not yield any promising results and were combined 
with undesirable side effects such as reaction to the injection site, hypoglycemia, weakness, 
mild skin eruption, and dyspnea (Lai et al., 1997, Borasio et al., 1998, Nagano et al., 2005b, 
Sorenson et al., 2008). In addition, a phase 1/2 clinical trial for VEGF is currently ongoing 
where intracerebroventricular administration of VEGF is being assessed in ALS patients 
(NeuroNova AB, 2011). 
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The persistent failure in clinical trials have been estimated to be due to various factors 
(Scott et al., 2008, Ludolph et al., 2010, Kaneb, 2012), including the following points:  
• The preclinical studies carried out on ALS using the potential therapeutic agents are 
often performed on the mutant SOD1G93A mouse model, which is a model of FALS, 
whereas the majority of patients taking part in the clinical trials suffer from SALS and 
could potentially display different pathological mechanisms in comparison to FALS. 
• The mutant SOD1G93A mouse model, expresses the mutant allele at significantly higher 
levels in comparison to FALS patients which may consequently result in different 
disease characteristics in these animals in comparison to patients. 
• Effective results reported by preclinical studies often relate to onset of the disease and 
lifespan, whereas affected patients already have the disease when the treatment 
commence and thus disease progression is the most relevant parameter. This in turn 
indicates that if a certain therapeutic agent does not affect the progression of the 
disease, it is unlikely to be beneficial for the ALS patients. 
• To minimize pain and suffering for the animals involved in the preclinical studies a 
uniform humane end point is employed usually determined by a righting reflex within 
the allocated time frame, while the ALS patients live beyond this point and the end 
point is natural death from the disease. Thus, late-stage effects of the potential drug 
may be overlooked in preclinical studies and false results maybe generated.    
• Preclinical investigations employ fairly uniform animal cohorts in terms of their age, 
litter, food intake, and environment, while the ALS patients enrolled in clinical trials 
are more heterogeneous. 
• Badly-designed preclinical studies result in false positive results, thus all investigations 
involving SOD1G93A transgenic model must follow specific guideline established in a 
detailed and thorough study by Scott and colleagues in 2008. These guidelines include, 
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enrolling equal number of animals per experimental group (minimum n = 12 per sex, 
per group), employing same-gender litter matching, elimination of any animal 
experiencing a change in SOD1G93A transgene copy number and non-ALS death from 
the study. These criteria however are frequently neglected in preclinical studies. 
• Differences between mice and humans in terms of pharmacokinetics, corticospinal 
anatomy, and pharmacodynamics may not be considered thoroughly when dosing 
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1.7. Rationale of This Thesis  
As reported by our colleagues, there is a marked reduction in DAO activity in ALS 
patients carrying the DAOR199W mutation (Mitchell et al., 2010). Interestingly, in line with 
these findings Sasabe and colleagues (2012) reported that, (i) DAO malfunctioning is a 
common feature in the SOD1G93A animal model, (ii) DAO protein plays a crucial role in 
regulation of D-serine in the CNS, and thus inactivation of DAO protein equates decreased 
degradation of D-serine and the resultant increase in D-serine levels, (iii) reduced DAO 
activity is due to progressive repression in expression levels of the DAO gene that mediates 
the NMDA receptor (NMDAR) pathway (Sasabe et al., 2012). By taking these findings into 
account, in our first study we aimed to investigate and characterise the effects of the mutant 
DAOR199W protein in vivo through a well-designed large cohort survival study. 
As discussed in great details below, the levels of D-serine are elevated in both F/SALS 
patients and the SOD1G93A animal models (Sasabe et al., 2007), and there are clear links 
between ALS pathogenesis and D-serine mediated excitotoxicity through the NMDA receptor 
(Carriedo et al., 2000, Urushitani et al., 2001, Jiang et al., 2009, Brunet et al., 2009, Papouin 
et al., 2012, Spalloni et al., 2013). Considering the urgent need for an efficient therapeutic 
agent targeting both sporadic and familial ALS, the second investigation aimed to test the 
possible therapeutic benefits of the wild DAOWT protein via its overexpression in vivo 
through a carefully designed large cohort survival study. This has formed the second part of 
this thesis. 
In the third part of the thesis, by taking into account the limitations of the current 
treatment and the promising data gained from preclinical studies focusing on gene therapy, 
we aimed to develop a therapeutic approach concerning the delivery of a neurotrophic factor, 
IGF-I.  
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1.7.1. The Potential Role of DAO in ALS 
Extensive research indicates that DAO and its substrates, D-amino acids, are involved 
in regulation of a vast array of physiological pathways (Smith et al., 2010). Over the past few 
years one particular ligand for DAO, namely D-serine, has received a lot of attention. It has 
been demonstrated that as well as being synthesized in the CNS this particular D-amino acid 
(D-serine) plays a crucial role in neuronal signalling where it acts as the dominant co-agonist 
of the NMDA glutamate receptor subtype (Shleper et al., 2005, Panatier et al., 2006). It has 
been established that activation of the NMDA receptor is only facilitated in the presence of a 
co-agonist (Johnson and Ascher, 1987, McBain et al., 1989). D-serine has been identified as 
the main NMDAR endogenous co-agonist that upon binding acts towards increasing the 
affinity of the receptor for glutamate (Fadda et al., 1988, Papouin et al., 2012), promotes 
turnover of the receptor through internalization (Nong et al., 2003), and decreases receptor 
desensitization, thus modulating receptor function (Lerma et al., 1990).  
Over the years compelling evidence shed light on D-serine mediated glutamate 
excitotoxicity through the NMDA receptors and its contribution towards pathogenesis of 
ALS (Spalloni et al., 2013). In an investigation using the mutant SOD1 mouse model Jiang 
and colleagues revealed that as symptoms develop the NMDA receptors of the spinal 
interneurons are the potential source of over-excitation of motor neurons (Jiang et al., 2009). 
Other studies further demonstrated NMDA induced motor neuron degeneration in 
organotypic spinal cord cultures of chick embryo (Brunet et al., 2009), and NMDAR-
mediated neurotoxicity leading to mitochondrial Ca2+ overload and generation of reactive 
oxygen species (ROS) in cultured motor neurons (Carriedo et al., 2000, Urushitani et al., 
2001). An investigation carried out by Sasabe and colleagues in 2007 demonstrated an 
increase in spinal cord levels of D-serine in both patients (SALS/FALS) and SOD1G93A 
mouse model and the concentration of the D-serine continued to increase in the latter as the 
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disease progressed. The authors also reported reduced NMDAR-mediated motor neuron cell 
death upon removal of the endogenous D-serine from the spinal cord primary cultures of 
SOD1G93A mouse model (Sasabe et al., 2007). In another study Thompson and colleagues 
(2012) demonstrated that D-serine levels were significantly reduced in SOD1G93A mouse 
model upon partial deletion of serine racemase (SR) (an unusual enzyme responsible for 
synthesis and degradation of D-serine (Foltyn et al., 2005)). Further reduction of D-serine 
levels were observed when SR was removed completely, and the authors also reported that 
knocking out SR was associated with early onset of symptoms but prolonged survival 
(Thompson et al., 2012). In line with these findings Papouin and co-workers showed that 
silencing synaptic NMDARs provides neuroprotection against NMDA induced excitotoxicity 
(Papouin et al., 2012).  
Interestingly, as described previously, a study conducted by Mitchell and colleagues 
(2010), demonstrated a new mutation in the DAO gene associated with ALS phenotype at 
position R199W (DAOR199W). This study demonstrated that the mutation abolishes the 
enzymatic activity of the DAO protein. By using primary motor neuron and motor neuron 
cell lines, our colleagues further demonstrated that the mutation leads to development of 
abnormal cellular features including loss of projection, rounded atrophic or shrunken cell 
bodies. Presence of the mutant protein also promoted the formation of ubiquitinated protein 
aggregates and apoptosis (Mitchell et al., 2010). This in vitro study suggests that even in the 
presence of the endogenous DAO protein, the R199W mutation is pathogenic.  
Considering that D-serine is a known substrate for DAO and by taking the above 
discoveries into account we hypothesized that elevation of D-serine in ALS leads to 
excitotoxicity resulting in motor neuron death. Thus, introduction of a molecule such as DAO 
at high levels could result in breakdown of the excess D-serine at the cellular level, and 
consequently delaying disease onset, slowing down progression, and prolonging survival in 
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ALS. We therefore proceeded by generating two unique transgenic mouse strains namely 
DAOR199W and DAOWT, where the former overexpressed the mutant human allele as seen in 
the ALS patients and the latter overexpressed the wild type form of the human DAO protein. 
Both transgenic lines expressed the named alleles in various organs including the spinal cord.  
The primary focus of this thesis however was to investigate and establish the role of 
both mutant and wild type DAO proteins in ALS pathology in terms of disease onset, disease 
progression and survival of a well-known mouse model of ALS, the high copy number 
SOD1G93A mouse.       
We therefore hypothesize that the presence of the mutant DAO protein (DAOR199W) 
should exacerbate the SOD1G93A phenotype, resulting in early disease onset, accelerated 
disease progression and a shorter lifespan in the double transgenic animals 
(DAOR199W/SOD1G93A). Presence of the DAOWT at high concentrations in the double 
transgenic animals (DAOWT/SOD1G93A) on the other hand, should ameliorate the SOD1G93A 
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1.7.2. Developing a Therapeutic Approach using IGF-I 
Failure in the clinical trials using exogenous proteins suggests that gene therapy 
techniques may be a useful tool for treatment of ALS. This approach generally employs viral 
vectors, facilitating the delivery of potentially therapeutic genes encoding proteins such as 
anti-apoptotic factors (B cell lymphoma-2 (Bcl-2) and heat shock protein 27 (HSP27)), 
growth factors (IGF-I and VEGF) or neurotrophic factors (GDNF and BDNF), therefore 
maintaining motor neuron function and survival (Azzouz, 2006). This approach offers a more 
controlled and localized delivery of the target gene and have shown success in animal models 
of ALS.  
Thus, gene therapy techniques have been subjected to extensive research over the past 
decades, giving rise to valuable data, indicating the efficiency of these techniques in delivery 
of various genes specifically in the case of IGF-I, raising hope for possible future clinical 
trials (Kaspar et al., 2003, Kaspar et al., 2005, Lepore et al., 2007, Dodge et al., 2008, 
Riddoch-Contreras et al., 2009).  
Gene delivery using adeno-associated viral (AAV) vectors to deliver IGF-I to various 
sites such as lumbar region, hindlimb muscles, intrathecal or deep cerebellar nuclei in animal 
models of ALS demonstrated that delivery of the IGF-I resulted in increased muscle mass, 
increased motor neuron survival, increased motor function, delayed disease onset and 
progression, prolonged survival, preserved morphology of motor neurons and decreased 
gliosis (Kaspar et al., 2003, Lepore et al., 2007, Franz et al., 2009, Dodge et al., 2008).  
While viral deliveries has resulted in some promising data, a recent study by Riddoch-
Contreras and colleagues (2009) demonstrated that delivery of naked plasmid encoding either 
of the murine IGF-I isoforms (IGF-IA and MGF) resulted in an increase in motor unit, a 
significant improvement in hindlimb muscle strength, and an increase in motor neuron 
survival. The authors further reported that treatment with the MGF isoform produced a 
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significant survival rate in motor neurons in comparison to the Igf-IA isoform (Riddoch-
Contreras et al., 2009).  
These results further confirmed the potential of IGF-I as a therapeutic agent, making 
this particular neurotrophic factor a very attractive molecule for the treatment of ALS. In 
addition, results generated by Riddoch-Contreras (2009) further encouraged us to design an 
experiment and employ the cost effective method of gene therapy, local plasmid injection, in 
combination with an even more efficient method of gene delivery, electroporation, into the 
high copy number SOD1G93A ALS mouse model at 90 days of age and closely monitor the 
effect of two murine Igf-I isoforms (Igf-IA and MGF) in these animals in terms of disease 
progression and survival.  
For this part of the investigation we hypothesized that local delivery of the Igf-I 
constructs with electroporation technique would provide an efficient method of gene delivery. 
Thus treating high copy number SOD1G93A animals with the generated constructs at 90 days 
of age should slow disease progression and extend survival. In addition, we hypothesized that 
the MGF isoform would provide a more efficient treatment option in comparison to the IGF-
IA isoform.  
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1.8. Specific Aims of This Thesis 
• To investigate the progressive loss of motor neurons in transgenic mice 
overexpressing the mutant human DAO gene (DAOR199W) and to monitor the 
development of the ALS-like phenotypes and survival in double transgenics 
expressing both DAOR199W and SOD1G93A transgenes by closely following the 
guidelines of Scott and colleagues (2008).  
• To investigate the effect of overexpression of the wild type form of the human DAO 
gene (DAOWT) on the development of the ALS-like phenotypes and survival in double 
transgenics expressing both DAOWT and SOD1G93A transgenes by closely following 
the guidelines of Scott and colleagues (2008). 
• To generate constructs encoding either murine IGF-I isoforms (i.e. IGF-IA or MGF) 
and investigate their effect in terms of disease progression and survival in the high 
copy number SOD1G93A transgenic mice. 
 
	  
	   	  
	   52 
 
 
2.0 Materials  
& Methods  
  
	   53 
2.1. Materials 
2.1.1. Reagents 
Acetic Acid: Fischer Scientific 
Agar: OXOID 
Agarose (Ultrapure): Invitrogen  
Amersham HyperfilmTM ECL: GE Healthcare Life Sciences 
Amido Black: Sigma 
Ampicillin sodium salt: Sigma 
Antarctic Phosphatase: NEB, UK  
Barium Chloride: Sigma 
β-Mercaptoethanol: Sigma 
Boric acid: Fischer Scientific 
Bovine Hyaluronidase: Sigma  
Bromophenol Blue: BDH 
10-beta Competent E. coli (High Efficiency): NEB, UK 
Chicken Embryo Extract: Sera Laboratories International 
Chloroform: Fisher Scientific  
Chromic potassium sulphate: Sigma 
Complete Mini Protease Inhibitors cocktail tablets: Roche Applied Sciences  
Color Marker Ultra-low Range (M.W. 1.060-26.600 kDa): Sigma 
Cryo M-bed: Bright 
Di-methyl pyrocarbonate (DMPC): Sigma 
DMEM (1X) + GlutaMAX-I: Life Technologies 
2.5mM dNTPs: Invitrogen  
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DPX: VWR 
EcoRI: NEB, UK 
Ethanol: Fisher Scientific  
ECL Prime Western Blotting Detection Reagent: GE Healthcare Life Sciences 
EDTA: BDH 
Electroconductive cream for ECG & EEG: Eurocamina  
Fentanal/fluanisone (Hypnorm): Vetapharma Ltd 
Fetal Bovine Serum: Invitrogen 
Ficoll: Sigma 
Gallocyanin: Aldrich 
Gamma Interferon (γ-IFN): Chemicon 
Gelatin type A from porcine skin: Sigma  
Glycin: AnalaR 
Horse Serum: PAA Laboratory  
Isopentane: Fisher Scientific 
Isopropanol: AnalaR  
Kanamycin B sulfate salt: Sigma 
L-Glutamine: Invitrogen 
Lysogeny Broth (LB) SOC: NEB, UK 
Matrigel Basement membrane matrix: BD Bioscience 
Methanol: AnalaR  
Midazolam (Hypnovel): Roche 
Non-essential Amino Acids: Invitrogen 
Non-Fat Dried Milk Powder: Marvel 
Nonidet P40: BDH  
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NuPAGE LDS Sample Buffer: Life Technologies  
NuPAGE MOPS SDS Running Buffer: Life Technologies 
NuPAGE Novex 4-12% Bis-Tris Gels (1.0-mm thick): Life Technologies 
PageRuler Prestained Protein Ladder 10-170kDa: Thermo Scientific 
Paraformaldehyde (PFA): BDH  
PmaxGFP: Lonza 
Penicillin-Streptomycin in 0.9% NaCl: Sigma 
Pentobarbital: Merial, UK  
Phosphate Buffered Saline (PBS): Sigma 
Potassium chloride (KCl): AnalaR  
Proteinase K: Invitrogin   
RNA Bee: Amsbio 
SIGMAFAST 3,3′-Diaminobenzidine tablets: Sigma  
Sodium Chloride (NaCl): BDH 
Sodium Deoxycholate: Sigma 
Sodium Dodecyl Sulfate (SDS): BDH  
Sodium Hydrogen Phosphate (NaH2PO4): VWR 
Sodium Hydroxide (NaOH): BDH  
Sodium Phosphate (Na2HPO4): Sigma 
Sucrose: Sigma  
SYBR Safe DNA Gel Stain: Invitrogen 
T4 DNA Ligase: Roche Diagnostics  
Tris Base: Fisher Scientific   
Triton X-100: Sigma 
Trypsin-EDTA Solution: Sigma  
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Tryptone: Fisher Scientific 
Tween 20: BDH  
Water for Injections: Norbook 
Xylene: Fisher Scientific 
Yeast extract: OXOID 
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2.1.2. Kits  
Amaxa Cell Line Nucleofector Kit V: Lonza 
Avidin/Biotin blocking kit: Vector Laboratories, UK 
BCA Protein Assay: Thermo Scientific  
Brilliant II SYBR green QPCR master mix reagent: Stratagene  
DNeasy Blood and Tissue Kit: QIAGEN 
Endofree Plasmid Giga Kit: QIAGEN  
Lipofectamine LTX with Plus Reagent: Invitrogen 
PCR Enhancer System: Invitrogen  
QIAprep Spin Mini Prep Kit: QIAGEN  
QIAquick Gel Extraction Kit: QIAGEN  
QIAquick PCR Purification Kit: QIAGEN 
Taq DNA Polymerase, Recombinant: Invitrogen  
Taq DNA Polymerase 1000 Units: QIAGEN  
TOPO TA (pCR 2.1-TOPO TA Vector): Invitrogen  
Transcriptor Frist Strand cDNA Synthesis Kit: Roche Applied Science 
Vectastain ABC kit: Vector Laboratories, UK 
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2.1.3. Antibodies 
Table 1. List of the Primary Antibodies and the dilution used.
Table 2. List of the Secondary Antibodies and the dilutions used. 






Antibody Supplier Application Dilution 
Mouse IGF-I, Antigen Affinity-purified 
Polyclonal Goat IgG	  
R&D 
Systems	   WB	   1:250 
Polyclonal rabbit anti D-amino acid oxidase 





Rabbit Polyclonal anti-beta-Tubulin Abcam WB 1:10,000 
Polyclonal rabbit anti-Ubiquitin Dako IHC 1:200 
Goat anti-Choline Acetyl Transferase Millipore IHC 1:100 
Antibody Supplier Application Dilution 
Goat anti-rabbit IgG (H+L)-HRP Bio-Rad WB 1:50,000 
Polyclonal rabbit anti-goat 
Immunoglobulins/HRP Dako WB 1:2,000 
Polyclonal swine anti-rabbit/Biotinalated Dako IHC 1:200 
Polyclonal rabbit anti-goat 
Immunoglobulins/Biotinalated Dako IHC 1:500 
Product Name Supplier Application Concentration 
D-Amino Acid Oxidase, 
from porcine kidney Sigma WB 100ng 
Recombinant Murine IGF-I PeproTech   WB 6ng 
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2.1.4. Primers 
All primers were purchased from Invitrogen  





































































Table 4. List of the primers used. 
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2.1.5. Equipment  
AlphaDigiDocTM RT imaging system: Alpha Innotech  
Bench Centrifuge (Biofuge Pico): Heraeus  
BTX ECM830 electroporator: Kramel Biotech 
BTX Tweezertrodes: Kramel Biotech 
Camera DC500: Leica Application Suit 
Chromo4 Real Time PCR-Detector: Bio-Rad  
Compact X4 Automatic X-ray Film Processor: X-OGRAPH Imaging Systems 
Cryostat: Bright (Model OTF)  
DigiGait Imaging System: Mouse Specifics, Inc. 
DNA Gel Electrophoresis Tank: Bio-Rad 
Electrophoresis Power Pac HC: Bio-Rad  
Inverted Wide Field Microscope: Leica DMIRB 
Mini Protean II Electrophoresis Cell System: Bio-Rad 
Mini Trans-Blot Absorbent Filter Paper: Bio-Rad  
Mx3000p Q-PCR system: Stratagene  
Nanodrop ND-1000 Spectrophotometer: Thermo Scientific  
Nitrocellulose membranes for blotting (pore size 0.2µm): Sigma 
Nucleofector II Device: Lonza 
Nunc EasYFlasks, Cell Culture Treated: Thermo Scientific 
Nunc Petri Dishes: Thermo Scientific 
Nunclon Delta Surface (6 round wells): Thermo Scientific 
PAP Pen for immunostaining: Sigma 
PCR machine: Techne TC-512  
PVDF membrane (0.2µm pore size): Millipore 
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Superfrost plus glass slides and coverslips: VWR  
Thermo pad: Harvard apparatus 
Upright Bright Field Microscope: Leica DM4000B 
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2.1.6. Solutions 
Agar Plates 15g of Agar was added to 1L of LB Miller media. Agar was 
dissolved by autoclaving, upon addition of the appropriate 
antibiotic, the almost cooled solution was poured at 25ml per 
plate.  
Amido Black Stain 0.5g Amido Black added to 125ml Isopropanol, 50ml Acetic 
Acid and 325 ml ddH2O. 
Amido Black De-stain 125ml Isopropanol mixed with 50ml Acetic Acid in ddH2O to 
500ml. 
DNA Gel Loading Buffer For a 6x solution, 1.5ml Ficall (glycerol) was dissolved in 10ml 
ddH2O by incubation at 60˚C for 4 hours. Once dissolved, add a 
few crystals of bromophenol blue and a few crystals of xylene 
cyanol (by touching the end of a separate pipette tip into each 
powder and then into the Ficall solution). Mix well and aliquot, 
then store at room temperature. 
Ear Biopsy Buffer (10x) 500mM KCl, 100mM Tris-HCl (pH 8.3), 0.1mg/ml Gelatin, 
0.45% v/v Tween 20, 0.45% v/v Nonidet P40, added to ddH2O 
and autoclaved to sterilise. 5mg/mL Proteinase K was then 
added to the buffer following autoclaving and stored at -20°C.  
Gelatin 6g NaH2PO4, 26.9g Na2HPO4, 100g Sucrose, and 75g Gelatin 
was mixed in 1L of ddH2O. Solution was boiled to dissolve and 
stored at -20˚C. 
Hyaluronidase    Prepared in sterilised saline at the concentration of 0.4U/µl. 
Nissl Solution   50g of Chromic potassium sulphate was dissolve in 500ml of 
ddH2O by heating at 70oC and continuous stirring. The solution 
was brought to boil upon addition of 1.5g gallocyanin and 
simmered whilst stirring for approximately 30 minutes. The 
solution was then cooled to room temperature and filtered 
before use. 
LB Miller Media (1L) 10g Tryptone, 5g Yeast Extract and 10g Nacl in ddH2O to 1L. 
Solution was autoclaved to sterilise.  
PBS 1 tablet of PBS was dissolved per 200ml of ddH2O. 
RIPA Buffer  100ml was prepared by addition of 50mM Tris (pH 8), 150mM 
NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS to 
ddH2O. 1 tablet of Complete Mini Protease Inhibitors cocktail 
was then added per 10ml of solution.  
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Stripping Solution  0.1M β-Mercaptoethanol, 2% SDS and 62.5mM Tris-HCl (pH 
6.8) were dissolved in ddH2O.  
TBE (5X)    54g Tris Base, 27.5g Boric Acid, and 0.5M EDTA were 
dissolved in ddH2O with gentle heating and stirring to aid 
dissolving, the volume was then made to 1L. 
TBS/T  TBS was prepared by dissolving 1.21g Tris Base (pH 8) and 
8.76g NaCl in 1L of ddH2O. Upon dissolving 500µl of Tween 
20 was added to the solution to make TBS/T. 
Transfer Buffer  6g Tris Base, 28.8g Glycine, 0.5g SDS were dissolved in 1L of 
ddH2O. 
1% Agarose Gel 1g of agrose was added to 100ml of TBE (0.05x) solution and 
dissolved by boiling in a microwave for approximately 1 
minute. Prior to pouring, 5µl of SYBR Safe DNA Gel Stain 
(final concentration of 10,000x) was added to the solution. Gel 
was poured in the appropriate container and allowed to set for 
approximately 1 hour at room temperature.  
4% PFA 40g PFA dissolved in PBS in the presence of NaOH, prepared 
to 1L, pH 7.4.  
30% Sucrose  30g Sucrose was added to 100ml PBS solution, autoclaved to 
sterilise.  
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2.2. Methods 
All experiments reported throughout this thesis that involved use of an animal subject, 
were carried out under a project license from the UK Home Office in accordance with The 
Animals (Scientific Procedures) Act 1986, which was approved by the Royal Veterinary 
College ethical committee. 
In addition, where a colleague conducted a particular experiment clear notes have 
been made throughout this Chapter to acknowledge their contribution.  
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2.2.1 Survival Studies  
In this part of the investigation we employed three lines of transgenic mice namely 
high copy number SOD1G93A, DAOR199W and DAOWT.  
The overall design of our survival studies as well as the cage conditions, were initially 
optimised by Dr Hannah Kaneb (Kaneb, 2012).     
 
2.2.1.1 High Copy Number SOD1G93A Mouse Model  
Male mice overexpressing human SOD1 bearing the G93A mutation causing an ALS 
phenotype [B6SJL-TgN SOD1G93A1 Gur/J, Stock number 002726] (Gurney et al., 1994) were 
initially purchased from the Jackson Laboratory (Bar Harbor, ME). They were maintained as 
hemizygotes by breeding with wild type F1 hybrid C57BL6xCBA/Ca females. The 
SOD1G93A mice have been generated on this background for over 28 generations, and animals 
on this background have similar disease characteristics (as previously assessed by hindlimb 
electrophysiological parameters (Sharp et al., 2008) and longitudinal monitoring of 
neurological score and body weight (Kaneb et al., 2011) and life span compared to the 
original and more widely used B6SJL hybrid genetic background (Azzouz et al., 2004, Zheng 
et al., 2004). We did not observe any changes in terms of lifespan and disease progression in 
these animals with successive generations in our laboratory (Kaneb et al., 2011, Kaneb, 
2012). 
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2.2.1.2. DAOR199W & DAOWT Mouse Models 
The DAOR199W transgenic line and mice overexpressing the wild type DAO (DAOWT) 
were created and established in our laboratory in a collaboration between the de Belleroche 
and Wells groups using either human DAOR199W or human DAOWT cDNA, driven by a 
chicken β-actin promoter and cytomegalovirus enhancer, pCAGGS (Niwa et al., 1991). The 
linearized transgene was microinjected into pronuclei of fertilized eggs from 
C57BL6×CBA/Ca female mice, which were subsequently transferred to pseudopregnant 
recipients. Integration of the transgene into the genomic DNA was determined 3–4 weeks 
after birth, by collecting a small ear biopsy from the pups and screening for the transgene 
expression by using polymerase chain reaction (PCR). Upon successful transmission, 
transgene expression was confirmed by the de Belleroche lab in a range of tissues including 
the spinal cord via western blot and immunohistochemistry techniques. Hemizygote colonies 
from two independent founders were established and maintained by crossing over the 
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2.2.1.3. Double Transgenic Mouse 
 The double transgenic (DT) mouse models were generated following breeding of 
heterozygous high copy number SOD1G93A males with either heterozygous DAOR199W or 
heterozygous DAOWT females, generating 4 different genotypes per cross. Genotypes 
obtained from the crosses are listed below:  
 
 SOD1G93A x DAOR199W SOD1G93A x DAOWT 
Offspring 
SOD1G93A	   SOD1G93A	  
DAOR199W	   DAOWT 
SOD1G93A/DAOR199W	   SOD1G93A/DAOWT	  
Wild Type 	   Wild Type 	  
 
2.2.1.4. Genotyping  
Following weaning, an ear biopsy (~1.5-3mm2 in size) was collected from all the 
offspring generated from the above crosses. DNA extraction was then performed by 
overnight incubation of the samples at 55°C in 1x ear biopsy buffer (50µl). Upon completion 
of the digestion process, proteinase K (Invitrogen)	   was deactivated at 100°C and samples 
were screened for the expression of the transgenes of interest (SOD1G93A, DAOR199W or 
DAOWT) using PCR. PCR conditions and reagents used for each particular genotype are listed 
in the following subsections (SOD1G93A in section 2.2.1.4a and DAO in section 2.2.1.4b).   
Upon completion of the PCR process, the amplified products were electrophoresed in 
1% agarose gel (recipe available in section 2.1.6). In the case of the SOD1G93A PCR, 5µl of 
the amplified product was mixed with 1µl of the DNA gel loading buffer (recipe available in 
section 2.1.6) prior to loading. In the case of the DAO PCRs 10µl of each sample was directly 
loaded onto the gel. Visualisation of the amplified DNA was facilitated by AlphaDigiDocTM 
RT imaging system (Alpha Innotech). 
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2.2.1.4a. The SOD1G93A Polymerase Chain Reaction  
PCR reaction mixture for one single reaction consisted of:  
• 9.35µl PCR-grade water 
• 2µl (10x) PCR buffer Mg free (Invitrogen) 
• 2µl PCR Enhancer (Invitrogen) 
• 0.8µl 2.5mM dNTPs (Invitrogen) 
• 2µl (10 pmol/µl) Forward Primer (Invitrogen)  
• 2µl (10 pmol/µl) Reverse Primer (Invitrogen) 
• 0.6µl (50mM) MgCl2 (Invitrogen) 
• 0.25µl Taq DNA Polymerase, recombinant (Invitrogen) 
• 1µl DNA template (digested ear sample) 
Primer sequences for the amplification of SOD1G93A transgene 
• Forward Primer: 5’-CATCAGCCCTAATCCATCTGA-3’ 
• Reverse Primer: 5’-CGCGACTAACAATCAAAGTGA-3’ 
PCR Cycling Conditions 
• Pre-heat lid to 105oC 
• Initial denaturation at 95oC for 3 minutes 
       35 cycles of 
• 95°C for 30 seconds 
• 60°C for 30 seconds 
• 72°C for 45 seconds 
• 72°C for 2 minutes 
• Final hold 4°C 
 
The PCR process amplifies a 236 base pair (bp) fragment from the exon 4 of the human 
SOD1 gene (Rosen et al., 1993). 
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2.2.1.4b. DAO Polymerase Chain Reaction  
PCR reaction mixture for one single reaction consisted of:  
• 35.75µl PCR-grade water 
• 5µl 10x PCR buffer (Qiagen) 
• 4µl 2.5mM dNTPs (Invitrogen) 
• 2µl 10pmol/µl Forward primer (Invitrogen) 
• 2µl 10pmol/µl Reverse primer (Invitrogen) 
• 0.25µl Taq DNA polymerase enzyme (Qiagen) 
• 1µl DNA template (digested ear sample) 
Primer sequences for the amplification of DAO transgene 
• Forward Primer: 5’-CTGCTAACCATGTTCATGC-3’ 
• Reverse Primer: 5’-GTGTTTGAAGGTCCAGTGC-3’ 
PCR Cycling Conditions 
• Pre-heat lid to 105oC 
• Initial denaturation at 95oC for 2 minutes 
35 cycles of 
• 95oC for 30 seconds 
• 55oC for 30 seconds 
• 72oC for 45 seconds 
• Final extension at 72oC for 3 minutes 
• Final hold at 4oC 
 
The PCR process amplifies a 1,008bp fragment from the exon 7 of the human DAO gene 
(Mitchell et al., 2010). 
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2.2.1.5. The Survival Studies Design 
Although a large number of studies have reported successful pharmaceutical 
interventions in various ALS mouse models, except for Riluzole none of the tested drugs 
could be prospectively translated into human therapeutics, and therefore a substantial amount 
of financial resources has been wasted (Ludolph et al., 2010). Currently the only drug 
available for the treatment of ALS is Riluzole, which has been shown to significantly prolong 
survival in the SOD1G93A mouse model. While this drug is commercially available, it only 
exerts a small beneficial effect in patients by extending life expectancy by a few months 
(Federici and Boulis, 2006). Scott and colleagues aimed to investigate this disparity and 
revealed several confounding variables that may result in generation of false positive data in 
survival studies involving the high copy number SOD1G93A mouse model (Scott et al., 2008). 
In a detailed study by employing a highly specialized computer model (SimLIMS), the 
authors collected data from 2,241 SOD1G93A mice that were maintained on a mixed hybrid 
genetic background (generated from mating B6SJLF1 females and hemizygous 
B6SJLTg/SOD1G93A males). This study demonstrated that several control measures must be 
employed when carrying out survival studies involving the high copy number SOD1G93A 
strain to ensure the reliability of the outcome. Thus, they concluded that an n-number of 24 
mice per experimental group per cohort (12 females and 12 males), same-gender litter 
matching, and elimination of any animal who have experienced a change in SOD1G93A 
transgene copy number or non-ALS deaths minimized the noise within the survival study to a 
virtual zero (Scott et al., 2008). 
Hence, following this study a guideline was generated for the preclinical testing of 
therapeutics for ALS, enabling researchers to control these variables and therefore increasing 
the validity of the results. In order of importance these variables include: the incidence of 
non-ALS deaths, the occurrence of a change in SOD1G93A transgene copy number, genetic 
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background, and epigenetic changes resulting in gender effect and littermate clustering (Scott 
et al., 2008, Ludolph et al., 2010). Therefore in order to ensure the accuracy and validity of 
our results, we carefully designed our survival studies following these guidelines. 
Specifically, we aimed to control for any potential variability that may have occurred due to 
non-ALS deaths by closely monitoring the health of all animals participating in our study 
throughout the duration of the investigation. Thus, data from any animal that died due to non-
ALS related causes was excluded from the final survival analysis. In addition, we examined 
possible variations in SOD1G93A transgene copy number by quantitative polymerase chain 
reaction (Q-PCR) in any animal demonstrating disease progression or survival characteristics 
that were substantially different from the mean value (Alexander et al., 2004), and therefore 
excluded those animals that have experienced a change in SOD1G93A transgene copy number. 
Furthermore, all experimental groups in our survival study were balanced for litter and age. 
And we negate any sex-effect by analyzing the data from all males and females separately 
(Kaneb, 2012). Moreover, we recruited a minimum of 12 animals per experimental group per 
sex in each survival study.  
As part of designing our survival study, we considered various assessment techniques 
for determining the onset of ALS related phenotypes. Although rotarod is regularly employed 
for evaluation of disease onset and progression in SOD1G93A mice (Ralph et al., 2005, Sharp 
et al., 2008, Towne et al., 2008), a recent study demonstrated that exercise delays the onset of 
motor deficits as well as increasing motor neuron survival (Carreras et al., 2010). Hence, we 
eliminated the use of this particular assessment technique to ensure the validity of our results. 
Paw grip endurance test was also considered for assessing ALS related phenotypes, which as 
indicated by Weydt and colleagues is an inexpensive and sensitive method, and can be used 
as an alternative to the rotarod technique for the SOD1G93A mice (Weydt et al., 2003). We 
were however concerned that the data obtained from this assessment technique were highly 
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user dependent, and hence it would prevent the possibility of a second operator helping to 
carry out the task should this be required (Kaneb, 2012).  
Given that we have previously performed two large cohort survival studies in our 
laboratory and successfully generated valuable data and published our results (Kaneb et al., 
2011, Kaneb, 2012), as with the previous studies we therefore decided to follow the 
guidelines developed and validated by Scott and co-workers at the ALS Therapy 
Development Institute (ALSTDI). These guidelines indicate that disease onset and 
progression should be determined through a combination of longitudinal monitoring of 
neurological score and body weight (Scott et al., 2008, Gill et al., 2009, Lincecum et al., 
2010). The neurological scoring system is developed through detailed monitoring of each 
individual animal, which in turn provides a non-invasive, rapid and unambiguous measure of 
disease onset and progression in high copy number SOD1G93A mice (Scott et al., 2008, Gill et 
al., 2009, Lincecum et al., 2010, Kaneb et al., 2011, Kaneb, 2012). In addition, based on the 
data generated from the previous survival analysis in our laboratory we determined the 
humane end point as the inability of the animal to right itself within 20 seconds of being 
placed on its side (Wang et al., 2002, Scott et al., 2008, Kaneb, 2012).  
Animals participating in all the in vivo studies were housed in a minimal disease 
facility at the Royal Veterinary College, with a ‘12:12’ hour ‘light:dark’ cycle, food and 
water ad libitum.  
Thirteen breeding trios each consisting of one high copy number SOD1G93A transgenic 
male and two DAOR199W females were set up simultaneously to generate a large cohort of 
aged matched pups with a mixture of genotypes namely SOD1G93A, DAOR199W, 
SOD1G93A/DAOR199W, and WT (non-transgenic wild type), for enrolment in the “SOD1G93A x 
DAOR199W” survival study.  
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In a separate study and at a different time point, ten breeding trios each consisting of 
one high copy number SOD1G93A transgenic male and two DAOWT females were set up 
simultaneously to generate a large cohort of aged matched pups with a mixture of genotypes 
namely SOD1G93A, DAOWT, SOD1G93A/DAOWT, and WT (non-transgenic wild type), for 
enrolment in the “SOD1G93A x DAOWT” survival study.  
Due to the low number of pups of certain genotypes generated from the first cohort, 
the breeders were carried onto the second round of breeding to generate an ideal number of 
genotypes per experimental group (n ≥ 12 per genotype, per sex). Following genotyping, 
littermates were separated in accordance to their sex (regardless of their genotype). 
Littermates of the same sex were housed together (not exceeding 5 animals per cage) to 
ensure consistency of the results in terms of age and gender. Hereafter the operator (myself) 
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2.2.1.6. Cage Conditions, Food and Water 
Based on our previous experience working with the high copy number SOD1G93A 
animal model (Kaneb, 2012), we set certain criteria in place in terms of cage conditions, to 
meet Home Office rules and regulations and to further minimise any possible discomfort to 
the animals, and most importantly avoiding any external factor that might interfere with our 
final results. These criteria are discussed below.  
Throughout the duration of the experiments, the cage condition including bedding and 
enrichment were kept consistent across all experimental groups. For our survival studies we 
defined a ‘standard’ cage as a cage with a thin layer of Alpha-dri bedding (Lillico), one fun-
tunnel (Lillico), a minimum amount of paper wool (Lillico), a standard number of dry food 
pellets (2 pellets per animal) in one corner of the cage on the bedding as well as ad lib in the 
food hoppers, with each individual cage housing a maximum of 5 animals.  
In our experience those animals developing the ALS related disabilities sometimes 
struggle with accessing food and water in their standard caging condition, their ability to 
chew on hard food is sometimes limited and as their bodily movements are often restricted by 
being tangled up in the paper wool and sometimes they are targeted by their otherwise 
healthier or unaffected cage-mates. Thus, as mice reached 100 days of age any animal that 
was awarded a score of ‘2’ on the scale of the neurological symptoms associated with 
dragging any part of one or both feet, was separated from the rest of its group and was housed 
in a fresh cage equipped with a thin layer of Alpha-dri bedding, a long sipper tube 
(Techniplast, UK) on the water bottle, two squares of shredded Nestlets (Lillico), two dry 
food pellets as well as a standard amount of mashed diet that was prepared with water and 
was served fresh on a daily basis in a clean Petri dish. Cages bearing the affected animals 
were flagged up for further daily examination and the cage condition was kept the same for 
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the remainder of the study. Throughout the duration of both survival studies, cages were 
cleaned on a weekly basis.  
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2.2.1.7. Survival Studies Analysis  
The development of ALS related disabilities were assessed by means of neurological 
scoring system for both hindlegs twice weekly for each mouse from approximately 30 days of 
age in the case of “SOD1G93A x DAOR199W” cross and from 40 days of age in the case of 
“SOD1G93A x DAOWT” cross. Neurological scores were assigned using a scale of 0-4, 
established by the ALSTDI through detailed observations of SOD1G93A mouse pathology 
(Scott et al., 2008, Gill et al., 2009, Lincecum et al., 2010).  
Criteria used to assign each score level were:  
• 0: Full extension of hindlegs away from lateral midline when mouse is suspended 
by its tail and mouse can hold this for 2 seconds, suspended 2-3 times.  
• 1: Partial or full collapse of leg extension towards lateral midline (weakness) or 
trembling of hindlegs during tail suspension.  
• 2: Toes curl under at least twice during walking of 12 inches or any part of foot is 
dragging along cage bottom (a clean cage with no bedding was used for this 
analysis to permit easy viewing of the toes).  
• 3: Minimal joint movement or rigid paralysis, foot not being used for forward 
motion.  
• 4: Mouse cannot right itself within 20 seconds from one or both sides when placed 
on its side. This is referred to as the righting reflex from hereafter.   
As demonstrated by ALSTDI and practiced by Scott and colleagues (2008) weight 
assessment and neurological scoring is the most reliable and gentle combination of measuring 
the onset of the disease, which also allows identification of non-ALS-mediated deaths. Loss 
of body weight in high copy number SOD1G93A mice is usually a gradual and continuous 
process, commencing at approximately 90 days of age until the animal dies. Rapid weight 
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loss in a short period of time that does not match the normal pattern can therefore be a sign of 
non-ALS related problems (Scott et al., 2008).     
Hence, thorough neurological examination of all animals was carried out on each 
scoring day in conjunction with assessment of weight and the affected animals developing an 
ALS-like phenotype were terminated when they reached the humane endpoint; determined as 
the point in time that the mouse was unable to right itself within 20 seconds when placed on 
its side (Wang et al., 2002, Scott et al., 2008, Kaneb, 2012). To accurately determine the end 
point for individual animals, their righting reflex was tested twice daily from 100 days of age. 
Once an animal reached the end point, it was euthanized via cervical dislocation, the date and 
cause of their death were recorded and an ear and tail biopsy was collected for PCR and Q-
PCR respectively to reconfirm the genotype and examination of SOD1G93A transgene copy 
number, as changes in the latter affect disease progression and ultimately survival (Kaneb, 
2012).  
It is noteworthy that in order to ensure the accuracy and validity of the results, both 
survival studies were carried out in a blinded manner, where the investigator was ‘blinded’ to 
the genotypes and the genotype of the animals were only revealed upon termination of the 









	   78 
2.2.1.8. Graphical Representation & Statistical Analysis 
In order to demonstrate overall changes in neurological score and body weight, mean 
values for neurological scores and body weight were plotted for each experimental group 
over time until the last animal in a particular genotype group reached the end stage. In the 
case of SOD1G93A and the double transgenics, as animals reached the humane end point, the 
final readings recorded for the neurological score and weight for each individual animal were 
carried forward until the point in time at which the last animal in that particular group died. 
This was done to avoid decomposition of the mean neurological score and weight values, a 
common practice in survival analyses employing longitudinal assessment of both named 
variables (Gill et al., 2009, Lincecum et al., 2010, Kaneb, 2012). However, conducting 
repeated analyses on correlated serial measurements for the same subjects could result in loss 
of statistical validity. As advised by Matthews and colleagues this phenomenon can be 
avoided by employing relevant summary measures for neurological score and weight data 
(Matthews et al., 1990). The statistical analyses in our study were therefore conducted on the 
selected summary measures. These summary measures include: time taken to reach peak 
weight (the earliest indicator of disease onset), time taken to reach the neurological score of 2 
in both hindlimbs (defined as the onset of neurological symptoms), time from peak weight to 
death (an indicator of disease progression), and time to reach a score of 4 (the uniform 
humane end point selected for this study) (Kaneb, 2012).  
The selected summary measures represent ‘time to event measures’ and were 
analysed via Kaplan-Meier survival analyses, the log-rank test was also performed to 
determine the statistical significance amongst experimental groups. The log-rank test assess 
the hypothesis that the presence of the DAO transgene did not change the time taken to reach 
the event being analysed and thus the Kaplan-Meier curves for all groups are identical. 
Therefore a low P-value indicates that the differences between the curves did not occur due to 
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chance, with the threshold for significance being set at (P ≤ 0.05) for all analyses (Kaneb, 
2012). All Kaplan-Meier survival analyses were carried out using Graphpad Prism 6 
software. 
In the case of assessment of overall body weight, animals were weighed 
longitudinally and values were plotted as ‘mean group body weight’ at each particular age 
using Excel software. Since each genotype group generated through the crosses was 
considered as a new strain of mice, it was therefore concluded by our statistician that 
differences in body weight between the different experimental groups were not statistically 
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2.2.1.9. Assessment of SOD1G93A Transgene Copy Number Variations  
Any animal that displayed an outlying survival time in comparison to the rest of its 
group was subjected to SOD1G93A transgene copy number assessment. The evaluation was 
carried out using a Q-PCR technique established by Alexander and colleagues (2004) 
(Alexander et al., 2004). This technique tracks the quantity of the PCR products produced 
throughout each cycle via the intensity of the fluorescence generated by the SYBR green dye, 
a fluorescent dye present in the PCR reaction mix that intercalates between the double strands 
of the DNA, emitting florescence upon intercalation (Schneeberger et al., 1995).  
The assessment of variation in SOD1G93A transgene copy number was evaluated by 
determining the difference in cycle threshold (∆CT) between the SOD1G93A and the Il-2 
reference gene. The cycle threshold is defined as the cycle at which a significant rise in 
SYBR fluorescence is initially detected in comparison to the baseline. Hence, two sets of 
reactions were prepared in parallel from the same animal, one amplifying the human 
SOD1G93A (hSOD1G93A) transgene and the other amplifying an endogenous reference gene 
with a known copy number of 2, mouse interleukin-2 (mIl-2) (Alexander et al., 2004). Since 
we initially purchased our SOD1G93A mice from the Jackson laboratory and maintained them 
in our facilities we expected our colony to bear approximately 25 copies of the hSOD1G93A 
transgene. Thus, cycle threshold (CT) values obtained from the reaction amplifying the 
hSOD1G93A transgene will be lower in comparison to those obtained from amplification of the 
mIl-2 reference gene. The ΔCT was computed as the difference between the CT value of the 
hSOD1G93A and the CT of the mIl-2 reference gene (ΔCT = mIl-2 CT − hSOD1G93A CT). The 
ΔCT values of the outlying animals were compared to those obtained for a subset of control 
mice. Any mice whose ∆CT value (disregarding the -/+ sign), differed by more than 2 
standard deviations from the average ∆CT value of the control group was considered an 
outlier and therefore excluded from the final analysis (Alexander et al., 2004, Kaneb, 2012).  
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2.2.1.10. Quantitative Polymerase Chain Reaction (Q-PCR)  
 Throughout the duration of our survival studies, upon death of each individual animal a 
small piece of tail was removed from the tip of the tail (approximately 0.5cm in length), for 
potential assessment of variations in SOD1G93A transgene copy number should the animal 
require further investigations.  
 The tail samples from the animals in question along with some carefully selected 
controls were treated using a DNeasy blood and tissue kit (Qiagen) as per the manufacturer’s 
instructions to extract genomic DNA. The purity as well as the concentration of the purified 
DNA solution was then determined using a Nanodrop ND-1000 Spectrophotometer 
instrument (Thermo Scientific).  
The extracted DNA sample was then used for real time amplification following the 
guidelines listed below as reported by Alexander and colleagues (2004).  
A single reaction mix consisted of: 
• 2ng template DNA in a volume of 9µl H2O 
• 15µl of Brilliant II SYBR green Q-PCR Master Mix (Stratagene)  
• 3µl forward primer (Invitrogen) 
• 3µl reverse primer (Invitrogen) 
In our experiments we maintained the same final concentration for our forward and reverse 
primers as determined by Alexander and co-workers (2004), 0.4µM in the case of human 
SOD1G93A and 0.5µM for Il-2 (Alexander et al., 2004). For the primer sequences please refer 
to Table 4 (subsection 2.1.4).   
To ensure the validity of the results all samples were prepared in duplicates, and a no 
template control was also prepared for both human SOD1G93A and the mouse Il-2 primers in 
each set of experiment to confirm that the master mix in use was not contaminated with 
genomic DNA. 
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The Chromo4 Real Time PCR-Detector detection system (Bio-Rad) was employed for 
the Q-PCR and the assessment of the results. The following cycling conditions were used:  
• Initial activation of Sure Start Taq polymerase at 95°C for 10 minutes  
  40 cycles of 
• 95°C for 30 seconds 
• 60°C for 1 minute 
•  72°C for 30 seconds  
 The raw data generated from the plates for human SOD1G93A transgene and mouse Il-2 
gene were consequently collected, average CT values were calculated for each duplicate and 
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2.2.2. Gait Analysis  
Upon completion of the “SOD1G93A x DAOR199W” survival study, animals expressing 
the DAOR199W mutant transgene and their non-transgenic wild type littermates were recruited 
in a gait analysis study.  
The gait investigation was carried out using the DigiGait Imaging System (Mouse 
Specifics, Inc.). As described by Vincelette and collegues (2007), this an automated system 
equipped with transparent treadmill belt with a motorized but adjustable speed, and a video 
camera. The camera is located underneath the belt capturing the image of the ventral side of 
the animals automatically pixelating and vectorizing the ventral view of the mouse. The 
collected images are automatically analysed via the DigiGait software where the area for each 
individual paw is recorded in correspondence to its movement. A periodic wave curve is 
therefore generated displaying the advance and retreat of all four limbs in relation to the 
treadmill belt through each stride. The paw portions that are in contact with the belt are 
automatically recognized as the stance phase of a stride by the software and the paw portions 
not in contact with the treadmill belt are consequently identified as the swing phase of a stride 
(Vincelette et al., 2007). In addition, various other gait dynamics (i.e. over 40 parameters) are 
determined for each individual limb by the software that are extracted from the period of time 
spent in various portions of the walking phase, including paw area at peak stance, paw angle, 
brake, swing, stride length, and stepping frequency, some of which are described in Table 5. 
Prior to the study, a small pilot experiment was conducted using both male and female 
non-transgenic wild type littermates (n = 3 per sex) who have previously participated in the 
“SOD1G93A x DAOR199W” survival study. By carrying out this experiment we aimed to select 
a suitable and unified speed bearing in mind that gender, weight and age will affect overall 
gait performance of the animal. Thus by randomly selecting these non-transgenic wild type 
littermates from our survival study we aimed to account for these factors across all the 
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participating animal. To avoid any possible training affects and the possible consequent error 
in the interpretation of the final results, animals participating in the pilot study were not 
recruited in the final gait analysis. During the pilot investigation a range of various speeds 
were examined to determine an optimum speed under which animals of both sex could 
comfortably perform the walking task. The suitable treadmill speed was determined to be 
15cm/s, which was therefore employed for the gait study for both males and females. Each 
animal was monitored only once and for a maximum of 1 minute, where at least six complete 
strides were recorded.  
Upon completion of the study the data generated by the DigiGait software was 
transferred onto an Excel file, values for each parameter for the matching limbs were 
averaged and animals carrying the DAOR199W transgene were compared to their wild type 
littermates for each parameter. The data set was initially subjected to normality test, 
following which should the data successfully pass the normality test a two-tailed, unpaired t-
test statistical analysis was carried out on the data set. However if the data set did not pass the 
normality test, it was subjected to a Mann-Whitney test. The threshold for significance was 
set at (P ≤ 0.05) for all analyses. All statistical analyses were performed using Graphpad 
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Gait Index Measurement Unit Description 
Stride 
Seconds 
The sum of stance and swing duration 




The weight bearing portion of the stride 
in which the paw remains in contact with 
the belt. 
Swing 
Seconds The portion of the stride in which the paw is not in contact with the belt. 
Brake 
Seconds The time interval between initial and maximal paw contacts with the belt. 
Paw Angle 
Degree 
Angle of the paw during peak stance in 
relation to the long axis of the body. 
Paw Area at Peak Stance 
Cm2 
The maximal paw area in contact with 
the treadmill during the stance phase of 
the step cycle. 
Table 5.	  Definition of DigiGait parameters for a single limb.  
Descriptions of gait parameters used to evaluate changes in gait for the DAOR199W mutant males and 
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2.2.3. Spinal Cord Collection & Preparation  
Animals were deeply anaesthetized by intraperitoneal (IP) administration of 
pentobarbital (Merial, UK) overdose (approximately 120-150µl). Under terminal anesthesia 
the animals were subjected to transcardial perfusion with ice-cold PBS followed by ice-cold 
4% PFA (prepared in PBS, recipe available in section 2.1.6). Upon completion of the 
perfusion process, the spinal column was removed and post-fixed in 4% PFA at 4°C 
overnight. The spinal cord was then extracted from the spinal column and cryoprotected in 
30% sterilized sucrose solution (prepared in PBS, recipe available in section 2.1.6) at 4°C, a 
process that often requires a few days upon which the spinal cord sinks towards the bottom 
the container within the sucrose solution.  
The lumbar region of the spinal cord was then selectively dissected, and embedded in 
cubes of gelatin (recipe available in section 2.1.6) and mounted on a cork block held in place 
with cryo M-bed (Bright). This process involved, vertically mounting the spinal cord on the 
cork block with the most caudal end placed on the cork block. The specific place facing the 
ventral side of the spinal cord was marked on the cork to ease orientation of the block in the 
cryostat and ensure that the ventral side meets the knife first (Kaneb, 2012). The mounted 
spinal cord was then snap-frozen in cooled isopentane solution (Fisher Scientific) (-55°C, +/-
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2.2.4. Cryosectioning & Immunohistochemistry 
 All the immunohistochemistry procedures carried out throughout the duration of this 
thesis were for the purpose of demonstration only and were carried out on the spinal cord 
sections collected from all of our transgenic lines namely SOD1G93A, DAOR199W and DAOWT. 
Protocol used for the SOD1G93A transgenics, were initially optimized by Dr Hannah Kaneb 
(Kaneb, 2012).   
 All animals were maintained as described previously and were euthanized at the 
appropriate time point. The spinal cord was then collected and processed as described in the 
previous subsection (2.2.3), and cryosectioned from the L3-L5 of the lumbar spinal cord at 
20µm thickness. Sections from each individual spinal cord were collected in a serial manner 
and were mounted onto superfrost plus glass slides (VWR) at 300µm intervals (every 15th 
section) and stored at -20°C until further use (Kaneb, 2012). Sections were then 
immunostained for either choline acetyltransferase (ChAT), D-amino acid oxidase (DAO) or 
ubiquitin (Ub) (for full details of dilutions please refer to Tables 1 and 2, section 2.1.3).  
 Prior to incubation with the primary antibodies, slides were air dried at room 
temperature for approximately 30 minutes, followed by blocking of the endogenous biotin 
using the Avidin/Biotin Blocking kit (Vector Laboratories, UK). However, in the case of the 
DAO antigen, sections were initially permeablised by incubation in 0.2% Triton X-100 
prepared in PBS for 30 minutes followed by the Avidin/Biotin blocking step. Sections were 
then blocked for 30 minutes in 5% non-fat dried milk solution (Marvel) prepared in 
PBS/Tween-20 (0.05%), to minimize non-specific binding of the primary antibody. This was 
then followed by 1 hour incubation with the appropriate primary antibody, and the 
consequent 30 minutes incubation with the appropriate biotinylated secondary antibody 
(dilutions are listed in Tables 1 and 2, section 2.1.3). Immunoreactivity of the sections were 
determined by using the peroxidase detection system, Vectastain ABC kit (Vector 
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Laboratories, UK) and SIGMAFAST 3,3′-Diaminobenzidine tablets (Sigma). Upon 
immunodetection, slides were subjected to Nissl counter-staining for 10 minutes (recipe 
available in section 2.1.6). This was then followed by a brief wash in distilled water, 
dehydration via graded alcohol, two 1 hour long incubations in xylene (Fisher Scientific), and 
DPX (VWR) coverslipping.  
 In order to minimize variability between the results, sections from various animals that 
were due to be stained for the same antigen were treated in the same session at the same time. 
This way we ensured that sections from any animal that was to be subjected to direct 
comparisons were treated identically. In addition, relevant positive and negative controls 
were also included at all times in all the staining procedures to ensure the validity of the 
results being produced. 	  
 All results generated from the immunohistochemistry studies were assessed by using an 
upright bright field microscope (Leica) and localisation of the motor neurons within the 
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2.2.5. Western Blot Analysis 
Samples from three different experiments were analysed by western blot throughout 
the duration of this thesis, we aimed to reconfirm the expression of the DAO protein triggered 
by the presence of either DAOR199W or DAOWT transgenes. We also analysed samples from in 
vivo and in vitro studies where we monitored the expression of our IGF-I chimeric expression 
plasmids. However, due to the small size of the proteins in question, the overall techniques 
employed for western blot analysis were highly similar, and thus where different settings 
have been applied they are clearly highlighted throughout the following subsection.  
Samples collected from the in vivo and in vitro experiments were processed 
differently upon collection as reported below.  
All animal tissues were collected post-mortem following cervical dislocation, snap-
frozen in liquid nitrogen and stored at -80°C. Tissues were then weighed and grounded in the 
presence of liquid nitrogen using a pestle and mortar, and incubated on ice for 30 minutes in 
chilled RIPA/Protease inhibitors (Roche) solution (RIPA recipe available in section 2.1.6). 
The mixtures were centrifuged at 4°C for 15 minutes at 15,000rpm, upon completion the 
supernatants were removed and subjected to protein quantification using the BCA protein 
assay kit (Thermo Scientific). Samples were therefore prepared and processed per 
manufacturer’s protocol and the final concentration was determined using a Nanodrop ND-
1000 Spectrophotometer (Thermo Scientific) instrument. At the time of IGF-I in vivo 
experiment however, due to lack of an efficient protein assay system we aimed to 
demonstrate equal loading by using a loading control system where we probed all blots for 
beta-tubulin. Thus for these particular experimental groups, samples were subjected to 
western blot analysis immediately after collection of the supernatant.    
For the in vitro experiments both media and cells were subjected to western blot 
analysis. Upon complete removal of media, cells were incubated with 500µl of 
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RIPA/Protease inhibitors solution for 5 minutes, scraped off and collected into separate tubes. 
Samples were then incubated on ice for 15 minutes, centrifuged at 4°C for 15 minutes at 
15,000rpm, after which the resultant supernatant was removed and subjected to western blot 
analysis. Given that our purpose for the cell culture experiments was to only demonstrate the 
expression of IGF-I protein in vitro we decided a protein assay was not worthwhile, as it 
would not have yielded any extra information towards the final results.  
Following protein extraction, appropriate amounts of protein were prepared (100µg in 
the case of DAO) or in the absence of information on the concentrations of the proteins in the 
samples equal volumes of the samples were prepared (15µl, in the case of IGF-I muscle 
samples and cell culture experiments). Sample preparation involved the appropriate volume 
of the samples mixed with NuPAGE LDS loading dye (Life Technologies) and 2% β-
mercaptoethanol (Sigma), followed by denaturation via boiling at 100°C for 3 minutes and 
loading in the NuPAGE Novex 4-12% Bis-Tris (Life Technologies) precast gels.  
For the purpose of detection and in order to monitor the binding affinity of our 
antibodies (both primary and secondary) to our protein of interest, a known positive control 
was used in every single gel set. The optimal concentration of the positive control in use was 
determined through a dot blot procedure (full details in the next subsection 2.2.6), where we 
aimed to select the best dilution that would emit a reasonably strong signal at various 
exposure time intervals. Thus, the selected concentration for the recombinant murine IGF-I 
pure protein (PeproTech) was determined to be 6ng and the optimal concentration for the 
DAO protein, from porcine kidney (Sigma) was 100ng. Two sets of molecular weight 
markers were used, given the very small molecular weight of the IGF-I pure protein (7.6kDa) 
an ultra low molecular weight marker Color Marker Ultra-low Range (Sigma) was used 
which ranged from 1.060-26.600kDa, and a standard high molecular weight marker 
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PageRuler Prestained Protein Ladder 10-179kDa (Thermo Scientific) was used for 
experiments involving the DAO protein (39.4kDa).     
Upon loading, all gels were run in NuPAGE MES SDS running buffer (Life 
Technologies) (1x) at 200V for approximately 1 hour and the process was terminated upon 
full expansion of the molecular weight marker. Proteins were then transferred from the gel 
onto PVDF membrane (Millipore) with particularly small pore sizes (0.2µm) suitable for 
small proteins. Prior to transferring the membrane was activated by soaking in methanol 
(AnalaR) for 1 minute and rinsed in chilled transfer buffer. The transfer procedure was 
carried out by preparing a transfer sandwich consisting of two layers of sponge and mini 
trans-blot filter papers (Bio-Rad) encasing the gel and the membrane, held together in a 
transfer cassette. Proteins were then transferred for 1 hour at a constant current of 30V and 
80V, for IGF-I and DAO proteins respectively. The PVDF membrane was then air dried and 
the successful transfer of the proteins onto the membrane was confirmed by sequential 
treatment of the membrane with the following solutions, methanol (AnalaR) to re-activate the 
membrane, amido black staining solution to identify the presence of the protein products, 
distilled water to wash off the excess amido black solutions, amido black de-staining solution 
to remove the remainder of the stains, and TBS/T (0.05% Tween) to remove any excess de-
staining solution and preparing the membrane for probing.  
Upon confirmations of the successful protein transfer non-specific binding of the 
primary antibody was minimised by blocking the membrane in 5% milk solution prepared in 
TBS/T (0.05% Tween), followed by 1 hour incubation with the appropriate primary and 
secondary antibody respectively (both antibodies were prepared in TBS/T (0.05% Tween)) at 
room temperature (for details on the concentration of antibodies refer to Table 1 and 2, 
subsection 2.1.3). The excess antibody solution was rinsed off by washing the membrane in 
TBS/T upon completion of each antibody incubation step and the final wash was followed by 
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1 minute (for DAO protein) and 30 seconds (for IGF-I protein) incubation with ECL prime 
(GE Healthcare). The signals were then captured onto Amersham Hyperfilm ECL (GE 
Healthcare) and developed by Compact X4 Automatic X-ray film processor (X-OGRAPH 
Imaging Systems). 
All the western blot analyses carried out throughout the duration of this thesis were 
for the purpose of confirming the expression of the protein of interest. With the exception of 
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2.2.5.1. Quantification of the DAOWT via western blot analysis 
Considering the encouraging results obtained from the DAOWT study, we aimed to 
quantify the fold increase of this protein in the spinal cord of our transgenic animals in 
comparison to their non-transgenic wild type littermate. Thus, in a preliminary experiment 
the fold increase of the DAOWT protein in the spinal cord was quantified using western blot 
analysis employing both DAOWT transgenics (n = 3, 2 males and 1 female) and non-
transgenic wild type littermates (n = 3, 2 males and 1 female).  
As described in the previous section following protein transfer onto the PVDF 
membranes, all membranes were stained in amido black to ensure success of the protein 
transferring process onto the membrane as well as approximately demonstrating equal protein 
loading amongst lanes. This was followed by blocking the membrane for 1 hour in 5% milk 
probing the PVDF membrane with the anti D-amino acid oxidase polyclonal primary 
antibody (Nordic Immunology) and Goat anti-rabbit IgG (H+L)-HRP (Bio-rad) secondary 
antibody (both antibodies were prepared in TBS/T (0.05% Tween), (for details on the 
concentration of antibodies refer to Table 1 and 2, subsection 2.1.3). Signals were then 
developed using ECL prime (GE Healthcare). The membrane was then washed in TBS/T 
(0.05% Tween), stripped at 60°C for 30 minutes (stripping solution’s recipe available in 
section 2.1.6), washed in TBS/T (0.05% Tween) (twice, 10 minutes each time), blocked for 1 
hour in 5% milk and re-probed for endogenous beta-tubulin loading control (Abcam, for full 
details of the dilutions please refer to Tables 1 and 2, subsection 2.1.3). The signals were then 
developed using ECL prime reagents.  
Analyses of the bands were carried out using ImageJ64 software where bands were 
analysed and quantified based on their intensities. First the intensity of the bands from the 
DAOWT blot were measured for each individual sample, followed by measurement of the 
band intensity for endogenous beta-tubulin in each corresponding lane. Each value from the 
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DAOWT blot was then normalized against beta-tubulin loading control, by dividing the 
DAOWT values by the corresponding value generated from the beta-tubulin. The approximate 
change in DAOWT protein fold in the transgenic animals was then calculated through division 
of the average value for this group by the average value obtained for the non-transgenic wild 
type control group.  
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2.2.6. Dot Blot 
Dot blots were carried out for determining the optimum concentration of the pure 
proteins required as positive controls in the western blot process.  
The protocol was obtained from Abcam and the procedure was as follow, a 
nitrocellulose membrane (Sigma) was marked with small circles using a pencil to indicate the 
region being targeted with various concentrations of the pure protein. A selection of dilutions 
were prepared, using the pure protein sample in question and PBS as the diluent. 2µl of each 
sample was slowly pipetted onto the nitrocellulose membrane at the centre of each circle, and 
upon completion the membrane was allowed to air dry. 
Non-specific binding of the primary antibody was minimised by blocking the 
membrane in 5% milk solution prepared in TBS/T (0.05% Tween), followed by 1 hour 
incubation with the appropriate primary and secondary antibody (both antibodies were 
prepared in TBS/T) at room temperature (for details on the concentration of antibodies refer 
to Tables 1 and 2, subsection 2.1.3). The excess antibody solution was rinsed off by washing 
the membrane in TBS/T (0.05% Tween) upon completion of each antibody incubation step 
and the final wash was followed by 1 minute incubation with ECL prime (GE Healthcare). 
The signals were then developed using Amersham Hyperfilm ECL (GE Healthcare) and 
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2.2.7. Igf-I Cloning 
2.2.7.1. Murine Igf-I 
Messenger RNA for the Igf-IA isoform was obtained from tibialis anterior (TA) 
muscles of female mice (C57BL6×CBA/Ca mice). After cervical dislocation muscles were 
snap-frozen in liquid nitrogen and stored at -80°C until further processing. Due to naturally 
low levels of the Igf-IB (Mgf) isoform in the muscle tissue, we stimulated the muscle tissue 
with a myotoxic agent, Barium Chloride (BaCl2) (Sigma), to induce injury and consequently 
increase the yield of Mgf mRNA in the regenerating muscle. In a procedure that was carried 
out by professor Dominic Wells, female mice (C57BL6×CBA/Ca mice) were deeply 
anaesthetised by IP administration of hypnorm/hypnovel (Vetapharma/Roche) prepared in 
injection grade water (1:1:2 by volume) at a dosage of 9ml/kg. Under anaesthesia animals 
received 25µl of BaCl2 agent at the concentration of 1.2% (prepared in saline solution) into 
their TA muscle. Animals were then euthanized via cervical dislocation and the treated TA 
muscles were collected at 1 day time intervals, with last sample being collected 4 days after 
injection, upon collection tissues were snap-frozen in liquid nitrogen and stored at -80°C. 
Frozen muscles were weighed and grounded in the presence of liquid nitrogen using a 
pestle and RNA was extracted using RNA-Bee (Amsbio) (more details available in 
subsection 2.2.10 of this chapter). The extracted RNA was measured for its purity and 
concentration using a Nanodrop ND-1000 Spectrophotometer instrument (Thermo Scientific) 
and was consequently converted to complementary DNA (cDNA) using the Transcriptor First 
Strand cDNA Synthesis Kit (Roche) following the manufacturer’s recommendations. The 
presence of the cDNA was confirmed by screening for a housekeeping gene, Il-2 using PCR 
(protocol available in subsection 2.2.12). The cDNA was then used to amplify two murine 
Igf-I isoforms namely Igf-IA and Mgf (PCR protocol available in subsection 2.2.13).  
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Since the molecular size of the two isoforms were highly similar (Igf-IA: 713bp and 
Mgf: 765bp in size), the amplified Igf-I products were separated on a 3% agarose gel 
overnight at a constant current (30V) via gel electrophoresis. The isoforms were identified by 
their molecular size and purified using the QIAquick Gel Extraction Kit (Qiagen) following 
the manufacturer’s instructions. To ensure a high yield of both Igf-I isoforms, each purified 
isoform was subjected to second round of amplification using a reduced number of cycles (15 
cycles). The presence of the PCR product and absence of contamination from the adjacent 
bands (i.e. the second isoform) was verified by gel electrophoresis, following which bands 
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2.2.7.2. TOPO Cloning Vector 
The amplified Igf-I isoforms were sub-cloned into a TOPO TA vector (pCR2.1-TOPO 
TA Vector, Invitrogen), according to manufacturer’s instructions. Ligated products were 
transformed into 10-beta Competent E. coli (NEB, UK) following the manufacturer’s 
guidelines and plated onto agar plates supplemented with 50µg/µl of Kanamycin antibiotic 
(Sigma) and incubated overnight at 37°C. Upon overnight incubation, colonies were picked 
and screened for the positive transformation of the isoform of interest, using a colony 
screening PCR technique (described in detail in subsection 2.2.11). Colonies identified as 
positively transformed for the gene of interest were further cultured in 5ml of Lysogeny broth 
(LB Miller) overnight at 37°C with vigorous agitation. The next day plasmids were extracted 
and purified using QIAprep Spin Miniprep Kit (Qiagen) in accordance with the 
manufacturer’s protocol. Plasmids were sequenced (sequencing conducted by GATC 
Biotech) and results were compared to a reference sequence obtained from the NCBI (Igf-IA 









	   99 
2.2.7.3. pCAGGs/Igf-I Plasmid Construct 
The TOPO plasmids bearing the gene of interest (either Igf-IA or Mgf) and the host 
expression vector, pCAGGS (Niwa et al., 1991) were subjected to restriction digestions using 
the enzyme EcoRI (NEB, UK). To reduce self-ligation, the pCAGGS plasmid was treated 
with Antarctic phosphatase (NEB, UK), which removed the phosphate groups from the 5’ end 
of the plasmid vector. Both the gene of interest and the plasmid vector were thereafter 
purified using QIAquick PCR Purification Kit (Qiagen). A ligation reaction was prepared 
with the aim of inserting the gene of interest (Igf-IA or Mgf) into the pCAGGS expression 
vector using DNA ligase (NEB, UK). In addition to the experimental groups, two control 
reactions were also prepared, including an open expression vector which was treated with 
Antarctic phosphatase (NEB, UK) enzyme and DNA ligase (NEB, UK), lacking the insert 
fragment, to assess self-ligation. The second control reaction contained the digested-
phosphatase treated plasmid (pCAGGS) and insert, however no DNA ligase was used to 
monitor the presence of any undigested plasmids. Ligation products were then transformed 
into 10-beta Competent E. coli cells (NEB, UK) according to the manufacturer’s instructions. 
Transformed cells were plated onto agar plates supplemented with 50µg/µl of Ampicillin 
antibiotics (Sigma) overnight at 37°C. After overnight incubation, colonies were picked and 
further incubated in 5ml of LB Miller media overnight at 37°C with vigorous agitation. After 
overnight incubation, the plasmids were extracted and purified using QIAprep Spin Miniprep 
kit (Qiagen).  
The presence of the fragment of interest within the plasmid vector was confirmed by 
EcoRI (NEB, UK) restriction digestion where the fragments generated from the digestion 
process were visualised on 1% agarose gel via gel electrophoresis. Upon confirming correct 
insertion of the Igf-IA and Mgf fragments, large preparations of endotoxin free pCAGG-Igf-
IA and pCAGG-Mgf plasmids were prepared using the Endofree Plasmid Giga Kit (Qiagen) 
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following the manufacturer’s instructions. The resultant purified plasmid was subsequently 
diluted in injection grade water, its concentration and purity was determined using a 
Nanodrop ND-1000 Spectrophotometer instrument (Thermo Scientific) and stored at -20°C. 
The identities of the chimeric plasmid vectors (pCAGGS/Igf-IA and pCAGGS/Mgf) were 
further confirmed through sequencing conducted by GATC Biotech, the sequenced products 
were compared to a reference sequence available on NCBI (Igf-IA accession number: 
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2.2.8. Transfection of Cell Lines 
This experiment made use of two different cell lines, the mouse Neuroblastoma 
(Neuro2A) and immortomouse myoblasts (H2K 2B4) cell lines. 
Neuro2A cells were maintained in DMEM media (Life Technologies) combined with 
1% non-essential amino acids (Invitrogen), 10% fetal bovine serum (Invitrogen) and 1% 
penicillin-streptomycin antibiotics (Sigma) at 37°C with 5% CO2. Cells were seeded in 6 well 
plates (Thermo Scientific) at the density of 2.5x105 per well, 24 hours prior to transfection. 
The transfection experiment was carried out on the following day using the Lipofectamine 
LTX reagent kit (Invitrogen) according to the manufacturer’s protocol, where the 
Lipofectamine/plasmid complex was prepared at the ratio of 10:1 and thus a total of 1.25µg 
plasmid DNA was used per well. Transfection efficiency was assessed via visualization of 
GFP transfected cells 24 hours post-transfection using an inverted wide field microscope 
(Leica) and upon transfection confirmation both cells and media were collected for the 
analysis of transgenes expression via western blot. 
H2K 2B4 cells were maintained in Matrigel coated flasks to encourage adhesion. 
Matrigel was diluted in DMEM at a concentration of 0.1mg/ml, nunc EasYFlasks (Thermo 
Scientific) were then coated with a thin layer and incubated for 30 minutes at 37°C, after 
which excess Matrigel was removed and cells were seeded. H2K 2B4 cells were cultured in 
differentiation DMEM media consisting of 5% horse serum (PAA Laboratories), 2% L-
Glutamine (Invitrogen) and 1% penicillin-streptomycin (Sigma). Transfection of this 
particular cell line was carried out via the Nucleofection technique, where 5×105 H2K 2B4 
cells were resuspended in 100µl of Amaxa solution V (Lonza). The plasmid DNA was then 
added to the mixture at the concentration of 2µg, and the cell suspensions were nucleofected 
using programme B-032 on the Nucleofector II machine (Lonza). Treated cells were plated in 
6 wells plates (pre-coated in 0.1 mg/ml Matrigel) where each well was seeded with 5×105 of 
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transfected cells, and plates were incubated at 37°C with 5% CO2. Cells were allowed to 
differentiate into myotubes for 3 days during which time cells were not provided with fresh 
medium in order to minimise disturbance and encourage the formation of myotubes (Muses 
et al., 2011). Transfection efficiency was assessed via visualization of GFP transfected cells 
24 hours post-transfection using an inverted wide field microscope (Leica) and upon 
completion of the three days incubation period cells were harvested and analysed for 
transgenes expression via western blot. 
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2.2.9. Electroporation Procedure 
The following procedures were performed by professor Dominic Wells. 
Animals (C57BL6×CBA/Ca mice) were deeply anaesthetised by IP administration of 
hypnorm/hypnovel (Vetapharma/Roche) prepared in injection water (1:1:2 by volume) at a 
dosage of 9 ml/kg. Both hindlimbs were shaved and 2 hours prior to the electroporation 
procedure, all muscle types to be subjected to electroporation were injected with a total of 
125ml of hyaluronidase (Sigma) (25µl into TA, and 100µl into quadriceps and gastrocnemius 
(50µl per muscle), to break down hyaluronan in the extracellular matrix and thus making the 
muscle fibers more accessible for the plasmid molecules to be injected (Ferrer et al., 2004). 
Following injection the recipients were placed at 37°C in a warm chamber for 2 hours.  
Upon completion of the 2 hours period, animals were briefly exposed to 5% 
Isoflorane in a gas chamber and upon losing consciousness were placed on a thermo pad to 
maintain their body temperature and positioned under a mask with constant flow of 
Isoflurane, and the unconsciousness state was maintained at 3% Isoflurane flow rate. Under 
deep anesthetic state the selected muscle groups were injected with the total amount of 125ml 
of either pCAGG/Igf-IA, pCAGG/Mgf, or pCAGGS naked plasmid at the concentration of 
1µg/µl (TA 25µl, quadriceps and gastrocnemius 50µl each). Upon each individual injection 
the treated muscle was subjected to electroporation, where the BTX Tweezertrodes (Kramel 
Biotech) were covered with Electroconductive cream for ECG & EEG (Eurocamina), 
electrodes were placed on either side of the treated muscle and the muscle was electroporated 
at 175V/cm in ten 20-ms2 wave pulses at 1Hz using a BTX ECM830 (Kramel Biotech) as 
previously described (Ferrer et al., 2004). Post-treatment all animals were placed in a warm 
chamber at 37°C to recover from the anaesthetic, and upon regaining complete consciousness 
and full recovery animals were transferred into their home cages.  
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The treated animals were euthanized via cervical dislocation 2 weeks post-treatment 
and the treated muscles were collected, snap frozen and processed for western blot analysis as 
described previously.  
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2.2.10. RNA Extraction  
Frozen muscle tissue was grounded into powder in the presence of liquid nitrogen 
using a pestle and mortar. 1ml RNA-Bee (Amsbio) was added per 50mg of tissue and 
samples were centrifuged for 10 minutes at 12,000rpm, at 4°C. The supernatant was then 
thoroughly mixed with chloroform (Fisher Scientific) (0.2ml per 1ml of RNA-Bee), followed 
by 5 minute incubation on ice and centrifugation at 4°C for 15 minutes at 12,000rpm. 
The aqueous phase was added to 0.5ml of isopropanol (AnalaR), incubated at room 
temperature for 10 minutes and centrifuged at 4°C for 5 minutes at 1,200rpm. The pellet was 
washed in 75% ethanol (Fisher Scientific) by vortexing before centrifuging at 7,500rpm for 
10 minutes at 4°C. The pellet was consequently air dried at room temperature, dissolved in 
dimethyl procarbonate (DMPC, Sigma) treated water at 60°C for 10 minutes. The final 
concentration of the RNA was determined by using a Nanodrop ND-1000 Spectrophotometer 
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2.2.11. Colony Screening by Polymerase Chain Reaction 
The PCR reaction mixture was prepared using the protocol in subsection 2.2.13. 
Colonies were picked using a fresh sterilised toothpick and dipped into allocated tubes 
containing the PCR mixture, and the toothpick contaminated with the bacterial colony was 
subsequently streaked onto a fresh agar plate. For the purpose of identification at a later stage 
of the protocol a number was allocated to each colony, and the process was carried out for 
maximum of 60 colonies. The agar plate was incubated at 37°C for 6-8 hours and the PCR 
mix were subjected to amplification followed by running the amplified products on a 1% 
agarose gel.  
Thus, following PCR, colonies screened positive for the transgene of interest were 
picked from the incubated plate and further incubated in 5ml of LB Miller medium overnight 
at 37°C with vigorous agitation. After overnight incubation, the plasmid was extracted and 












	   107 
2.2.12. Il-2 Polymerase Chain Reaction  
Reaction mixture for one single reaction consisted of:  
• 9.35µl PCR-grade water 
• 2µl (10x) PCR buffer Mg free 
• 2µl PCR Enhancer  
• 0.8µl 2.5mM dNTPs 
• 2µl (10 pmol/µl) Forward Primer  
• 2µl (10 pmol/µl) Reverse Primer 
• 0.6µl (50mM) MgCl2  
• 0.25µl Taq DNA Polymerase, recombinant 
• 1µl DNA template (digested ear sample) 
Primer sequences for the amplification of Il-2 gene 
• Forward Primer: 5’-CTAGGCCACAGAATTGAAAGATCT-3’ 
• Reverse Primer: 5’-GTAGGTGGAAATTCTAGCATCATCC-3’ 
PCR Cycling Conditions 
• Pre-heat lid to 105oC 
• Initial denaturation at 95oC for 3 minutes 
       35 cycles of 
• 95°C for 30 seconds 
• 60°C for 30 seconds 
• 72°C for 45 seconds 
• 72°C for 2 minutes 
• Final hold 4°C 
 
The PCR process amplifies a 324 base pair (bp) fragment from the mouse Il-2 gene 
(Alexander et al., 2004).  
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2.2.13. Igf-I Polymerase Chain Reaction 
Reaction mixture for one single reaction consisted of:  
• 22.13µl PCR-grade water   
• 5µl (10x) PCR buffer    
• 5µl Enhancer     
• 5µl (10 pmol/µl) Forward primers     
• 5µl (10 pmol/µl) Reverse primers   
• 2µl (2.5mM) dNTPs     
• 1.25µl (1.5 mM) MgCl2     
• 0.62µl Taq Polymerase   
• 4µl DNA template (cDNA)   
Primer sequences for the amplification of IGF-I gene 
• Forward Primer: 5’-GCTCTAACATCTCCCATCTCTCTGG-3’ 
• Reverse Primer: 5’-GGGAAATGCCCATCTTTGTAATG-3’ 
CR Cycling Conditions  
• Pre-heat lid to 105oC 
• Initial denaturation at 95oC for 2 minutes 
       35 cycles of 
• 95°C for 30 seconds 
• 56°C for 30 seconds  
• 72°C for 1 minute 
• 72°C for 7 minutes 
• Final hold 4°C 
 
The PCR process amplifies two fragments with the sizes of 713bp (Igf-IA) and 765bp (MGF) 
from the mouse Igf-I gene
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2.2.14. Statistical Tests & Software  
A variety of statistical tests and mathematical evaluations were used as noted 
throughout the appropriate sections. Tests employed for each individual experiment as well 
as the software that was used for each test are listed below. 
• Survival studies: Kaplan-Meier survival analyses and log-rank test (Graphpad Prism 
6) 
• Body weight & neurological score analysis: group mean (Excel) 
• Variation in SOD1G93A transgene copy number: ΔCT calculations (Excel) 
• Gait analysis: normality test, two tailed unpaired t-test, Man-Whitney test (Graphpad 
Prism 6)  
• Protein quantification: measurement of band intensity and calculation of fold increase 
(ImageJ64 and Excel respectively)  
In the case of statistical analysis significance was taken at P ≤ 0.05.  
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3.0 Animal Models  
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3.1. Introduction 
Amyotrophic lateral sclerosis (ALS) has been classified as the third most common 
neurodegenerative disorder in the western world, with the majority of cases (approximately 
95%) occurring at random throughout the population and therefore regarded as sporadic ALS 
(SALS) (Byrne et al., 2011). The remaining ALS patients develop the hereditary form of the 
disease known as familial ALS (FALS) (Cozzolino et al., 2008, Robberecht and Philips, 
2013). Following the discovery of various mutations leading to the ALS phenotype in 
humans, animal models were developed to facilitate further investigation of this disorder and 
to provide insights into the underlying molecular mechanisms causing ALS.  
One well-characterised animal model that has been used extensively in ALS research 
is the high copy number SOD1G93A transgenic mouse. This transgenic mouse model carries 
approximately 25 copies of the human SOD1G93A transgene that bears a missense mutation 
encoding amino acid Alanine instead of Glycine (G→A) at position 93. Currently it 
represents the best available animal model for studying ALS, as it develops severe motor 
neuron (MN) degeneration, closely resembling the human disease (Gurney et al., 1994, 
McGoldrick et al., 2013).  
By about 30 days of age, the animal develops aggregation of mutant SOD1 protein in muscles 
and motor neurons as well as mitochondrial abnormalities in various tissues (Gurney et al., 
1994, Johnston et al., 2000, Higgins et al., 2003, Turner et al., 2003). Aging in these animals 
is associated with denervation of neuromuscular junctions (NMJs), astrogliosis and 
progressive loss of motor units at the cellular level (Levine et al., 1999, Frey et al., 2000, 
Fischer et al., 2004, Nguyen et al., 2012). These sequence of events at the cellular level 
consequently lead to development of ALS-like symptoms which become evident at 
approximately 90 days of age, presenting as weakness and fine tremor in the hindlimbs. As 
the disease progresses, symptoms progressively worsen and due to the loss of a great number 
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of motor neurons in the spinal cord, the animal experiences severe paralysis which is 
followed by death at approximately 130 days of age (Gurney et al., 1994, Frey et al., 2000, 
Fischer et al., 2004, Nguyen et al., 2012).  
Following the recent discovery of the R199W mutation in the DAO gene leading to 
ALS phenotype in humans (Mitchell et al., 2010), two new lines of transgenic mice were 
developed in a collaboration between the Wells and de Belleroche groups. The newly 
developed transgenic lines were either heterozygous for overexpressing the mutant form of 
the human DAO gene (R199W) and were therefore called DAOR199W, or overexpressing the 
wild type form of the human DAO protein and were thus referred to as DAOWT (unpublished 
data). While some cellular abnormalities were already confirmed in the newly developed 
DAOR199W transgenic animal (as described in Chapter 1. Introduction, subsection 1.7.1), little 
was known about the possible clinical phenotype overexpression of the mutant and the wild 
type DAO protein might induce. Hence, a part of this thesis has been dedicated to investigate 
the effect of overexpression of DAOR199W and DAOWT transgenes on a wild type background 
in two longitudinal large cohort survival studies, where the animals were closely monitored 
for their overall body weight in combination with a neurological scoring system (Scott et al., 
2008, Ludolph et al., 2010).  
Bearing in mind that the high copy number SOD1G93A mouse is the most well-known 
and the best characterised animal model currently available for the study of ALS, the 
following Chapter also demonstrates some very well-established characteristics of this 
particular transgenic line, aiming to draw a comparison between our own lines of transgenic 
models and the SOD1G93A. The following Chapter therefore aims not only to summarise the 
characteristics of the three transgenic lines recruited throughout this thesis but also to build a 
background picture of these particular models together with initial experiments that underpin 
the subsequent experimental Chapters. 
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3.2. Results 
All techniques and the materials employed in the following Chapter have been 
explained in detail in Chapter 2. Materials and Methods.  
In order to paint a clear picture, the following experimental Chapter represents data 
gained throughout the duration of this thesis in combination with some data obtained by my 
colleagues in our laboratory as well as some materials from the literature.  
It is noteworthy that all the animal models discussed in the following Chapter have 
been fully characterized, either in the literature (in the case of the high copy number 
SOD1G93A), or in the de Belleroche’s laboratory in the case of DAO transgenic lines. 
However, since the latter data is unpublished, we deemed it was necessary to include these 
data in the appropriate sections in order to build a solid background for the upcoming 
Chapters. Hence, small n numbers have been used as all the listed findings have already been 
established elsewhere and thus our pure purpose was to demonstrate the already existing data. 
The exact n number for each experimental setting is stated in the relevant figure legend, and 
where figures are representatives of previously established data, clear statements are made 
under the legend indicating the exact n numbers employed in the initial experiment.   
Additionally a mixture of male and female has been employed in the upcoming subsection, as 
we did not expect any gender differences in terms of gene expression. This a based on the 
findings by Anagnostou and colleagues, where analysing the expression of a selection of 
genes associated with FALS revealed no significant gender differences in human spinal cord 
samples (n = 19 controls and n = 39 ALS cases) (Anagnostou et al., 2010).     
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3.2.1 High Copy Number SOD1G93A Mouse Model  
The high copy number SOD1G93A mouse model bears approximately 23-25 copies of 
the human mutant SOD1G93A transgene and is considered the standard model for FALS and 
ALS therapeutic studies (Gurney et al., 1994, Scott et al., 2008). They display distinct 
features related to ALS, which has made them very popular in ALS research over the years. 
Due to the wide use of this animal model in ALS research they are very well characterised 
both in terms of cellular characteristics and development of ALS-like symptoms and survival. 
Thus, in the following subsection we aimed to only demonstrate some of the key 
characteristics of these animals.     
Although the animal appears asymptomatic early in its lifespan, as the disease 
progresses the animal suffers from progressive and ultimately severe paralysis, at which stage 
the symptoms of the disease are highly apparent in comparison to a non-transgenic wild type 
animal of the same age. These symptomatic features are shown in Figure 1.  
Examining the left panel in Figure 1 displays the symptomatic animal versus an aged 
matched non-transgenic wild type at a stationary position. Due to severe motor neuron 
degeneration the SOD1G93A animal shows clear muscle wasting and atrophy in comparison to 
the non-transgenic wild type mouse on the top. In addition, as a result of excessive muscle 
loss the body shape of the affected animal has changed which resulted in a very visible 
kyphosis (arched back). The animal bearing the SOD1G93A transgene also displays a coarse 
coat, which is absent in the non-transgenic wild type.  
Studying the non-transgenic wild type panel on the right demonstrates that upon tail 
suspension a healthy non-transgenic wild type mouse is able to stretch out its hindlimbs in a 
straight line away from the lateral midline, with its paws spread out. However, the panel on 
the right of this picture shows a SOD1G93A mouse suffering from severe paralysis where the 
hindlimbs appeared curled up and display a full collapse towards the midline.  
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At the pre-symptomatic stages of the disease, animals carrying the mutant transgene 
display similar phenotypes to the non-transgenic wild type animals. However as the disease 
progresses, the hindlimbs weaken and gradually bend which is then followed by a full 
collapse towards the lateral midline and the animal is estimated to be reaching the end stage 
of the disease. Examining the paws in both pictures displaying the SOD1G93A further indicate 
that due to paralysis the animal is unable to maintain the normal position of the digits, hence 
the paws appear abnormal and are not widely spread as seen in the non-transgenic wild type 
animals. 
Furthermore, both pictures illustrate that the SOD1G93A animals are considerably 
thinner along their flanks in comparison to the non-transgenic wild type animals. 
As the paralysis worsens and the disease progresses, the animal is regarded to have 
reached the end stage at approximately 130 days of age, determined by its inability to right 


















Figure 1.	  Phenotypic characteristics of SOD1G93A mouse model versus the non-transgenic 
wild type.	  
Figure represents typical phenotypic characteristics of a SOD1G93A mouse model at a symptomatic 
stage. 
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3.2.1.1. ChAT Immunohistochemistry  
Malfunctioning of the cholinergic system has been established as a common feature of 
ALS. Choline acetyltransferase (ChAT) is an enzyme that transfers an acetyl group from 
acetyl coenzyme A to choline, forming acetylcholine (ACh) at the synaptic endings of 
cholinergic neurons (such as motor neurons), and it is known to be highly specific in 
monitoring the functional state of the cholinergic neurons in the central and peripheral 
nervous systems (Casas et al., 2013).  
In order to display disease progression and the consequent loss of motor neurons 
throughout the course of the disease for the next two subsections of this experimental 
Chapter, comparisons have been drawn between different ages using high copy number 
SOD1G93A transgenic animals versus their non-transgenic wild type littermates. For this 
purpose based on the evidence provided by the body of literature and the data that has been 
collected in our own laboratory over the past few years, 4 different ages were selected for the 
SOD1G93A mice to demonstrate disease progression. The selected ages include 30 days, when 
the animals are pre-symptomatic and no physical changes are observed; 70 days, the animals 
are still pre-symptomatic at this age, but abnormal changes has been observed at the cellular 
level; 90 days, this is regarded as the symptomatic age as the clinical phenotypes of the 
disease become apparent at this age; and 110 days, a point in the disease course where the 
ALS symptoms worsen, severe paralysis is developed and the animals are very close to the 
end stage (Gurney et al., 1994, Fischer et al., 2004, Kaneb, 2012). While the majority of the 
animals carrying the SOD1G93A transgene survive beyond the latter time point, we selected 
this particular age as our final time point, as various studies indicate that the pathological 
changes at the cellular level were increasingly apparent and highly similar to those of the 
animals at the end stage (Fischer et al., 2004). Also because strict rules are enforced in our 
animal unit that does not allow SOD1G93A animals that are not participating in a survival 
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study to live beyond this age, in order to minimise suffering and discomfort for the animal. 
All the animals, including the SOD1G93A as well as the non-transgenic wild type mice 
employed in this part of the investigation were aged matched littermates.  
In the murine SOD1G93A model of ALS the motor neurons within the lumber region of 
the spinal cord are mainly affected, and thus we examined sections between the L3-L5 of the 
spinal cord at all selected ages (30, 70, 90 and 110 days) in the SOD1G93A mice and their aged 
matched non-transgenic wild type littermates.  
In addition, choline acetyletransferase (ChAT) has been established as the most 
specific marker for assessing the functional state of cholinergic neurons (Casas et al., 2013). 
For this reason we employed a ChAT/Nissl counter stain to identify motor neurons within the 
selected regions of the spinal cords and consequently to analyse the morphology and health of 
the motor neurons at each time point.  
As demonstrated in Figure 2, when stained for ChAT the majority of the motor 
neurons in the non-transgenic wild type animal (A) display ChAT uniformly throughout their 
whole cell body. Similar observations were made for the SOD1G93A animal at 30 days of age 
(B) where the staining patterns as well as the motor neuron’s morphology were highly similar 
to that of the non-transgenic wild type littermate (A). 
Disease progression becomes more apparent at 70 day of age in the SOD1G93A mouse 
(C), where uniform ChAT staining is reduced, and majority of the motor neurons in this 
region of the spinal cord display a punctate pattern of ChAT stain (annotated by solid 
arrows). In addition, comparison of the motor neurons at 70 days (C) to those of the non-
transgenic wild type (A) also indicates that their morphology is undergoing a change, as the 
cell bodies appear atrophic and smaller in size, a feature of a degenerating motor neuron 
(indicated by the broken arrow). 
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As the animals age further, dramatic changes occur at the cellular level which are 
highly visible at 90 days (D), where the punctate pattern of the ChAT stain is more evident 
and frequent in comparison to those motor neurons in a younger SOD1G93A animal at 30 days 
(B). Majority of the motor neurons in the picture display abnormally shaped and atrophic cell 
bodies at this age (90 days, D) in comparison to the non-transgenic wild type (A).  
Examining the spinal cord sections at 110 days (E) in the SOD1G93A mouse and 
comparing it to the non-transgenic wild type littermate (A), demonstrates that almost all 
motor neurons in the lumbar region developed severe atrophy (indicated by the broken arrow) 
and a punctate ChAT staining pattern (annotated by the solid arrow), a feature of 
degenerating motor neurons. 
Similar patterns (as displayed in (A)) were observed in all aged matched non-
transgenic wild type littermates, hence one picture was selected as a representative for all the 










Representative figure demonstrating ChAT 
(brown)/Nissl (purple)-stained sections from the ventral 
horns (lumbar region) of SOD1G93A females at different 
ages (B-E) versus a non-transgenic wild type littermate 
(A) (n = 1 female mouse per age group, per 
experimental group).  
(A) Uniform and consistent staining of the motor 
neurons (MNs) in a non-transgenic wild type.  
(B) Spinal cord sections from a SOD1G93A at 30 days of 
age. Similar to non-transgenic wild type mouse, MNs 
are stained with ChAT overlaying the Nissl stain 
(brown/purple). 
(C) Punctate ChAT staining pattern in a 70 days old 
SOD1G93A mouse (solid arrows), and a change in MN’s 
morphology (broken arrow). 
(D) Consistent punctate ChAT staining pattern (present 
in majority of MNs) at 90 days in SOD1G93A mouse 
(solid arrows) and atrophic abnormalities in MN’s cell 
body.  
(E) Severe cellular changes at 110 days in the SOD1G93A 
mouse, the very small populations of MNs that are alive 
display highly atrophic cell bodies. 
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Figure 2.	   Effect of the mutant SOD1G93A 
toxicity on motor neuron health and survival, 
determined by ChAT/Nissl counter stain. 
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3.2.1.2. Ubiquitin Immunohistochemistry 
Ubiquitin is a small protein consisting of 76 amino acids that is expressed in all the 
eukaryotic cells, and is well-known for its involvement in the protein degradation pathway, 
ubiquitination, which is emerging as a specific, rapid and reversible type of post-translational 
modification (Bendotti et al., 2012). 
In the case of ALS extensive research has demonstrated the accumulation of ubiquitin 
rich protein aggregates in motor neurons which is considered as a neuropathological feature 
of the disease and a common hallmark present in both SALS and FALS patients as well as in 
animal and cellular models of this disorder (Migheli et al., 1990, Leigh et al., 1991, Bendotti 
et al., 2004). 
Examination of the lumbar region of the spinal cord in the SOD1G93A mice indicates 
that the formation of ubiquitin-positive aggregates in motor neurons correlates with disease 
progression (Bendotti et al., 2012). We assessed the time dependent accumulation of 
ubiquitinated aggregates in the lumber region (between the L3-L5) at our selected ages (30, 
70, 90 and 110 days) in SOD1G93A transgenic mice and their aged matched non-transgenic 
wild type littermates, results of which are displayed in Figure 3.     
Figure 3 indicates that the majority of the motor neurons in the non-transgenic wild 
type animal (A) have been stained with ubiquitin, where the staining is demonstrated to be 
present uniformly throughout the cytoplasm. Comparing this Figure to that of the SOD1G93A 
mouse at 30 days (B) demonstrates that at this very early pre-symptomatic age motor neurons 
display an impression of a faint but patchy staining pattern within their cell body, which 
indicates the formation of ubiquitinated aggregates as previously reported by others. 
Studying sections of the spinal cord at 70 days in the SOD1G93A mouse (C) indicates a 
more apparent staining pattern, where the motor neurons displayed in the picture bear 
ubiquitinated aggregates in comparison to the non-transgenic wild type (A).  
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The Figure illustrates that as the disease progresses more protein aggregates 
accumulate in the cellular matrix and this is particularly visible at 90 days of age (D) in the 
SOD1G93A animal. The picture displays a more intense staining pattern in comparison to the 
staining presented at 70 days (C), it is also notable that the aggregates are present in a 
consistent pattern throughout the cytoplasm of the motor neurons as indicated with the solid 
arrow.  
At 110 days of age (E), when the SOD1G93A animal is near the end stage, very visible 
and highly intense aggregates are formed within the motor neuron cell body (annotated by the 
solid arrow) and in other structures which may be dendrites (indicated by the broken arrows). 
These aggregates are likely to be toxic and detrimental towards the health and function of the 
cell and eventually lead to cell death. 
Similar staining patterns (as displayed in (A)) were observed in all aged matched wild 
type littermates, hence one picture was selected as a representative for all the wild type 















Representative figure demonstrating ubiquitin 
(brown)/Nissl (purple)-stained sections from the 
lumbar region of SOD1G93A males at different ages 
(B-E) versus a non-transgenic wild type littermate 
(A) (n = 1 male mouse per age group, per 
experimental group).  
(A) MNs in the non-transgenic wild type animal 
stained with ubiquitin, where the staining is 
demonstrated to be present uniformly throughout 
the cytoplasm.  
(B) Early accumulation of ubiquitinated aggregates 
in MNs at 30 days age (pre-symptomatic stage) in a 
SOD1G93A mouse. 
(C) Patchy ubiquitin staining pattern in the MNs of 
a 70 days old SOD1G93A mouse.  
(D) Intense accumulation of ubiquitinated 
aggregates in MN’s cell body in a 90 days old 
SOD1G93A mouse (solid arrow).  
(E) Intense staining of ubiquitinated aggregates at 
110 days in the SOD1G93A mouse (solid arrow). 
Intense ubiquitin staining can also be seen in other 
structures which may be dendrites (broken arrows). 
Scale bar in (A) applies to all the other 4 Figures 











Figure 3.	   Age dependent formation of 
ubiquitinated aggregates in motor neurons in 
SOD1G93A mouse versus non-transgenic wild type 
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3.2.2. Mice Overexpressing Mutant DAOR199W 
Upon discovery of the DAOR199W mutation and its link to ALS, the cellular and animal 
models of this mutation were established and investigated to determine the possible 
pathogenic effects of the mutant DAOR199W protein. Therefore in the following subsection we 
aimed to demonstrate the effects of this mutation in the animal model generated in our 
laboratory.  
Although already confirmed in the de Belleroche’s laboratory, we first reconfirmed 
the overexpression of the mutant DAOR199W protein in various tissues of the mouse model 
paying attention to the spinal cord and in particular to the lumbar region of the spinal cord as 
this region has been shown to be severely affected in ALS.  
It has been established that the endogenous DAO protein is ubiquitously expressed in every 
single tissue in the human body. However, a study carried out by Konno and colleagues 
(1997) demonstrated for the first time that DAO is absent in mouse liver (Konno et al., 1997). 
In the case of our DAOR199W transgenic mouse model, we expected the DAOR199W protein to 
be ubiquitously expressed in all tissue types including the liver, as the DAOR199W transgene 
was under the influence of the CAGG promoter/enhancer which is based on the β-actin 
promoter and so should drive the transgene expression in all tissues.  
Figure 4 demonstrates the western blot analysis for the expression of DAOR199W in 
eight major tissues of the mutant mouse in comparison to a non-transgenic wild type 
littermate. As displayed in the Figure, the endogenous DAO protein is not detected in the 
liver, small intestine, brain, spinal cord and lung collected from the non-transgenic wild type 
littermate at the selected exposure time. The Figure also indicates a hint of endogenous DAO 
expression in the skeletal muscle and heart, but fairly strong expression levels are detected in 
the kidney of the non-transgenic wild type animal. 
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Examination of the expression levels of the DAOR199W protein in the mutant animal 
indicates that although a ubiquitous expression was expected in the presence of the CAGG 
promoter/enhancer, the mutant protein is only present in some tissues. Notably the mutant 
DAO protein is absent in the liver and small intestine of the mutant animal. Further 
examination of the first row in Figure 4 indicates that the transgenic animal expresses the 
DAOR199W protein at detectable levels in both brain and the spinal cord in comparison to the 
non-transgenic wild type lanes where the endogenous DAO protein is not detected.  
The second row in Figure 4 demonstrates that the mutant DAOR199W protein is 
expressed at very high levels in the kidney in comparison to the same tissue from the non-
transgenic wild type littermate. Extremely high expression levels of the mutant protein are 
found in both skeletal muscle and heart of the mutant DAOR199W mouse. The lung from the 
mutant animal also demonstrates fairly strong expression levels of the mutant DAOR199W 
protein.  
As described previously these results were previously confirmed elsewhere (n = 21 
DAOR199W mice (17 females and 4 males), and n = 9 non-transgenic wild type littermates (7 
females and 2 males)), and therefore the pure purpose of this blot was demonstration. As we 
did not plan to quantify the expression levels of DAOR199W protein, we decided a protein 
assay prior to the western blot analysis was sufficient to ensure equal loading of the samples 
and thus probing for a loading control post analysis was not necessary.     
In order to further confirm the expression of the mutant DAOR199W in the spinal cord 
and possibly its site of localisation within the spinal cord, we carried out an 
immunohistochemistry analysis involving the lumbar region, where we drew a comparison in 
terms of DAO expression levels in both mutant DAOR199W and non-transgenic wild type 
littermates. These results are presented in Figure 5, and as the Figure indicates the 
endogenous DAO protein is expressed at low levels mainly in the grey matter of the spinal 
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cord in the non-transgenic wild type animal (A). The magnified picture (A’) further shows 
that the few motor neurons in this region which express the endogenous DAO, express the 
protein at low levels, highlighted by the very faint brown colour stain (annotated by the solid 
arrows). It is noticeable that most of the motor neurons in both pictures (A and A’) are stained 
in Nissl (purple), which is probably an indication of low levels of endogenous DAO 
expression that are almost undetectable.  
Comparing this panel (A and A’) to the one on the right (B and B’) shows that in the spinal 
cord sections from the mutant DAOR199W animal almost all the motor neurons express the 
mutant form of the DAO protein, this is demonstrated by a more intense staining present in 
the grey matter (B) in comparison to the section from the non-transgenic wild type animal 
(A). The magnified picture at the bottom of this panel (B’) further indicates the 
overexpression of the mutant DAOR199W in the motor neurons as all the motor neurons in this 
area are stained in a dark brown colour (annotated by broken arrows) in comparison to the 
non-transgenic wild type picture on the left (A’), where majority of the motor neurons have 
been stained in a lighter brown colour (i.e. expressing the endogenous DAO at low levels) or 
stained in purple which is likely to be an indication of the low levels of the endogenous DAO.  
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Figure demonstrating western blot analysis of the mutant DAOR199W protein overexpression in eight 
different tissues from a mutant DAOR199W female mouse in comparison to a non-transgenic wild type 
female littermate (n = 2 DAOR199W female mice and 2 non-transgenic females). 
Each tissue from the mutant animal was ran in parallel with the same tissue from a non-transgenic 
wild type littermate. 
The bands in the first column on the left in both panels are a commercially available pure DAO 
protein obtained from porcine kidney that was used as a positive control (weighing approximately 
40kDa).    
Representative figure of n = 21 DAOR199W mice (17 females and 4 males), n = 9 non-transgenic wild 
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Figure 4.	  Western blot analysis demonstrating the expression of the mutant D-amino acid 
oxidase in various tissue of the DAOR199W transgenic mouse versus a non-transgenic wild 
type littermate. 
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Figure demonstrating DAO protein (brown)/Nissl (purple)-stained sections from the lumbar region of 
DAOR199W male mouse (B and B’) versus a non-transgenic wild type male littermate (A and A’).  
(A) Cryosections of spinal cord from a 19.5 months old non-transgenic wild type male mouse (n = 1). 
(B) Cryosections of spinal cord from a 19.5 months old mutant DAOR199W male mouse (n = 1). 
Boxed areas show regions of spinal cord that are magnified to display the intensity of the DAO 
staining and its localisation in motor neurons in both non-transgenic wild type animal (A’) and 
DAOR199W littermate (B’). Solid and broken arrows indicate intensity of the staining in non-transgenic 
wild type and mutant animals respectively.   
The scale bar in (A & B) represents 1000µm, and in (A’ & B’) represents 200µm.  
Representative figure of n = 24 DAOR199W mice (18 females and 6 males), n = 22 non-transgenic wild 






Figure 5.	   D-amino acid oxidase expression in the lumbar region of the spinal cord of 
mutant DAOR199W transgenic and non-transgenic wild type mice, determined by DAO/Nissl 
counter stain.	  
B 
19.5 Months DAOR199W  
B’ 
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3.2.2.1 ChAT Immunohistochemistry 
Although already confirmed in the de Belleroche lab, in order to demonstrate the 
effect of the mutant DAOR199W protein in vivo and to reveal whether DAOR199W has any effect 
on the health of motor neurons, we carried out an immunohistochemistry analysis.  
As presented in Figure 6, ChAT analysis demonstrated that normal healthy motor 
neurons in the non-transgenic wild type animal (A) display a uniform staining pattern where 
ChAT is consistently present across the motor neuron’s cell body. Comparing this Figure to 
that of the mutant animal (B) presented on the right, indicates that while the majority of 
motor neurons display a similar ChAT staining pattern throughout their cell body, some 
motor neurons developed a punctate staining pattern (indicated by solid arrows).  
Additionally, comparing the morphology of motor neurons in the mutant animal (B) to those 
of the non-transgenic wild type animals (A), indicates that, although the majority of motor 
neurons in the mutant mouse (B) display a similar morphology to those of the non-transgenic 
wild type (A), some motor neurons in this region display an abnormally shaped cell body 
where they appeared atrophic and misshaped (annotated by broken arrows). As mentioned 
previously the punctate ChAT staining pattern combined with atrophic cell bodies are both 
characteristics of dying motor neurons.        
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Figure demonstrating ChAT (brown)/Nissl (purple) stained sections from the ventral horns (lumbar 
region) of a 19.5 months old mutant DAOR199W male (B) versus a non-transgenic wild type littermate 
(A).  
(A) Cryosections of spinal cord from a 19.5 months old non-transgenic wild type male mouse (n = 1).  
(B) Cryosections of spinal cord from a 19.5 months old mutant DAOR199W male mouse (n = 1), 
displaying a punctate ChAT staining pattern (solid arrows). Some motor neurons in these animals 
appear misshaped and atrophic (broken arrows).  
Scale bar in (A) applies to both Figures and represents 100µm. 
Representative figure of n = 24 DAOR199W mice (18 females and 6 males), n = 22 non-transgenic wild 
type littermates (15 females and 7 males). 
 
 
Figure 6.	   Toxic effects of DAOR199W mutation on motor neuron health determined by 
ChAT/Nissl counter stain. 
19.5 Months Old WT  
A 
19.5 Months Old DAOR199W  
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3.2.2.2. Ubiquitin Immunohistochemistry 
Although already confirmed in the de Belleroche lab, in order to further demonstrate 
the effect of the DAOR199W mutation in our mutant mouse model we carried out ubiquitin 
staining using a DAOR199W mutant mouse and a non-transgenic wild type littermate, results of 
which are presented in Figure 7.     
The majority of the motor neurons in the ventral horn of the non-transgenic wild type 
animal (A) have been stained with ubiquitin, where the staining is present uniformly 
throughout the cytoplasm of the motor neurons. Comparing this Figure to that of the animal 
expressing the mutant DAOR199W protein (B) highlights the impression of some ubiquitinated 
protein aggregates in the motor neurons (indicated by arrows).  
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Figure demonstrating ubiquitin (brown)/Nissl (purple) stained sections from the lumbar region of 
DAOR199W male	   (B) versus a non-transgenic wild type male littermate (A).  
(A) Cryosections of spinal cord from a 19.5 months old non-transgenic wild type male mouse (n = 1).  
(B) Cryosections of spinal cord from a 19.5 months old transgenic DAOR199W male mouse (n = 1), 
impression of some ubiquitinated aggregates are present in the cytoplasm of some motor neurons 
(arrows). 
Scale bar in (A) also applies to (B) and represents 100µm. 
Representative figure of n = 24 DAOR199W mice (18 females and 6 males), n = 22 non-transgenic wild 
type littermates (15 females and 7 males). 
 
 
Figure 7. Formation of ubiquitinated aggregates in motor neurons in mutant DAOR199W 
versus non-transgenic wild type littermate determined by ubiquitin/Nissl counter stain. 
19.5 Months Old WT  
A 
19.5 Months Old DAOR199W 
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3.2.2.3. Quantification of Motor Neurons  
Based on the cellular abnormalities associated with overexpression of the mutant 
DAOR199W protein, we aimed to monitor the possible toxic effects of DAOR199W expression 
on motor neuron survival. We therefore performed an extensive and thorough motor neuron 
cell count in the lumber region of the spinal cord in both DAOR199W mutants and their non-
transgenic wild type littermates monitoring both sexes. This part of the investigation was 
carried out as a collaboration between the Wells and de Belleroche groups (unpublished 
data). Animal maintenance and spinal cord collections were carried out by myself; 
cryosectioning, staining and motor neuron quantification were performed by Miss Jacqueline 
Robbins under the supervision of Dr Praveen Paul.    
Data collected from this study is presented in Figure 8 and indicates that 
overexpression of the mutant DAOR199W protein leads to motor neuron cell loss in the lumbar 
region of the spinal cord. The Figure demonstrates a significant overall loss of motor neurons 
(19.7%) in animals overexpressing the mutant DAOR199W allele at the selected time point in 
comparison to their aged match non-transgenic wild type littermates. In particular a 
significant loss of motor neurons (25.5%) was observed in females carrying the mutant 
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Lumbar region (L3-L5) motor neuron (MN) quantification in DAOR199W mice and non-transgenic wild 
type littermates, aged 14-15 months. Lumber MNs were stained with ChAT and every third section 
was quantified for both males and females (n = 6 DAOR199W female and 5 male mice; n = 6 non-
transgenic male and 6 female littermates).  
The number of MNs in DAOR199W mice was significantly reduced by 19.7%, compared to those of the 
non-transgenic wild type mice (P = 0.023*, one-tailed, unpaired t-test, P ≤ 0.05). Specifically, the 
mutant males displayed a 16.5% MN loss (not significant), whereas the mutant females showed 
25.5% MN cell loss (significant, P = 0.0132*, one-tailed, unpaired t-test).  
Histograms show means for 40 sections per animal ± SEM. 
 























Motor neuron counts in wildtype and R199W DAO mice aged 14-15 months. Lumbar 
motor neurons in regions L3-L5 were stained with anti-ChAT antibody and every 
third section quantified for both mal  and female wildtype and R199W DAO mice.  
The u ber of motor neurons in R199W DAO mice was reduced by 19.7% 
compared to wildtype mice (one-tailed, unpaired t-test, *p<0.05). Specifically, the 
motor neuron loss was 16.5% in males (not significant) and 25.5% in females 
(significant, p=0.0132*, one-tailed, unpaired t-test). Histograms show means for 40 



























Figure 8. Quantification of motor neurons in the lumber region of the animals 
overexpressing the DAOR199W mutation versus their non-transgenic wild type littermate. 
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3.2.2.4. Survival Study  
Upon confirmation of the loss of motor neurons in the lumber region (L3-L5) of the 
animals carrying the DAOR199W mutation, we carried out a large cohort survival study to 
closely monitor the effect of this mutation in the transgenic animals in terms of health and 
survival and to investigate any possible phenotype the mutation may trigger.   
In this part of the investigation two different genotypes were used, animals 
heterozygous for DAOR199W mutation and their non-transgenic wild type littermates 
expressing the endogenous DAO protein, where both males and females were subjected to 
investigation over a period of one year. The possible effects of overexpressing the mutant 
allele (DAOR199W) were assessed by using a neurological scoring system (as described in 
detail in Chapter 2. Materials and Methods, subsection 2.2.1.7). Both hindlimbs were 
examined twice a week commencing at approximately 30 days of age in conjunction with the 
assessment of body weight as suggested by Scott and colleagues (Scott et al., 2008).  
Results presented in Figures 9 and 10 show that there are distinct differences in body 
weight between the sexes. Male animals are heavier in terms of total body weight in 
comparison to their female littermates. Both graphs further demonstrate that DAOR199W 
mutant mice in both sexes had a trend towards a lower body weight in comparison to their 
non-transgenic wild type littermates. However, both the non-transgenic wild type animals and 
those expressing the mutant DAOR199W transgene consistently continued to gain weight as 
they aged.  
Studying the graphs demonstrating the combined neurological score for animals 
overexpressing the DAOR199W protein in both sexes (Figures 11 and 12), shows that none of 
the animals developed any specific neurological signs as a result of overexpressing the 
mutant allele, and what was recorded is most likely to be noise as the recording for 
neurological scores for both non-transgenic wild type and transgenic animals overlap.    
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Figure 9. Longitudinal assessment of body weight in DAOR199W females versus their non-
transgenic wild type littermates. 
Mean group body weight plotted for DAOR199W and non-transgenic wild type female mice over time 
from approximately 30 days of age until the study was terminated (n = 23 DAOR199W mice and 17 
non-transgenic littermates). DAOR199W females are presented in blue, and the non-transgenic wild type 
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Figure 10. Longitudinal assessment of body weight in DAOR199W males versus their non-
transgenic wild type (WT) littermates. 
Mean group body weight plotted for DAOR199W and non-transgenic wild type male mice over time 
from approximately 30 days of age until the study was terminated (n = 15 DAOR199W mice and 16 
non-transgenic littermates).  
DAOR199W males are presented in purple, and the non-transgenic wild type littermates are displayed in 
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Figure 11.	  Longitudinal assessment of neurological score in DAOR199W females versus their 
non-transgenic wild type littermates. 
Mean group combined neurological score plotted for DAOR199W and non-transgenic wild type female 
mice over time from approximately 30 days of age until the study was terminated (n = 22 DAOR199W 
mice and 17 non-transgenic littermates). A combined neurological score was calculated for each 
mouse at each time point through summation of the neurological scores recorded for its left and right 
hindlimbs.  
DAOR199W females are presented in blue, and the non-transgenic wild type littermates are displayed in 
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Figure 12.	  Longitudinal assessment of neurological score in DAOR199W males versus their 
non-transgenic wild type littermates.	  
Mean group combined neurological score plotted for DAOR199W and non-transgenic wild type male 
mice over time from approximately 30 days of age until the study was terminated (n = 15 DAOR199W 
mice and 16 non-transgenic littermates). A combined neurological score was calculated for each 
mouse at each time point through summation of the neurological scores recorded for its left and right 
hindlimbs.  
DAOR199W males are presented in purple, and the non-transgenic wild type littermates are displayed in 
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3.2.2.5. Gait Analysis  
While the assessment of body weight and neurological score did not demonstrate any 
significant phenotype in the mutant animals carrying the DAOR199W transgene, we observed 
some unusual appearances in the body shape of the mutant animals that were absent in their 
non-transgenic wild type littermates. As demonstrated in Figure 13, animals bearing the 
transgene appeared thinner in terms of body size and they developed a kyphosis that was 
more severe in females than males (indicated by arrows).  
With this in mind and in order to further explore the possible effects of the loss of 
motor neurons in the lumbar region of the spinal cord of our transgenic animals (as displayed 
in Figure 8), we carried out a gait analysis study for both non-transgenic wild type and 
mutant DAOR199W animals, using both males and females from our survival study where the 
animals were assessed for their footfall, body movements and mechanics. 
The gait analysis technique measures over 40 parameters, and while there is a trend in 
some of these parameters where the measurements obtained for the mutant animals are 
different in comparison to the data collected for the non-transgenic wild type littermates, 
overall no major differences were observed in terms of gait upon comparison of the 
DAOR199W mutant animals to their non-transgenic wild type littermates. However, some of 
the most common parameters measured by the gait system are displayed in Figures 14 to 17 
for females and males respectively where the hindlimbs as well as the forelimbs for each 
individual group were examined. Full details of the gait technique are described in Chapter 2. 
Materials and Methods, subsection 2.2.2. For the definitions of the gait indices please refer to 
Table 6. 
Data shown in Figures 14 and 15 suggest that while stride and stance time of the 
mutant females were highly similar to that of the non-transgenic wild type in both hind- and 
forelimbs, swing time in these animals (for both fore and hindlimbs) show a slight increase in 
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comparison to the same parameter for their non-transgenic wild type littermates. In addition, 
variable results were obtained for the braking time in the mutant animals. The graphs 
demonstrate that the mutant females have a shorter braking time during stance for their 
hindlimbs, whereas they display a slightly longer braking time for their forelimbs in 
comparison to their non-transgenic wild type littermates.    
Furthermore, studying the graph representing the paw angle in the mutant females 
indicates that the degree of the angle at which the animal places its hindpaws on the surface 
significantly increased (P = 0.0435) in comparison to their non-transgenic wild type 
littermates. Comparing this graph to that of the forepaws indicates that a larger negative value 
was obtained for this particular parameter in DAOR199W females in comparison to their non-
transgenic wild type littermate. While the differences between the two genotypes did not 
reach significance (P = 0.1361), it is apparent that the paw angle in the forepaws has reduced 
greatly in the mutant females in comparison to their non-transgenic wild type littermate.  
Studying the graphs demonstrating the paw area for both limbs in the female mice, 
shows an increase in this variable for the mutant females, indicating the animals 
overexpressing the mutant DAOR199W allele use a larger surface area in terms of spreading 
their paws when their entire paws are placed on a surface in comparison to their non-
transgenic wild type littermates.    
The same set of gait indices are presented for both the mutant and non-transgenic wild 
type males in Figures 16 and 17. These data suggest that the stride and stance time in the 
hindlimbs of male mice (Figure16) carrying the mutant transgene show a slight increase in 
comparison to those of the non-transgenic wild type. However, these two parameters almost 
remained unchanged in the forelimbs of the DAOR199W transgenic males in comparison to the 
non-transgenic wild type littermates.  
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Unlike females, swing and brake time in the hindlimbs of the mutant males remained 
unchanged in comparison to the non-transgenic wild type animals. But similar to the data 
from the female mutants (Figure 15), both of these parameters showed an increase in the 
forelimbs of the DAOR199W male mice in comparison to the non-transgenic wild type 
littermates.  
Moreover, unlike female mutants, the data presented for the degrees of paw angle in 
DAOR199W transgenic males display a positive value which in comparison to the non-
transgenic wild type data indicates an increase for this parameter in both limbs. Studying the 
graph for paw area at stance for the mutant males however, shows a decrease in this 
particular parameter for the hindlimbs in comparison to the non-transgenic wild type, 
whereas similar to females the same measurement in the forelimbs of the DAOR199W males 
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Figure represents abnormal phenotypes observed in both males and females carrying the DAOR199W 
mutant transgene. The arrow indicates kyphosis of the spine, no similar phenotypes were observed in 
















Figure 13.	   Abnormal phenotypic features observed in the DAOR199W transgenic mouse 
model.  
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Gait Index Measurement Unit Description 
Stride Seconds 
The sum of stance and swing duration 
(duration of one complete stride for 
one paw). 
Stance Seconds 
The weight bearing portion of the 
stride in which the paw remains in 
contact with the belt. 
Swing Seconds The portion of the stride in which the paw is not in contact with the belt. 
Brake Seconds The time interval between initial and maximal paw contacts with the belt. 
Paw Angle Degree 
Angle of the paw during peak stance 
in relation to the long axis of the 
body. 
Paw Area at Peak Stance 
Cm2 
The maximal paw area in contact 
with the treadmill during the stance 




Table 6.	  Definition of DigiGait parameters for a single limb.  
Descriptions of gait parameters used to evaluate changes in gait for the DAOR199W mutant males and 









	   145 
Mean group combined, plotted for hindlimbs of the mutant DAOR199W (black bars) and non-transgenic 
wild type (white bars) female mice. This was done through averaging the individual values generated 
by the DigiGait system for each hindlimb of a particular animal (n = 12 DAOR199W mice and 10 non-
transgenic littermates). 	  
Stride (sum of stance and swing), stance (weight bearing portion of the stride in which the paw 
remains in contact with the belt), swing (when the paw is not in contact with the belt) presented in the 
top panel, with P values of 0.5238, 0.7560 and 0.273 respectively (two-tailed, unpaired t-test, P ≤ 
0.05).  
Brake (time intervals between initial and maximal paw contacts with the belt), paw angle (angle of the 
hindpaw during peak stance in relation to the long axis of the body) and paw area at peak stance 
(maximal paw area in contact with the treadmill during the stance phase) presented in the bottom 
panel, with P values of 0.4509, 0.0435*, 0.0673 respectively (Mann-Whitney test carried out for brake 
time and two-tailed, unpaired t-test for the other two parameters, P ≤ 0.05). Asterisk indicates a 
significant difference in term of the degree of paw angle between non-transgenic wild type controls 
and DAOR199W mice. 


































































































































Figure 14. Assessment of various gait indices in the hindlimbs of DAOR199W females 
versus non-transgenic wild type littermates. 
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Mean group combined, plotted for forelimbs of the mutant DAOR199W (black bars) and non-transgenic 
wild type (white bars) female mice. This was done through averaging the individual values generated 
by the DigiGait system for each forelimb of a particular animal (n = 12 DAOR199W mice and 10 non-
transgenic littermates).  
Stride (sum of stance and swing), stance (weight bearing portion of the stride in which the paw 
remains in contact with the belt), swing (when the paw is not in contact with the belt) presented in the 
top panel, with P values of 0.5756, 0.7461 and 0.4994 respectively (two-tailed, unpaired t-test, P ≤ 
0.05).  
Brake (time intervals between initial and maximal paw contacts with the belt), paw angle (angle of the 
forepaw during peak stance in relation to the long axis of the body) and paw area at peak stance 
(maximal paw area in contact with the treadmill during the stance phase) presented in the bottom 
panel, with P values of 0.4934, 0.1361, 0.2839 respectively (two-tailed, unpaired t-test, P ≤ 0.05).  




































































































































Figure 15. Assessment of various gait indices in the forelimbs of DAOR199W females versus 
non-transgenic wild type littermates. 















Mean group combined, plotted for hindlimbs of the mutant DAOR199W (black bars) and non-transgenic 
wild type (white bars) male mice. This was done through averaging the individual values generated by 
the DigiGait system for each hindlimb of a particular animal (n = 10 DAOR199W mice and 10 non-
transgenic littermates).  
Stride (sum of stance and swing), stance (weight bearing portion of the stride in which the paw 
remains in contact with the belt), swing (when the paw is not in contact with the belt) presented in the 
top panel, with P values of 0.2412, 0.1719 and 0.8795 respectively (two-tailed, unpaired t-test, P ≤ 
0.05).  
Brake (time intervals between initial and maximal paw contacts with the belt), paw angle (angle of the 
hindpaw during peak stance in relation to the long axis of the body) and paw area at peak stance 
(maximal paw area in contact with the treadmill during the stance phase) presented in the bottom 
panel, with P values of 0.8531, 0.5487, 0.3670 respectively (two-tailed, unpaired t-test, P ≤ 0.05).  








































































































































Figure 16. Assessment of various gait indices in the hindlimbs of DAOR199W males versus 
non-transgenic wild type littermates. 















Mean group combined, plotted for forelimbs of the mutant DAOR199W (black bars) and non-transgenic 
wild type (white bars) male mice. This was done through averaging the individual values generated by 
the DigiGait system for each forelimb of a particular animal (n = 10 DAOR199W mice and 10 non-
transgenic littermates).  
Stride (sum of stance and swing), stance (weight bearing portion of the stride in which the paw 
remains in contact with the belt), swing (when the paw is not in contact with the belt) presented in the 
tope panel, with P values of 0.6525, 0.8290 and 0.4079 respectively (two-tailed, unpaired t-test, P ≤ 
0.05).  
Brake (time intervals between initial and maximal paw contacts with the belt), paw angle (angle of the 
forepaw during peak stance in relation to the long axis of the body) and paw area at peak stance 
(maximal paw area in contact with the treadmill during the stance phase) presented in the bottom 
panel, with P values of 0.4107, 0.1653, 0.2502 respectively (two-tailed, unpaired t-test, P ≤ 0.05).  






































































































































Figure 17. Assessment of various gait indices in the forelimbs of DAOR199W males versus 
non-transgenic wild type littermates. 
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3.2.3. Mice Overexpressing the Wild Type DAO (DAOWT)  
As a control for the transgenic mice overexpressing the mutant DAOR199W allele we 
generated a second line of transgenic animals, overexpressing the wild type form of the DAO 
protein (DAOWT). This was to ensure that any phenotype generated in the mutant DAOR199W 
mice was not just related to the overexpression of DAO itself. While the data presented here 
were already confirmed in the de Belleroche’s laboratory, for demonstration purposes only 
we aimed to carry out a similar analysis to that presented previously for the DAOR199W 
transgenic mice in the following section.  
As before, non-transgenic wild type animals and transgenic mice overexpressing 
DAOWT were used for this part of the experiment, where the endogenous DAO expression 
levels as well as the expression levels induced by the presence of the DAOWT transgene were 
examined by western blot, results of which are displayed in Figure 18. Studying this Figure 
demonstrates that only some tissues from the transgenic animals express the DAO protein 
over the endogenous level (as demonstrated by the non-transgenic wild type littermates). 
Examining the first row indicates that as with the DAOR199W line (Figure 4), the DAO protein 
is absent in liver and small intestine of both transgenic and non-transgenic wild type 
littermates. The Figure demonstrates that there maybe endogenous DAO expression in the 
non-transgenic wild type brain, spinal cord and lung, whereas there are noticeably detectable 
expression of the endogenous DAO protein in kidney, skeletal muscle and heart of these 
animals. Although very faint there is a hint of expression of the DAO protein in the brain 
tissue of the transgenic animal, at more noticeable levels in comparison to the same tissue 
from the non-transgenic wild type littermate. Levels of the DAO protein in the spinal cord 
collected from the transgenic animals also appears to be slightly higher than that of the 
endogenous levels as displayed in the column representing spinal cord tissue from the non-
transgenic wild type littermate.  
	   150 
The second row demonstrates that DAO protein is present at high levels in kidney of 
the transgenic animal in comparison to that of the non-transgenic wild type littermate. While 
it is not very clear, the picture indicates that levels of DAO protein in the skeletal muscle 
tissue is highly similar to that of the non-transgenic wild type littermate. Similarly both heart 
and lung of the DAOWT transgenic animal show an expression level highly similar to that of 
the endogenous levels as demonstrated in the non-transgenic wild type lane, although the 
bands are not very well defined in these lanes.  
As described previously these results were confirmed elsewhere (n = 6 DAOWT mice 
(2 females and 4 males) and n = 9 non-transgenic wild type littermates (7 females and 2 
males)) and therefore the pure purpose of this blot was for demonstration. As we did not plan 
to quantify the expression levels of DAOWT protein, we decided a protein assay prior to the 
western blot analysis was sufficient to ensure equal loading of the samples and thus probing 
for a loading control post analysis was not necessary for this particular blot.     
Considering the extremely faint band presented for expression of the DAO protein in 
the spinal cord of the transgenic animals (as demonstrated in Figure 18) and taking into 
account that loss of α-motor neurons from the lumbar region of the spinal cord are the main 
feature in ALS, we deemed it was crucial to monitor and re-confirm the expression of the 
DAO protein in this particular tissue in the DAOWT animals. We therefore carried out a 
western blot analysis on the spinal cord from 3 DAOWT transgenic animals versus a non-
transgenic wild type littermate as presented in section (A) of Figure 19. The Figure 
demonstrates that the DAO expression is higher in the spinal cord of the transgenic animals in 
comparison to that of the endogenous DAO in the non-transgenic wild type littermate 
(annotated by the red box). As part of our analysis we believed it would be valuable to carry 
out a preliminary analysis of fold change in the DAOWT transgenic animals. For this purpose 
the same samples used in Figure 19A were employed in addition to 2 more control samples. 
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Unfortunately following numerous attempts the qualities of the final results were not as clear 
as blot A, evidently blots varied greatly from one setting to another. Our numerous trouble 
shooting attempts led us to conclude that this inconsistency between blots maybe due to a 
decrease in efficiency of our primary antibody, a hypothesis that requires further 
investigation. In addition, this inconsistency between blots encouraged us to include blot 19A 
to demonstrate that there is indeed an increase in the levels of the DAOWT protein in the 
spinal cord of our transgenic animals in comparison to their non-transgenic littermates.  
Furthermore, we quantified the expression levels of the DAO protein in our transgenic 
animals (n = 3, 2 males and 1 female) versus the endogenous DAO protein in the non-
transgenic wild type littermates (n = 3, 2 males and 1 female), using beta-tubulin as a loading 
control (Figure 19B and B’	  respectively) (for full details of analysis please refer to Chapter 
2. Materials and Methods, subsection 2.2.5.1). While a larger n number would be preferable 
(e.g. n = 8 animals per genotype), our preliminary analysis indicates that there has been an 
approximate 8 fold increase in the expression levels of the DAO protein in our transgenic 
animals (for graphs of intensities and the fold change calculations please refer to Appendix I).      
Next, to further confirm the higher expression levels of the DAOWT protein and its site 
of localisation in the spinal cord of these transgenic animals, we performed an 
immunohistochemistry analysis involving the lumbar region, where we drew a comparison in 
terms of DAO expression levels in both DAOWT transgenic and the non-transgenic wild type 
littermate, results of which are presented in Figure 20. 
The Figure indicates the expression of the endogenous DAO protein at moderately 
low levels in the grey matter of the spinal cord in the non-transgenic wild type animal (A). 
This observation is further confirmed by the enlarged picture (A’), where the counter stain 
with Nissl demonstrates that only a small population of motor neurons in this region express 
the endogenous DAO (stained in brown colour, annotated by solid arrows). The picture 
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suggests that majority of the motor neurons in this area of the spinal cord express the DAO 
protein at low and almost undetectable levels as indicated by the purple colour Nissl stain (in 
both A and A’). 
The second panel on the right (B and B’) presents a spinal cord section from a 
DAOWT transgenic animal. The top picture in this panel (B) demonstrates that almost all 
motor neurons in the grey matter of the spinal cord express the wild type form of the DAO 
protein as displayed by the intense and uniform brown staining in this area. This picture also 
indicates a more intense staining pattern in the white matter of the spinal cord, which is not as 
intense in the same area in the non-transgenic wild type animal (A).  
Moreover, the magnified picture at the bottom (B’) of this panel further demonstrates 
the overexpression of the DAO in the motor neurons (annotated by broken arrows), as all the 
neurons are stained in a dark brown colour in comparison to the non-transgenic wild type 
picture on the left (A’), where most of the motor neurons are stained in purple (Nissl) which 
confirms the low expression levels of the endogenous DAO protein in these cells.  
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Western blot analysis confirming the expression of DAO protein in eight different tissues from a 
transgenic DAOWT male mouse in comparison to a non-transgenic wild type male littermate.  
Each tissue from the transgenic animal was ran in parallel with the same tissue type from a non-
transgenic wild type littermate (n = 1 per experimental group).  
The bands in the first column on the left in both panels are a pure DAO protein obtained from a 
porcine kidney that was commercially available and was used as a positive control (weighing 
approximately 40kDa). 
Representative figure of n = 6 DAOWT mice (2 females and 4 males), n = 9 non-transgenic wild type 
























































































Figure 18. Western blot analysis demonstrating the expression of the D-amino acid 
oxidase in the DAOWT transgenic mouse versus a non-transgenic wild type littermate in 
various tissues. 
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(A and B) Western blot analysis confirming the expression of DAO protein in the spinal cord tissue of 
DAOWT transgenic male (n = 2) and female (n = 1) mice in comparison to non-transgenic wild type 
littermate (n = 1 male in A and n = 2 males and 1 female in B). Spinal cord tissues from the transgenic 
animals were run in parallel with the same tissue type from a non-transgenic wild type littermate. The 
red box represents the presence of DAO protein in the spinal cord of DAOWT transgenics and the non-
transgenic wild type littermate. The band in the first columns on the left is the pure DAO protein 
obtained from a porcine kidney that was commercially available and was used as a positive control 
(weighing approximately 40kDa). 
 (B’) Analysis of the endogenous beta-tubulin used as a loading control for blot (B), which was 
employed for quantification of the DAOWT protein in transgenics and their non-transgenic littermates 
(weighing approximately 55kDa). 
(A) Representative figure of n = 6 DAOWT mice (2 females and 4 males), n = 9 non-transgenic wild 























DAOWT WT B’ 
Figure 19. Western blot analysis demonstrating the expression of D-amino acid oxidase in 
the spinal cord of DAOWT transgenic mice versus non-transgenic wild type littermate. 
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  DAO protein (brown)/Nissl (purple)-stained sections from the lumbar region of DAOWT male mouse 
(B and B’) versus a non-transgenic wild type littermate (A and A’).  
(A) Cryosections of spinal cord from an 8 months old non-transgenic wild type male mouse (n = 1). 
(B) Cryosections of spinal cord from an 8 months old mutant DAOWT male mouse (n = 1). 
Boxed areas show regions of spinal cord that are enlarged to show (A’ and B’) to display the intensity 
of the DAO staining in motor neurons (arrows) in non-transgenic wild type animal (A’) and DAOWT 
littermate (B’). Solid and broken arrows indicate intensity of the staining in non-transgenic wild type 
and mutant animals respectively.   
The scale bar in A also applies to B and represents 1000µm. The scale bar in A’ also applies to B’ and 
represents 200µm.  
Representative figure of n = 15 DAOWT mice (7 females and 8 males), n = 13 non-transgenic wild 
type littermates (7 females and 6 males). 
 
Figure 20. D-amino acid oxidase expression in the lumbar region of the spinal cord of 
DAOWT transgenic and non-transgenic wild type mice, determined by DAO/Nissl counter 
stain. 
A 
8 Months Old WT  
A’ 
8 Months Old DAOWT  
B 
B’ 
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3.2.3.1. ChAT Immunohistochemistry 
Although already confirmed in the de Belleroche lab, as part of characterising our 
DAOWT transgenic mice we carried out ChAT staining to investigate the possible toxic 
effects overexpression of the DAOWT protein may exert on motor neurons in terms of their 
health, these results are presented in Figure 21. 
Analysing the staining patterns in Figure 21 indicates that ChAT staining is 
consistently spread across the motor neuron’s cell body in the non-transgenic wild type 
animal (A). ChAT staining in the transgenic animal overexpressing the wild type DAO 
protein on the right (B) demonstrates similar staining pattern to that of the non-transgenic 
wild type, where most of the motor neurons display a uniform ChAT staining across their cell 
bodies. In addition, examining the motor neurons in the DAOWT transgenic mouse (B), 
reveals that the motor neurons in the transgenic animal display a healthy and well shaped cell 
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ChAT (brown)/Nissl (purple)-stained sections from the ventral horns (lumbar region) of 8 months old 
DAOWT male (B) versus a non-transgenic wild type littermate (A).  
(A) Cryosections of spinal cord from an 8 months old non-transgenic wild type male mouse (n = 1).  
(B) Cryosections of spinal cord from an 8 months old transgenic DAOWT male mouse (n = 1). 
Scale bar in (A) applies to both Figures and represents 100µm. 
Representative figure of n = 15 DAOWT mice (7 females and 8 males), n = 13 non-transgenic wild 
type littermates (7 females and 6 males). 
 
 
Figure 21. Health of motor neurons in DAOWT transgenic animal versus a wild type 
littermate, determined by ChAT/Nissl counter stain. 
8 Months Old DAOWT  
B 
8 Months Old WT  
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3.2.3.2. Ubiquitin Immunohistochemistry 
Although previous investigations of the DAOWT transgenic animals (preformed by the 
de Belleroche team, unpublished data) showed no phenotype due to overexpression of the 
DAO protein, we aimed to further reconfirm these facts through ubiquitin staining, displayed 
in Figure 22.     
Analyzing both pictures in Figure 22 indicates that most of the motor neurons present 
in the ventral horn of the transgenic animal overexpressing the wild type DAO protein (B) 
display a uniform and consistent ubiquitin staining pattern, where the staining is present 
throughout the cytoplasm of these cells. Comparing this image to that of the non-transgenic 
wild type animal on the left (A) shows that the ubiquitin staining pattern present in the 
transgenic animal is highly similar to those of the non-transgenic wild type, and overall no 
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Ubiquitin (brown)/Nissl (purple)-stained sections from the lumbar region of DAOWT male (B) versus 
a non-transgenic wild type littermate (A).  
(A) Cryosections of spinal cord from an 8 months old non-transgenic wild type male mouse (n = 1).  
(B) Cryosections of spinal cord from an 8 months old transgenic DAOWT male mouse (n = 1). 
Scale bar in (A) applies to both Figures and represents 100µm. 
Representative figure of n = 15 DAOWT mice (7 females and 8 males), n = 13 non-transgenic wild 
type littermates (7 females and 6 males). 
 
 
8 Months Old DAOWT  
B 
8 Months Old WT  
A 
Figure 22. Ubiquitin/Nissl counter staining in the lumbar region of the DAOWT transgenic 
animal versus non-transgenic wild type littermate.  
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3.2.3.3. Survival Study  
In order to further explore any possible phenotype that overexpression of the wild 
type DAO protein may have induced in the transgenic animals, we set up a large cohort 
survival study to closely monitor these animals in terms of their health and survival.   
Hence, we recruited animals heterozygous for overexpressing the DAOWT and their 
non-transgenic wild type littermates expressing the endogenous DAO protein in our survival 
study, where both males and females were subjected to investigation over a period of 7 
months. During this period both groups were assessed weekly for their body weight and 
neurological scores in both hindlimbs as described in detail in Chapter 2. Materials and 
Methods, subsection 2.2.1.7.  
The assessments commenced at approximately 40 days of age and the results for the 
assessment of the body weight are presented in Figures 23 and 24. The graphs demonstrate 
distinct differences in terms of body weight across the sexes, where male animals (Figure 24) 
display a heavier body mass in comparison to their female littermates (Figure 23). However, 
no differences were observed in body weight between the two genotypes under investigation. 
Both graphs clearly show that body mass consistently increased with age across the sexes, 
and both genotypes within the same sex display highly similar body weights, a trend 
particularly visible in females (Figure 23). Overall no differences were observed in terms of 
body weight between the genotypes in either sex.  
Assessment of the neurological scores involving the DAOWT transgenic mice and 
their non-transgenic wild type littermates in both males and females displayed no differences 
between the genotypes or across the sexes. As all the animals were awarded the score zero 
throughout the duration of the study, the graphs are not shown.  
Since no obvious phenotype was observed in any of the transgenic animals compared 
to their non-transgenic littermates we decided not to proceed with the gait analysis study. 
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Figure 23. Longitudinal assessment of body weight in DAOWT females versus their non-
transgenic wild type littermates.	  
Mean group body weight plotted for DAOWT and non-transgenic wild type female mice over time 
from approximately 40 days of age until the study was terminated (n = 16 DAOWT mice and 21 non-
transgenic littermates).  
DAOWT females are presented in blue, and the non-transgenic wild type littermates are displayed in 
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Figure 24. Longitudinal assessment of body weight in DAOWT males versus their non-
transgenic wild type littermates.	  
Mean group body weight plotted for DAOWT and non-transgenic wild type male mice over time from 
approximately 40 days of age until the study was terminated (n = 17 DAOWT mice and 16 non-
transgenic littermates).  
DAOWT males are presented in orange, and the non-transgenic wild type littermates are displayed in 
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3.3. Discussion  
3.3.1 High Copy Number SOD1G93A Mouse Model  
The high copy number SOD1G93A mouse is the most common and well-known animal 
model available for the study of ALS and hence it has been under extensive research for 
nearly two decades. In terms of phenotypic features induced by the presence of the mutant 
SOD1G93A allele, it has been established that these animals have an extremely short lifespan, 
which varies slightly between the sexes, where the males live for approximately 130 days and 
females live for a slightly longer period, approximately 150 days. Although the animals 
appear normal early in their lifespan, by 45 days of age 40% of the endplates are denervated. 
Between approximately 47 and 80 days of age the ventral root of the spinal cord displays 
severe loss of motor axons, followed by loss of α-motor neuron cell bodies from the lumbar 
region of the spinal cord after day 80. At 90 days of age the ALS-like motor symptoms are 
initially detected, displayed as a fine tremor in the hindlimbs that is associated with muscle 
weakness and progressive muscle atrophy. By approximately 100 days of age a 50% decrease 
in the lower motor neurons is evident (Fischer et al., 2004). This severe and continuous motor 
neuron cell loss at the later stages of the disease consequently leads to progressive paralysis, 
which in turn is associated with continuous muscle wasting, persistent and significant weight 
loss, and ultimately death. Hence, the ALS-like symptoms become increasingly apparent as 
the animal age and the affected animals are easily differentiated from the non-transgenic wild 
type animals as displayed in Figure 1.   
The severe phenotype observed in these animals is associated with pathogenic 
changes at the cellular level including oxidative stress, glutamatergic toxicity, mitochondrial 
abnormalities, defective axonal transport, cytoskeletal dysfunction, and repeated denervation 
and reinnervation of neuromuscular junctions (NMJs) (Cozzolino et al., 2008). Mounting 
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evidence indicates that the changes in these mechanisms take place in a time dependent 
manner throughout the animal’s lifespan facilitating the progressive degeneration of motor 
neurons from caudal to rostral and the consequent phenotypic changes. In addition, the initial 
study carried out on the SOD1G93A mouse model by Gurney and colleagues (1994) 
demonstrated that most molecular and cellular changes in these mutant animals were highly 
apparent in the ventral root of the spinal cord, whereas the dorsal spinal cord was spared 
(Gurney et al., 1994). Furthermore, the motor neurons in mutant SOD1G93A mouse model 
display a progressive ‘dying back’ mechanism involving a selective synaptic weakening and 
denervation that has been shown to be initiated long before the onset of clinical symptoms 
(Frey et al., 2000, Fischer et al., 2004).  
Hence, with these in mind, here we confirmed the time dependent degeneration of the 
motor neurons through a ChAT staining (Figure 2) where we showed that at a young age (30 
days) the mutant SOD1G93A animal has highly similar features to its non-transgenic wild type 
littermate (Figures 2B). Considering the ‘dying back’ mechanism in ALS, our observations 
regarding the intact and unchanged morphology of the motor neurons at 30 days of age is 
compatible with the study that was done by Fischer and colleagues in 2004. They 
demonstrated that at 28 days of age 100% of NMJs were innervated and no evidence of axonal 
degeneration was observed at this age. From 80 days onwards they demonstrated continuous 
loss of motor neurons from the lumber region of the spinal cord which progressively worsened 
until the end stage of the disease (Fischer et al., 2004). Data presented in Figure 2C (70 days 
SOD1G93A) further agrees with these findings, where we observed a change in morphology of 
the motor neurons as well as a change in their cellular features, such as atrophy and impaired 
ChAT staining which are all hallmarks of degenerating cells. Aligned with various findings in 
different studies here we further demonstrated that the degenerating features in the SOD1G93A 
mice progressively worsened as the animal aged in comparison to their non-transgenic wild 
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type littermate.  
Another pathogenic hallmark of the ALS that has received a lot of attention over the 
years is the abnormal accumulation of the ubiquitinated protein aggregates, a feature that 
worsens with disease progression, as demonstrated in Figure 3. The Figure indicates that 
formation of the ubiquitin positive aggregates are initiated as early as 30 days of age in the 
SOD1G93A transgenic animals (Figure 3B). This feature becomes more apparent by 70 days of 
age (Figure 3C) and continues to increase in abundance until the animal reaches the end stage 
(Figure 3C-E). Given the ubiquitous expression of the mutant SOD1 G93A protein in body the 
reason for the selective loss of motor neurons in ALS remains to be elucidated. However, in a 
study that was carried out by Bendotti and colleagues in 2012, they proposed that unlike other 
cells in the central nervous system, motor neurons seem to be unable to degrade misfolded 
proteins. While it is not clear whether the accumulation of these aggregates is due to an 
increase in the synthesis of the SOD1G93A protein or dysfunctioning of the protein degradation 
system in the spinal cord, accumulation of these toxic materials within the motor neurons 
triggers a cascade of events which eventually leads to cell degeneration and death (Bendotti et 
al., 2012).  
 Thus, due to their high resemblance both at the cellular level and the phenotypic level 
to those of the human ALS patients, the high copy number SOD1G93A presents a good model 
for investigating ALS, and testing and developing therapies for this life threatening disorder. 
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3.3.2. Mice overexpressing the mutant DAO (DAOR199W) 
 The link between the mutation in the DAO gene at the R199W position and ALS led 
to the generation of a new line of transgenic animals overexpressing the mutant allele, namely 
DAOR199W. Upon generation, these animals were subjected to extensive research and various 
investigations by the de Belleroche group and ourselves to highlight any possible phenotype 
this mutation may trigger both at the cellular and behavioural level. Including numerous 
western blot analyses to confirm the expression of the mutant DAO protein in various tissues, 
as well as immunohistochemistry techniques to confirm the expression of the DAOR199W 
protein in the lumbar region of the transgenic animals and investigating the presence of 
ubiquitin aggregates in this particular region of the spinal cord. All the above studies were 
carried out by the de Belleroche group (unpublished data). However, detailed analyses of 
survival, neurological score and gait were carried out by myself, results of which were 
presented throughout the “3.2.2. mice overexpressing the mutant DAO (DAOR199W)” 
subsection of this Chapter.    
 Although confirmed previously, here we aimed to reconfirm mutant DAO expression 
by carrying out a western blot analysis targeting 8 main tissues with the aim of comparing our 
mutant transgenic line (DAOR199W) to their non-transgenic wild type littermates, as 
demonstrated in Figure 4. The Figure illustrates that the mutant DAOR199W protein is present in 
some tissue types but the expression levels vary between tissues, with Kidney, heart and 
skeletal muscle expressing the mutant protein more intensely in comparison to other tissues 
such as lung from the same transgenic animal. The expression level of the mutant DAOR199W 
protein is noticeably higher in the spinal cord and the brain of the mutant animal, whereas it is 
not detected in the non-transgenic wild type littermate. However, the mutant protein is absent 
in liver and the small intestine of the DAOR199W animal.   
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 We also assessed the overexpression of the mutant DAOR199W protein in the lumber 
region of the spinal cord in our mutant animals to ensure that all motor neurons in this region 
express the mutant protein (Figure 5). Comparing the sections from the mutant animal (B and 
B’) to those of the non-transgenic wild type (A and A’) confirms that almost all the motor 
neurons in this region of the spinal cord express high levels of the mutant DAOR199W protein. 
Studying the non-transgenic wild type picture (Figure 5A and A’) however indicates that 
majority of the cells in this area express the endogenous DAO protein at very low to almost 
undetectable levels under normal conditions. This observation also compliments the results 
obtained from the western blot analysis presented in Figure 4, and together they both suggest 
that the endogenous DAO protein is expressed at low levels in the spinal cord of the non-
transgenic wild type animals. Hence, results shown in Figures 4 and 5 confirm that with the 
exceptions of liver and small intestine, our transgenic animals overexpress the mutant 
DAOR199W protein in the tested tissues under the influence of the CAGG promoter/enhancer 
construct (β-actin promoter with the CMV enhancer). 
 By taking into consideration the toxic effects the overexpression of the mutant 
SOD1G93A protein causes in the cholinergic neurons, we aimed to demonstrate possible 
toxicities caused by overexpression of the mutant DAOR199W protein. Studying the images 
presented in Figure 6 suggests that overexpression of the mutant DAOR199W protein exerts 
some toxic effects on the motor neurons in the lumber region of the spinal cord, displayed by 
an impaired ChAT staining pattern. A clear punctate ChAT pattern is observed in the mutant 
DAOR199W animals (Figure 6B, solid arrows), which are highly similar to those seen in the 
SOD1G93A animals (Figure 2C-E, solid arrows). These results also indicate that like SOD1G93A, 
overexpression of the mutant DAOR199W protein promotes cell degeneration (Figure 6B, 
broken arrows), a characteristic that is absent in the non-transgenic wild type animals (Figure 
6A).   
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These observations are compatible with the cell culture studies that were carried out in 
the de Belleroche laboratory, where it was demonstrated that 72 hours post-transfection, 
neurons expressing the DAOR199W displayed a range of abnormalities including atrophic cell 
bodies and loss of projections in comparison to cells transfected with the wild type DAO 
(Mitchell et al., 2010).  
 Furthermore, we also confirmed the toxic effects of overexpressing the mutant 
DAOR199W protein on the motor neurons by demonstrating the formation of the ubiquitinated 
protein aggregates that were only present in the transgenic animals (Figure 7B, solid arrows), a 
feature that is absent in the motor neurons of the non-transgenic wild type animal (Figure 7B).  
This was initially reported by the de Belleroche laboratory through a series of cell 
culture experiments involving NSC-34 motor neuron cell line, where it was established that a 
prominent feature of the cells expressing the mutant DAOR199W allele was the presence of 
ubiquitinated protein aggregates. As presented by Mitchell and coworkers, in depth analysis of 
these observations then confirmed that these aggregates increased by threefold compared to 
untransfected cells and cells expressing either the wild type DAO or the GFP-vector. Our 
colleagues also showed that the number of abnormal cells, defined by atrophic shrunken cell 
body and lacking projections, increased upon expression of DAOR199W in comparison to the 
control and the wild type cells. In addition to these findings, it was revealed that the R199W 
mutation in the DAO gene induced a marked effect on cell viability. In this study they 
demonstrated that transfection of primary rat motor neuron with lentiviral vectors expressing 
DAOR199W significantly increased apoptosis in these cells compared to cells expressing either 
the vector or the wild type DAO, as assessed by the TUNEL assay (Mitchell et al., 2010). 
These findings suggest that even in the presence of the endogenous DAO protein, the R199W 
mutation is pathogenic. 
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The toxic effect of the DAOR199W mutation in terms of motor neuron cell and survival 
was investigated further in the mouse model of the DAOR199W in a collaborative study with 
the de Belleroche laboratory by quantification of the motor neurons in the lumber region of 
the spinal cord (Figure 8). The precise quantification of the ventral horn motor neurons (L3-
L5) of the transgenic animals versus their non-transgenic wild type littermates (n ≥ 5 per 
genotype, per sex) revealed a significant reduction in motor neuron numbers (25.5%, P = 
0.0132) in females and 16.5% reduction in males carrying the mutant allele in comparison to 
their non-transgenic wild type littermates (Figure 8).  
In addition, thorough cell culture studies carried out by Mitchell and colleagues 
confirmed that the R199W mutation leads to loss of enzymatic activity of the DAO protein, 
studying the ALS patients carrying the mutation also revealed a reduction in DAO enzyme 
activity (Mitchell et al., 2010). Interestingly the ddY/DAO− animals, a mouse strain found in 
outbred ddY (Konno and Yasumura, 1983) lacking DAO enzyme activity due to a natural 
point mutation that leads to substitution of amino acid glycine to arginine (G→R) at position 
181 (Sasaki et al., 1992), revealed that while these animals grow and reproduce normally they 
exhibit abnormal characteristics associated with the absence of DAO protein and the 
consequent abnormal NMDAR function (Almond et al., 2006).  
By bearing in mind the lethal effects of the DAOR199W mutation in human patients and 
as part of our plans to closely monitor and investigate the impact of this mutation in our newly 
generated animal model of ALS (DAOR199W), we carried out a longitudinal large cohort 
survival study over a period of one year (Figures 9-12). Our results for this part of the 
investigation reveals that the animals expressing the DAOR199W transgene had a slightly lower 
body weight at each age compared to their non-transgenic wild type littermates (Figures 9 and 
10).  
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In a study carried out by Konno and Yasumura (1984), the author showed that adult 
ddY/DAO− mice are unable to maintain their body weight at 2-3 months of age when provided 
with D-amino acid in the diet in comparison to the wild type animals (ddY/DAO+). In their 
study it was clearly demonstrated that in the absence of DAO enzyme, animals were unable to 
breakdown the D-amino acids present in their diet, which led to continuous and consistent 
weight loss throughout the duration of the investigation. Hence, the authors suggested that 
DAO is crucial for the breakdown of D-amino acids (Konno and Yasumura, 1984).  However, 
the authors did not indicate whether the participating animals were heterozygous or 
homozygous for the faulty DAO allele.  
As our animals also express the endogenous DAO protein, it is likely that the minor 
differences in overall body weight observed here is due to the presence of the endogenous 
protein that contributes towards the breakdown of the D-amino acids.  
Additionally, we observed some distinct differences in terms of physical appearance 
between the DAOR199W animals and non-transgenic wild types (Figure 13). Both males and 
females bearing the mutant transgene appeared very hunched and developed kyphosis, which 
was more noticeable in transgenic females than the males. This phenotypic difference between 
the wild type and mutant animals led us to design a gait analysis experiment (Figures 14-17). 
In this investigation we analysed both genotypes for their gait, footfall, and mechanics and 
measured over 40 parameters. Almost all the results obtained for this detailed investigation 
revealed no major significant differences between our transgenic line and their non-transgenic 
wild type littermates. 
However we observed that there was a significant difference between the hindpaw 
angle in the DAOR199W transgenic females and their non-transgenic wild type littermates (P = 
0.0435*, n ≥ 10) (Figure 14). Paw angle is defined as the angle of the paw (hind or fore) 
during peak stance in relation to the long axis of the body. Hence, a negative value for this 
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parameter indicates that the animal places its paw inward towards the long axis of its body 
every time the paw is placed on the surface of the treadmill. A positive value on the other hand 
is an indication of the paws being placed outwards away from the long axis of the body 
(Vincelette et al., 2007, Piesla et al., 2009, Hampton et al., 2011).  
This therefore means that the transgenic animals place their hindpaws in a straight line, which 
is almost parallel to the long axis of their bodies (with the mean value of -0.008333 ± 0.7330°) 
in comparison to their non-transgenic wild type littermates (with the mean value of -2.255 ± 
0.7275°). Considering the data obtained for the same parameter for the forepaws on the other 
hand suggest that possibly in order to maintain its balance due the changes in the paw angle 
the animal is forced to turn its forepaws inward (with the mean value of -1.241 ± 0.5678°) in 
comparison to their non-transgenic wild type littermates (with the mean value of -0.005000 ± 
0.5485°) who places its forepaws almost parallel to its body (Figure 15). In contrast, the 
reverse changes in the paw angle in the mutant female mice may reflect the kyphosis shown in 
Figure 13. This hypothesis however requires further investigations such as monitoring the 
possible time dependent loss of motor neurons and the consequent (if any) muscle atrophy.  
In conclusion, together with the data obtained from our survival study as well the 
cellular analysis, it can be concluded that overexpression of the mutant DAOR199W protein 
exerts some toxic effects at the cellular level, which are similar to those seen in the SOD1G93A 
transgenic mouse model. Although very minor, these changes induce some phathogenic 
effects, but they are not enough to trigger any major or life threatening phenotypic changes in 
this particular line of transgenic animals.  
This data is compatible with the bulk of literature that is available on transgenic 
animal models, where extensive research revealed that while a mutation can cause a lethal 
disease in humans, they often do not trigger any phenotype in the transgenic mouse models 
carrying the same mutation. And this certainly appears to be the case in our DAOR199W 
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transgenic line. As mentioned previously presence of the endogenous DAO protein may have 
played a part towards the mild phenotype observed in our mutant DAOR199W animals. This 
hypothesis however requires further investigations, either by examining the levels of DAO 
activity in the current DAOR199W animal model or by generating a new mouse model on a 
DAO knock out background bearing the mutant DAOR199W gene only. It is however 
important to note that we aimed to generate an animal model resembling similar genetic 
features to the human patients, since the effected individuals were heterozygous for the faulty 
DAOR199W protein, and the mode of inheritance for the mutant allele was autosomal 
dominant. Moreover, the in vitro investigations carried out by our colleagues as described 
previously indicate that even in the presence of the endogenous DAO protein, the R199W 
mutation is pathogenic in transfected neuronal cells (Mitchell et al., 2010).  
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3.3.3. Mice overexpressing the DAO protein (DAOWT) 
As a control for the transgenic mice overexpressing the mutant DAOR199W we 
generated a second line of transgenic animals, overexpressing the wild type form of the DAO 
protein (DAOWT). This was to ensure that any phenotype generated in the mutant DAOR199W 
mice was not just related to the overexpression of DAO itself. As displayed in Figures 18 we 
successfully confirmed overexpression of the wild type DAO protein in some tissues of this 
transgenic line. Interestingly despite the known ability of the CAGG promoter/enhancer to 
promote the ubiquitous expression of the transgene of interest, we showed that the DAO 
transgenes (both DAOR199W and DAOWT) failed to express in liver and small intestine of our 
transgenic lines.  
The low intensity of the bands presented in the western blot analysis for the transgenic 
animals overexpressing the DAOWT (Figure 18) in comparison to those seen for the same 
tissues from the DAOR199W mutant animal (Figure 4), may be a consequent of the transgene 
integration site. 
Although confirmed previously, we aimed to reconfirm the expression of DAO protein 
in the spinal cord of our transgenic animals as displayed in Figure 19A. Although very faint, 
the transgene expresses at slightly higher levels than the endogenous DAO protein in the 
spinal cord of the transgenic animals. In addition, we generated a preliminary set of data 
indicating an approximate 8 fold increase in DAO expression levels in our transgenics (n = 3 
mice per group, Figure 19B and B’).  
We further confirmed the expression of the DAO wild type protein in the lumbar 
region of the spinal cord of our transgenic animals by immunohistochemistry in Figure 20. The 
Figure clearly displays that majority of the motor neurons in the lumbar region in the DAOWT 
transgenic animal express the DAO protein (B and B’). This becomes particularly apparent 
when this panel is compared to the non-transgenic wild type panel presented on the left (A and 
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A’). The counter staining with DAO and Nissl reveals that majority of the motor neurons in the 
same area in the non-transgenic wild type animal appear purple in comparison to the intense 
brown colour displayed in DAOWT panel, suggesting the low level of DAO protein in the 
majority of non-transgenic motor neurons. Interestingly, both panels also suggest that while 
the presence of DAO is mostly concentrated in the grey matter of the spinal cord in the non-
transgenic wild type animal (A), its presence is notable in both the grey and white matter of 
the spinal cord in the DAOWT transgenic animal (B). Thus, these results suggest the ubiquitous 
expression of the wild type DAO protein expected of the CAGG promoter/enhancer, at the 
spinal level.  
Results presented in Figures 21 and 22 demonstrate that the DAOWT transgenic animals 
do not develop any abnormalities at the cellular level. Both of these Figures illustrate that all 
motor neurons in the lumbar region of the spinal cord in the DAOWT transgenic animals (B, in 
both Figures) display normal and highly similar morphology to those of the non-transgenic 
wild types (A, in both Figures). This fact is further demonstrated through the staining pattern 
in these cells where the cells picked up the stain in an exact same pattern as those displayed in 
the non-transgenic wild type animals for both ChAT and ubiquitin.  
Hence, these results confirm that overexpression of the wild type DAO protein does 
not exert any toxic effect at the cellular level as no abnormalities were observed in terms of 
motor neuron morphology and survival in the transgenic animals bearing the DAOWT 
transgene.         
Additionally we confirmed the health of the DAOWT transgenic animals in our survival 
study. Data presented in Figures 23 and 24 indicate that overall body weight in the DAOWT 
animals was highly similar if not the same as the non-transgenic wild type. Comparing this 
data to that of the DAOR199W animals (Figures 9 and 10), indicates that while mutant 
DAOR199W animals displayed a lower body weight throughout their lifespan compared to their 
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non-transgenic littermates, no differences was detected amongst the genotypes in the DAOWT 
transgenics.  
Distinct differences observed between our DAOWT transgenic line and the mutant 
DAOR199W model both at the molecular, cellular and the behavioural levels, the high 
similarities between the DAOWT and their non-transgenic wild type littermates strongly 
suggest that our latter line is not compromised by the transgene expression and therefore can 
be used in the future studies.  
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4.1. Introduction  
The human DAO gene is mapped to chromosome 12q24 (Fukui and Miyake, 1992), 
encodes a 39.4kDa flavin adenine dinucleotide (FAD)-dependent oxidase protein known as 
DAO. Expression of the DAO protein has been detected in the mammalian central nervous 
system (CNS), where its shown to be present at particularly high levels in both glial and 
neuronal cells (Sacchi et al., 2008, Sacchi et al., 2011, Popiolek et al., 2011).  
In 2010, our colleagues reported a mutation at position R199W in the DAO gene that 
was associated with ALS in humans. Following this discovery the de Belleroche group 
carried out extensive cell culture analysis using neuronal cell lines to demonstrate the toxic 
effects of this mutation in terms of cellular structure and survival. These studies revealed that 
the enzymatic activity of the DAO protein is eliminated in the presence of the R199W 
mutation. Similarly they observed a considerable reduction in DAO enzyme activity in a 
human ALS patient carrying the R199W mutation in the DAO gene in comparison to a 
control case.  
It was also demonstrated that transduction of primary motor neuron cultures with DAOR199W 
leads to a significant increase in apoptosis. Co-culturing of untransduced motor neurons with 
primary astrocytes transduced with lentiviral vector bearing the mutated DAOR199W transgene 
resulted in a substantial rise in the number of apoptotic motor neuron cells. Further cell based 
investigations revealed that expressing the mutant DAOR199W protein in motor neurons 
promotes cellular abnormalities such as loss of projections, atrophy and abundance of 
ubiquitinated aggregates, features absent in the same cell line expressing the wild type form 
of DAO or untransfected cells (Mitchell et al., 2010).          
Furthermore, under normal conditions the DAO enzyme is responsible for catalyzing 
the oxidative deamination of D-amino acids to their corresponding keto acids (Krebs, 1935, 
Pilone Simonetta et al., 1989). In particular, DAO has been shown to play a crucial role in 
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regulating the levels of D-serine, a co-agonist/activator of the N-methyl-D-aspartate (NMDA) 
glutamatergic subtype receptor (Mothet et al., 2000). Studying the spinal cord samples from 
both SALS and FALS patients revealed an elevation in levels of D-serine in affected 
individuals, and the authors also provided evidence that the SOD1G93A transgenic mice also 
showed an elevation in D-serine levels in their spinal cord during disease progression (Sasabe 
et al., 2007). Interestingly, transcription of enzymes involved in D/L-serine biosynthesis (3-
phosphoglycerate dehydrogenase and phosphoserine phosphatase) has been shown to be 
upregulated in motor neurons in another mouse model of ALS, SOD1G37R (Lobsiger et al., 
2007). All the above reports are also in line with findings that demonstrated a significant 
reduction in DAO enzymatic activity in the SOD1G93A mouse model of ALS (Sasabe et al., 
2012).  
Considering the patient phenotype and the in vitro data (mentioned above), we aimed 
to further investigate the effects of DAOR199W in ALS pathogenesis and survival. This was 
done through a large cohort survival study involving the DAOR199W and high copy number 
SOD1G93A mouse models. In this Chapter we therefore focused on examining the effect of the 
DAOR199W mutation on the survival of high copy number SOD1G93A transgenic mice. 
We hypothesised that presence of the DAOR199W mutant transgene in the double 
transgenic animals carrying both DAOR199W and SOD1G93A, would induce highly toxic affects 
which would cause an earlier onset of disease, progression at an accelerated rate and thus a 
considerably shorter lifespan in comparison to their SOD1G93A littermates.    
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4.2. Results 
Given the well-known nature of the high copy number SOD1G93A mouse model and 
its well-defined lifespan, in this part of the investigation we aimed to examine the effect of 
the DAOR199W mutation on survival of SOD1G93A in a longitudinal large cohort survival study. 
This was achieved by crossing heterozygous DAOR199W females with high copy number 
SOD1G93A male transgenic mice, which gave rise to a mixture of male and female offspring 
bearing either DAOR199W/SOD1G93A or SOD1G93A. Upon identifying the genotypes, all 
animals were recruited in the survival study, where the operator was blind to the genotypes. 
The development of ALS related disabilities for both genotypes were assessed by using a 
neurological scoring system (on a scale of 0 to 4, where 0 was equivalent of being normal and 
four was allocated to complete paralysis) of both hindlimbs twice a week commencing from 
approximately 30 days of age in conjunction with the assessment of body weight as reported 
by Scott and colleagues. The end point was established as the point in time that the mouse 
was unable to right itself within 20 seconds when placed on its side, at this stage the animal 
was culled and its final weight, as well as its age at death was recorded (Scott et al., 2008).  
The scoring criteria and survival analysis are described in full details in Chapter 2. 
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4.2.1. Assessment of Body Weight   
Results for the assessment of body weight are presented in Figures 25 and 26, and 
they indicate that as expected there are distinct differences between the sexes. These Figures 
demonstrate that male animals are heavier in terms of total body weight in comparison to 
their female littermates. Both graphs however demonstrate that all animals followed the same 
trend throughout their lifespan. All animals increased in their body weight steadily until they 
reached the maximum weight at approximately 88 days for males and 99 days for females, 
and the curves reached a peak at this point. After this point all the animals experienced a 
dramatic decrease in their body weight, which continued until the animal reached the end 
stage.  
In addition, Figure 25 which represents data for the assessment of body weight in 
females demonstrates distinct differences in terms of body weight between the double 
transgenic females and their SOD1G93A littermates, where the double transgenic animals 
(SOD1G93A/DAOR199W) are notably lighter in comparison to their SOD1G93A littermates, an 
effect absent in the males. Unlike females, the male littermates (Figure 26) display a highly 
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Figure 25. Longitudinal assessment of body weight in female SOD1G93A and double 
transgenic (SOD1G93A/DAOR199W) littermates. 
Mean group body weight plotted for SOD1G93A and double transgenic (SOD1G93A/DAOR199W) female 
mice over time from approximately 30 days of age until all the animals within a group reached the 
end stage and the study was terminated (n = 14 SOD1G93A mice and 22 double transgenics). As mice 
within groups died at different ages, in order to avoid decomposition of the mean at later stages, the 
final weights of all mice were carried forward when calculating group mean values, until the date at 
which the last mouse in that particular genotype group died. Error bars represent standard error of the 
mean (SEM). 
SOD1G93A females are presented in purple, and the double transgenic (SOD1G93A/DAOR199W) 
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Figure 26. Longitudinal assessment of body weight in male SOD1G93A and double 
transgenic (SOD1G93A/DAOR199W) littermates. 
Mean group body weight plotted for SOD1G93A and double transgenic (SOD1G93A/DAOR199W) male 
mice over time from approximately 30 days of age until all the animals within a group died and the 
study was terminated (n = 14 mice per experimental group). As mice within groups died at different 
ages, in order to avoid decomposition of the mean at later stages, the final weights of all mice were 
carried forward when calculating group mean values, until the date at which the last mouse in that 
particular genotype group died. Error bars represent standard error of the mean (SEM). 
SOD1G93A males are presented in blue, and the double transgenic (SOD1G93A/DAOR199W) littermates 



























Age (+/- 3 days) 
SOD1G93A 
Double Transgenic 
	   183 
4.2.2. Assessment of Neurological Scores 
All animals were assessed for their ALS related neurological symptoms on a twice a 
week basis. As described in detail in Chapter 2. Materials and Methods (subsection 2.2.1.7), 
at each analysis session, animals were awarded a score for each leg ranging from 0 to 4, using 
a scoring system established by ALSTDI and confirmed by a large and detailed study carried 
out by Scott and colleagues (Scott et al., 2008).  
As described previously, the scoring system indicates that the score of ‘0’ is 
considered as normal and it is defined as a full extension of hind legs away from the lateral 
midline when the animal is suspended by its tail, score ‘1’ is awarded upon collapse of hind 
legs towards the lateral midline due to muscle weakness or trembling of hindlegs during tail 
suspension. Score ‘2’ is associated with toe curling or dragging any part of the foot, animals 
are given a score ‘3’ when rigid paralysis or minimal joint movement is observed in the hind 
legs, and the animal is regarded to have reached the end stage when it is unable to right itself 
within 20 seconds when placed on its side, at which point score ‘4’ is awarded and the animal 
is euthanized (Scott et al., 2008). 
Overall analyses of the neurological score for both females and males are presented in 
Figures 27 and 28 respectively. Both graphs demonstrate that animals of both genotypes 
appeared normal early in their lifespan and did not develop any abnormalities until 
approximately 70 days of age. From this point onwards however, the neurological scores 
continuously and consistently worsened until the animals reached the score of 4 and were 
euthenised. The data presented demonstrates that both SOD1G93A and the double transgenic 
animals (SOD1G93A/DAOR199W) followed the same trend in terms of their neurological score 
in both males and females, and no overall differences seems to be present across the two 
genotypes. 
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Further analyses of the neurological scores were carried out in a form of summary 
measurements as described in a study by Matthews and colleagues (highlighted in Chapter 2. 
Materials and Methods, subsections 2.2.1.8). These summary measurements are presented in 
Figures 29-32 (Matthews et al., 1990).  
Figure 29 demonstrates the onset of neurological score, defined as the point in time at 
which the animal reached the score of 2 (displayed by toe curling or dragging any part of the 
foot). The Figure shows that the median value for reaching score 2 in double transgenic males 
was approximately 119 days, slightly later than their SOD1G93A littermates who reached this 
stage of the disease at approximately 113 days (P = 0.3865). Double transgenic females first 
displayed the neurological scores at the approximate median age of 125 days, which was 
significantly earlier in comparison to their SOD1G93A littermates whose median onset of 
neurological score was 131 days (P = 0.0239). In addition, comparison of the same genotypes 
across the sexes indicate that while there are no differences in terms of the onset of 
neurological symptoms between the animals bearing the double transgenes 
(SOD1G93A/DAOR199W males vs. females, P = 0.0518), there is a significant difference in the 
median time of onset between the SOD1G93A animals, where females had a significantly later 
onset in comparison to their male littermates (131 vs.113, P = 0.0004, Table 7B).    
Disease onset is described as the point in time the animal was at its highest weight 
(Figure 30). The graph illustrates that both SOD1G93A and double transgenics developed the 
disease at approximately the same time in both sex. Males developed the disease at the 
median age of 89 days, ten days earlier in comparison to their female littermates whose 
median disease onset was noted to be at approximately 99 days (Double transgenics males vs. 
females P = 0.1131; SOD1G93A males vs. females P = 0.1102) 
Figure 31 displays the progression of the disease, which is summarized as the period 
of time between the disease onset and the end stage. This graph clearly indicates that while 
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the disease onset is variable between the males and females, the rate at which the disease 
progresses is almost the same across all groups, ranging from 39 to 42 days (Double 
transgenic males vs. females P = 0.3318; SOD1G93A males vs. females P = 0.5786). 
Survival (Figure 32) is defined as the period of time between birth and the humane 
end point (determined by the righting reflex). These Figures reveal that there are no major 
differences in terms of survival time between the different genotypes in males, as further 
indicated in Table 7A. Both SOD1G93A and the double transgenic males display median 
lifespan of 129 and 126 days respectively (P = 0.2229).  
The graphs also demonstrate that there are no differences in terms of survival between 
the different genotypes in females, as the median survival time for both SOD1G93A and the 
double transgenic females was 136 and 135 days respectively (P = 0.8242, as displayed in 
Table 7A).  
Comparison of the survival curves across the genotypes (as demonstrated in the lower 
panel in Figure 32) indicates that as expected the SOD1G93A females had a longer lifespan 
(median of 136 days) in comparison to their male littermates whose lifespan was determined 
to be shorter with the median of 129 days. Although the differences in survival time between 
the males and females bearing the SOD1G93A transgene are highly apparent on the graph, they 
did not reach significance (P = 0.0771). Similar results were obtained for the double 
transgenic animals, females lived significantly longer (median of 135 days, P = 0.0241) in 
comparison to their male littermates (median of 126 days).  
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Figure 27. Longitudinal assessment of neurological scores in female SOD1G93A and double 
transgenic (SOD1G93A/DAOR199W) littermates. 
Mean group combined neurological score plotted for SOD1G93A and double transgenic 
(SOD1G93A/DAOR199W) female mice over time from approximately 30 days of age until all the animals 
within a group died and the study was terminated (n = 14 SOD1G93A mice and 22 double transgenics). 
A combined neurological score was calculated for each mouse at each time point through summation 
of the neurological scores recorded for its left and right hindlimbs. Error bars represent standard error 
of the mean (SEM).  
SOD1G93A females are presented in purple, and the double transgenic (SOD1G93A/DAOR199W) 
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Figure 28.	  Longitudinal assessment of neurological scores in male SOD1G93A and double 
transgenic (SOD1G93A/DAOR199W) littermates. 
Mean group combined neurological score plotted for SOD1G93A and double transgenic 
(SOD1G93A/DAOR199W) male mice over time from approximately 30 days of age until all the animals 
within a group died and the study was terminated (n = 14 mice per experimental group). A combined 
neurological score was calculated for each mouse at each time point through summation of the 
neurological scores recorded for its left and right hindlimbs. Error bars represent standard error of the 
mean (SEM).  
SOD1G93A males are presented in blue, and the double transgenic (SOD1G93A/DAOR199W) littermates 
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Kaplan-Meier plot demonstrating the time taken for the animals to reach the score of 2, otherwise 
referred to as the onset of the neurological symptoms, in both SOD1G93A and double transgenic (DT) 
male and female littermates (n ≥ 14 mice per experimental group - females: n = 14 SOD1G93A mice 
and 22 double transgenics; males: n = 14 SOD1G93A mice and 14 double transgenics).  
Results for the statistical analyses performed on the above data set are presented in Table 7B, where 
the threshold of significance was set at P ≤ 0.05.	  
Graph presents data for both male (blue) and female (purple) SOD1G93A mice as well as DT male 












Figure 29. Onset of neurological symptoms in SOD1G93A and double transgenic mice in 
both male and female littermates. 





















Double Transgenic (Males) 
SOD1G93A (Females)
Double Transgenic (Females) 
	   189 
Kaplan-Meier plot demonstrating the disease onset, defined as the point in time that the animal was at 
its maximum weight, in both SOD1G93A and double transgenic (DT) male and female littermates (n ≥ 
14 mice per experimental group - females: n = 14 SOD1G93A mice and 22 double transgenics; males: n 
= 14 SOD1G93A mice and 14 double transgenics).  
Results for the statistical analyses performed on the above data set are presented in Table 7B, where 
the threshold of significance was set at P ≤ 0.05.	  
Graph presents data for both male (blue) and female (purple) SOD1G93A mice as well as male (green) 

































Figure 30. Disease onset in SOD1G93A and double transgenic mice in both male and 
female littermates. 
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Kaplan-Meier plot demonstrating the disease progression, defined as the period of time between the 
peak weight and the end stage, calculated by subtracting the age at death from the age at onset (peak 
weight). The Graph represents data for both SOD1G93A and double transgenic (DT) male and female 
littermates (n ≥ 14 mice per experimental group - females: n = 14 SOD1G93A mice and 22 double 
transgenics; males: n = 14 SOD1G93A mice and 14 double transgenics).  
Results for the statistical analyses performed on the above data set are presented in Table 7B, where 
the threshold of significance was set at P ≤ 0.05.	  
Graph presents data for both male (blue) and female (purple) SOD1G93A mice as well as male (green) 
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Figure 31. Disease progression in SOD1G93A and double transgenic mice in both male and 
female littermates. 
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Kaplan-Meier plot demonstrating survival, determined as the time taken for the animal to reach the 
humane end point, in both SOD1G93A and double transgenic (DT) male and female littermates. The 
graph on the top panel represents the data from both SOD1G93A and DT male and female littermates (n 
≥ 14 mice per experimental group - females: n = 14 SOD1G93A mice and 22 double transgenics; males: 
n = 14 SOD1G93A mice and 14 double transgenics).  
The graph in the bottom panel on the left presents data for both male and female mice bearing the 
SOD1G93A transgene (blue and purple respectively). The long-rank test analysis indicates that there are 
no differences between the males and the females in terms of survival (P = 0.0771, threshold of 
significance was set at P ≤ 0.05).  
The graph in the bottom panel on the right presents data for both male and female DT mice (green and 
red respectively). The long-rank test analysis indicates that there are significant differences in terms of 
survival between the males and the females (P = 0.0241*, threshold of significance was set at P ≤ 
0.05). Results for the statistical analyses performed on the above data set are presented in Table 7B. 
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Figure 32. Survival of SOD1G93A and double transgenic mice in both male and female 
littermates. 
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(A) Median (days) 
SOD1G93A Double 
Transgenics 
Males Females Males Females 
Onset of Neurological Symptoms 113 131 119 125 
Disease Onset 89 99 88 99 
Disease Progression 42 41 39 42 
Survival  129 136 126 135 
 
(B) 
Log-rank Test (P Value) 




Females Males Females 
Onset of Neurological Symptoms 0.0004*** 0.0518 0.3865 0.0239* 
Disease Onset 0.1102 0.1131 0.8183 0.7358 
Disease Progression 0.5786 0.3318 0.2935 0.4750 
Survival 0.0771 0.0241* 0.2229 0.8242 
Table 7. Kaplan Meier time to event analyses for SOD1G93A and double transgenic 
(SOD1G93A/DAOR199W) in both males and females. 
(A) Median values obtained from Kaplan-Meier analysis for the time taken for mice to reach a score 
of 2 in both hindlimbs (onset of neurological scores), age at maximum weight (disease onset), disease 
progression and time taken for animals to reach the humane end point determined by its inability to 
right itself within 20 seconds of being placed on its side (survival) for both males and female 
littermates of either genotype groups.  
(B) The log-rank test assesses the null hypothesis that the Kaplan-Meier curves for all groups are 
identical (i.e. the presence of the DAOR199W transgene did not change the time taken to reach the event 
being analysed). Thus, low P-values indicate that differences between genotype groups did not occur 
due to chance. Log-rank analysis of the onset of neurological symptoms in females carrying the 
SOD1G93A transgene versus their double transgenic littermates revealed that there were significant 
differences between the groups for this particular measurement. A significant difference was also 
detected in survival between the double transgenic males and females via the log-rank test.  
Significant differences are indicated in bold and by asterisk in table (B). Underlined values indicate 
occasions where the P value was highly close to reach significance. Threshold of significance was set 
at P ≤ 0.05. 
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4.2.3. Assessment of SOD1G93A Transgene Copy Number 
According to Scott and coworkers, variations in SOD1G93A transgene copy number 
effect the final outcome of the study, and must be carefully monitored (Scott et al., 2008). 
Therefore to ensure the validity of our results, we monitored for possible variations in the 
SOD1G93A transgene copy number in any animal whose survival time appeared to be outlying 
compared to the rest of its group. This was carried out using the technique and criteria 
introduced by Alexander and colleagues (2004), described in full details in Chapter 2. 
Materials and Methods, subsections 2.2.1.9 and 2.2.1.10. 
The potential variation in SOD1G93A transgene copy number was assessed for 4 female 
and 3 male mice within each genotype group, as they displayed survival times that appeared 
to be outliers in comparison to the rest of the group. Although in some cases the survival 
times of the animal in question only differed slightly from those of their peers, in order to 
ensure the validity of the results it was essential to check for copy number variation in these 
animals.  
The ∆CT values (ΔCT = mIl-2 CT − hSOD1G93A CT), obtained for the outlying 
animals were compared to those obtained for a subset of control male and female mice. The 
control animals were selected on the basis that they displayed a survival time closest to the 
median survival (as displayed in Table 7A). Thus, any mice whose ∆CT value differed by 
more than 2 standard deviations from the average ∆CT value of the control group was 
considered an outlier and therefore excluded from the final analyses (Alexander et al., 2004, 
Kaneb, 2012).  
Detailed analysis of the outlying animals for both SOD1G93A and double transgenic 
genotypes are demonstrated in Tables 8 and 9 respectively. These data confirm that while 
none of the animals bearing the SOD1G93A transgene experienced a change in copy number, 3 
of the suspected animals expressing the double transgenes (SOD1G93A/DAOR199W) appeared to 
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have experienced a change in copy number and were therefore excluded from the analyses. 
As shown in Table 9, the two males and one female double transgenic animals excluded from 
the study displayed a survival time of 150, 206 and 191 days respectively which were 
significantly outside the range of median survival, as determined for their peers (as displayed 
in Table 7A).         
The survival times of the control and outlying animals that were assessed for the 
potential variation in SOD1G93A transgene copy number are summarized in Tables 8 and 9. 
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Assessments of copy number variation were performed for 3 males and 4 females (B) whose survival 
time appeared to be outlying compared to the controls (A). Controls were defined as the animals of 
the same sex within the genotype group under investigation. ∆CT values obtained for the outlying 
animals (B) were compared to those ∆CT values obtained for the subset of 2 male and 3 female 
control mice (A) whose survival was closest to the median survival determined for males and females 
control mice respectively (Table 7A). Hence, any animal in table (B) whose final ∆CT value differed 
by more than 2 standard deviations from the mean ∆CT calculated for the control mice (A) was to be 
excluded, none of the animals however met this criteria.  
The survival, mean and the standard deviation of the ∆CT values obtained for control mice as well as 
the survival and ∆CT values obtained for the outlying animals for which copy number variation was 
assessed are summarised in Tables A and B respectively. The median survival is presented in Table 
7A, where it was determined to be 129 and 135 days for control males and females respectively. 
 
(A) Controls Animal ID 
Age at 
Death 
ΔCT Average STDEV STDEVx2 
Males 
36M 125 10.04 
10.01 0.27 0.54 
50M 133 10.17 
Females 
2F 135 10.25 
45F 136 10.07 
80F 135 9.55 
Table 8. Assessment of copy number variation in males and females carrying the 
SOD1G93A transgene. 
(B) Outliers  Animal ID  
Age at 
Death 





17M 143 10.02	   -0.01 No 
31M 141 10.18	   -0.16 No 
44M 143 10.21	   -0.20 No 
Females 
4F 153 10.33	   -0.32 No 
52F 154 9.90	   0.12 No 
75F 154 9.80	   0.21 No 
78F 156 9.60	   0.42 No 
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Assessments of copy numbers variation were performed for 3 males and 4 females (B) whose survival 
times appeared to be outliers compared to the controls (A), defined as the animals of the same sex 
within their genotype group. ∆CT values obtained for the outlying animals (B) were compared to 
those ∆CT values obtained for the subset of 2 males and 2 females control mice (A) whose survival 
was closest to the median survival determined for males and females control mice respectively (Table 
7A). Hence, any animal in table (B) whose final ∆CT value differed by more than 2 standard 
deviations from the mean ∆CT calculated for the control mice (A) was to be excluded. 2 males and 1 
female met this criteria.  
The survival, mean and the standard deviation of the ∆CT values obtained for control mice as well as 
the survival and ∆CT values obtained for the outlying animals for which copy number variation was 
assessed are summarised in Tables A and B respectively. The median survival is presented in Table 
7A, where it was determined to be 125 and 134 days for control males and females respectively.	  
(A) Controls   Animal ID 
Age at 
Death 
ΔCT Average STDEV STDEVx2 
Males 
11M 125 9.36 
9.54 0.20 0.41 22M 125 9.46 
Females 
27F 133 9.50 
29F 133 9.83 
(B) Outliers  Animal ID  
Age at 
Death 





57M 150 8.80 0.74 Yes 
62M 147 9.36 0.17 No 
60M 206 8.69 0.85 Yes 
Females 
14F 154 9.29 0.25 No 
51F 160 9.32 0.22 No 
79F 161 9.35 0.19 No 
77F 191 8.59 0.95 Yes 
Table 9. Assessment of copy numbers variation in males and females carrying the double 
transgenes (SOD1G93A/DAOR199W). 
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4.3. Discussion 
In this study we aimed to test the hypothesis that the presence of the mutated 
DAOR199W along with the SOD1G93A transgene in the double transgenic animals triggers an 
earlier disease onset, accelerated disease progression and a shorter survival in both males and 
females in comparison to their SOD1G93A littermates. This hypothesis stemmed from a 
previous discovery of the R199W mutation in the DAO gene and its association with FALS in 
a three generational FALS kindred and the eventual death of the affected individuals, and the 
followed up cell culture studies (Mitchell et al., 2010).  
Hence, we investigated the effect of DAOR199W mutation in a well-known animal 
model of ALS, namely the high copy number SOD1G93A mouse, in terms of disease onset, 
progression and survival, through a large cohort, blinded survival study. Onset of the disease 
and its progression were analysed by twice weekly monitoring of weight and neurological 
scores, while survival was determined as the age at which the animal was unable to right 
itself within 20 seconds of being placed on its side. 
Our detailed analyses of the SOD1G93A and their double transgenic littermates 
(SOD1G93A/DAOR199W) demonstrate that animals of both genotypes followed the same overall 
pattern in terms of their overall body weight throughout their lifespan. All animals increased 
in their body weight steadily until they reached the maximum weight, after which all animals 
experienced a dramatic and continuous decrease in body weight until death. There are 
however distinct differences in maximum body weight amongst females as displayed in 
Figure 25, whereas both SOD1G93A and double transgenic males exhibit highly similar body 
mass throughout their lifespan (Figure 26).  
Since our transgenic animals retained the endogenous DAO alleles on the 
C57B16xCBA/Ca background, as well as expressing the DAOR199W mutant allele, we 
considered measuring the DAO activity in our DAOR199W transgenic animals. However, it has 
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been demonstrated that DAO activity is significantly reduced in the lumber region of the 
SOD1G93A mice to almost similar levels to that of the B6DAO+/− mice (Sasabe et al., 2012). 
With this in mind we concluded that it is highly likely that the effect of the endogenous DAO 
protein is suppressed in the presence of the SOD1G93A transgene in our double transgenic 
animals. Thus, at the time of this particular experiment, we decided that pursuing the time 
consuming, labour intensive and expensive technique of determining DAO activity in these 
animals was not worthwhile.  
It has been documented that enzymatic activity of the DAO protein varies between 
sexes, where females have approximately half the enzyme activity in comparison to males of 
the same age (Konno and Yasumura, 1983). Some studies also demonstrated that testosterone 
stimulates DAO activity, treatment of both human males and females with testosterone 
hormone resulted in an increase in renal DAO activity (Jotova et al., 1999). Other studies 
demonstrated that castration led to a decrease in DAO enzyme activity in mice whereas 
administration of testosterone restored the enzyme activity to levels greater than the normal 
(Clark et al., 1943, Van Bekkum and Kassenaar, 1954). 
Given that DAO enzyme is required for degradation of D-amino acids, which 
consequently contributes to maintaining the overall body weight (Konno and Yasumura, 
1984). It is possible that the presence of the SOD1G93A and the DAOR199W mutant transgenes 
in the double transgenic females suppressed or diminished the already low levels of the 
enzymatic activity of the endogenous DAO protein, preventing the animal from maintaining a 
similar body weight to that of their SOD1G93A littermates (Figures 25). 
The high similarities in body weight between the double transgenic males and their 
SOD1G93A littermates, could be due to the naturally higher levels of DAO enzymatic activity 
in males compared to females, which was not ablated by the presence of the double 
transgene. Thus, this level of DAO activity was enough for the animals to maintain their body 
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weight at the similar level as their SOD1G93A littermates. This level of endogenous DAO 
enzyme activity could also account for the lesser degree of the motor neuron loss in males as 
demonstrated in the previous Chapter, which unlike females did not reach significance 
(Chapter 2. Animal Models, subsection 3.2.2.3, Figure 8). This latter hypothesis could in turn 
be an indication of protective properties of the wild type DAO protein against motor neuron 
degeneration, a concept that is explored in more detail in the next Chapter. 
  Males and females also behaved differently in terms of onset of neurological 
symptoms, disease onset and survival (Figures 29, 30 and 32 respectively).  
The data suggests that the presence of the double transgenes (SOD1G93A/DAOR199W) in 
the double transgenic females triggered a significantly earlier onset of neurological symptoms 
in these animals (median of 125 days); 6 days earlier than their SOD1G93A littermates. 
Surprisingly, this was not the case for their double transgenic male littermates, whose onset 
was noted to be 6 days later than their SOD1G93A transgenic littermates (Figure 29), although 
the differences did not reach significance (median values, 119 vs. 113, P = 0.3865). 
Furthermore, despite the presence of the DAOR199W transgene, disease onset was 
unaffected across the genotype groups. The median onset of the disease differed by 
approximately 10 days between males and females, although this did not reach significance.  
Regardless of sex, genotype and onset, the disease progressed at highly similar rates 
amongst the groups (Figure 31).       
Distinct differences are also apparent between the sexes in terms of survival where 
females display a longer lifespan in comparison to their male littermates (Figure 32). While 
these differences did not reach significance when comparing SOD1G93A males and females, 
there are significant differences in lifespan between males and females in double transgenic 
animals. Double transgenic females survived for approximately 135 days in comparison to 
their male littermates whose median survival was noted to be as short as 126 days (Table 7).  
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It is well documented in the literature that female mice expressing the SOD1G93A 
transgene not only have a later onset of the neurological symptoms but also have a longer 
lifespan in comparison to the males of the same age and same genotype, which was also the 
case in our survival study (Figures 27, 28, 29 and 32). Precisely, the onset of the neurological 
symptoms was delayed by approximately 18 days in females expressing the SOD1G93A 
transgene in comparison to their male littermates (median values of, 131 vs. 113, P = 0.0004) 
and survival was extended by 7 days (median values of, 136 vs. 129, P = 0.0771). 
Interestingly however, while highly similar results were obtained for the double transgenic 
animals, the age of onset for neurological symptoms in females was only 6 days later than 
that of the males (median values of, 125 vs. 119, P = 0.0518). Survival in females on the 
other hand was significantly extended by 9 days compared to the males (median values of, 
135 vs. 126, P = 0.0241). Overall this data suggests the presence of the DAOR199W mutant 
transgene did not exert any significant effect on survival, as the animals of the same sex 
displayed highly similar survival time regardless of genotype. 
In addition to the sex differences we observed here, a study demonstrated that 
ovariectomized SOD1G93A female mice showed an accelerated disease progression (Choi et 
al., 2008), as well as shorter lifespan which was comparable to those of the SOD1G93A male 
mice (Groeneveld et al., 2004, Choi et al., 2008). Furthermore, the authors then demonstrated 
that administration of the 17β-estradiol on these females rescued the phenotype (Choi et al., 
2008). These findings therefore indicate that estrogen may play a role in slowing down 
disease progression and extending survival in female mice bearing the SOD1G93A transgene. 
In conclusion, our results indicate that although some differences are present between 
the different genotypes, overall the presence of the DAOR199W transgene alongside SOD1G93A 
did not exert any major effects on disease onset, progression or survival in either sex in our 
double transgenic animals (SOD1G93A/DAOR199W) compared to the SOD1G93A mice. This 
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could be due to the aggressive and accelerated nature of the phenotype enforced by the 
SOD1G93A mutation, which possibly masks any effect the DAOR199W mutation may trigger. It 
is also noteworthy that, in our previous investigations, where we monitored the affect of 
DAOR199W mutation at the cellular environment in our animal models, we investigated one 
age only (19.5 months, ~585 days old) and did not carry out a time course study to 
investigate the initiation of the pathogenesis that occurs at the cellular level as a result of the 
presence of the mutant DAOR199W protein. Hence, due to the very short lifespan of the 
SOD1G93A animals in general, should the resultant DAOR199W pathogenic changes at the 
cellular level commence at a later age than 136 days, it is unlikely that we would observe any 
affect during the lifetime of our double transgenic animals. Therefore it will be important to 
take the possible time dependent affects of the DAOR199W mutation into consideration in the 
future studies.       
It is also important to consider the presence of the endogenous DAO protein in these 
animal models in any future investigation, its possible affects can either be confirmed by 
analyzing the levels of enzymatic activity of the endogenous DAO protein or by developing a 
new line of transgenic animals bearing the DAOR199W mutation on a DAO knock out 
background, to ensure the absence and possible interference of the endogenous DAO protein.  
As mentioned in the previous chapter our aim was to generate a model resembling similar 
features to that of the human disease. As the human patients were heterozygous for the faulty 
DAOR199W allele, with an autosomal dominant mode of inheritance (Mitchell et al., 2010). 
Moreover, the in vitro investigations carried out by our colleagues confirmed that even in the 
presence of the endogenous DAO protein, the R199W mutation is pathogenic in transfected 
neuronal cells (Mitchell et al., 2010).  
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5.1. Introduction  
The N-methyl-D-aspartate receptor (NMDAR) is a subtype of the ionotropic glutamate 
receptors that exhibits relatively high permeability to calcium ions (Ca2+), which 
consequently links it to a range of physiological pathways, and thus dysfunction of this 
system is associated with a variety of pathological processes (Meldrum, 2000). 
The NMDAR is activated in the presence of the neurotransmitter glutamate and a 
coagonist, either glycine or D-Serine (Spalloni et al., 2013). However, the access of glycine 
to the NMDAR sites are strictly regulated through high-affinity glycine transport systems 
(Berger et al., 1998), enabling low glycine concentration at the NMDAR site, hence allowing 
D-serine to be the main coagonist substrate regulating the activity of NMDA receptors 
(Papouin et al., 2012) and in turn determining the excitability of glutamatergic neurons 
(Spalloni et al., 2013).  
Glutamate has been demonstrated as the main excitatory transmitter in the central 
nervous system (CNS) (Spalloni et al., 2013). Insufficient clearance of glutamate and the 
consequent increase or prolonged glutamatergic exposure may lead to excitotoxicity, which is 
detrimental to neurons (Choi, 1988, Arundine and Tymianski, 2003). Importantly, various 
studies have shown enhanced levels of glutamate in ALS patients, with a significant increase 
of this neurotransmitter in both CSF and plasma (Plaitakis and Caroscio, 1987, Rothstein et 
al., 1990).  
Furthermore, D-Serine, one of the coagonists of the NMDAR, has been shown to play a 
part in NMDAR-mediated neurotoxicity, that is involved in pathophysiological processes in 
neurodegenerative disorders (Shleper et al., 2005, Inoue et al., 2008, Mustafa et al., 2010, 
Hardingham and Bading, 2010). Interestingly, a previous study carried out by the de 
Belleroche group demonstrated that a point mutation associated with loss of activity in the 
enzyme responsible for the breakdown of D-serine (DAO) at position R199W is linked to 
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ALS (Mitchell et al., 2010). Following this discovery Sasabe and colleagues reported that 
DAO activity was significantly decreased in the spinal cord of SOD1G93A mouse model of 
ALS (Sasabe et al., 2012). In a different study the authors also documented that levels of D-
serine are elevated in the spinal cord of both ALS patients and in a SOD1G93A mouse model, 
and glial activation has been shown to be associated with an increase in expression levels of 
serine racemase (an unusual enzyme responsible for synthesis and breakdown of D-serine 
(Foltyn et al., 2005)), resulting in an elevation in levels of D-Serine (Sasabe et al., 2007). It 
has also been demonstrated that degradation of the endogenous D-serine by the DAO enzyme 
leads to a significant reduction in NMDAR neurotransmission (Mothet et al., 2000). 
By taking the above discoveries into account we hypothesized that increases in 
concentration of D-serine either due to elevated production through serine racemase or 
impaired clearance via DAO enzyme leads to accumulation of D-serine at the cellular level. 
This consequently results in continuous release of D-serine, followed by excessive and 
prolonged activation of the NMDAR, triggering toxicity and leading to motor neuron death 
and the ALS phenotype. With this in mind we further hypothesized that an increase in 
expression levels of the DAO enzyme might have the potential to promote D-serine 
degradation at a faster rate and so decrease the NMDAR activity. As described in the 
previous Chapter, following the association of the DAOR199W mutation and ALS, and based 
on the above hypothesis we designed a large cohort blinded survival study. This study 
involved offspring from a cross between our mice overexpressing the wild type DAO 
(DAOWT) protein and the well-known model of ALS, high copy number SOD1G93A, focusing 
on investigating the role of DAO overexpression in ALS-like phenotypes and survival. Thus, 
we further hypothesized that overexpression of the DAOWT would result in delayed disease 
onset, slower disease progression and prolonged survival in our double transgenic animals 
(SOD1G93A/DAOWT). 
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5.2. Results  
Following development of the DAOR199W transgenic mice and their cross with the 
high copy number SOD1G93A mice, we designed this experiment to examine the effect of the 
overexpression of the DAOWT protein in survival of the high copy number SOD1G93A animal 
model of ALS. This part of our investigation therefore consisted of a cross between 
heterozygous DAOWT dams and SOD1G93A transgenic sires, which gave rise to a selection of 
males and females offspring bearing either SOD1G93A/DAOWT or SOD1G93A. Upon 
identifying the genotypes, all animals were recruited in a longitudinal large cohort survival 
study, where the operator was blinded to the genotypes. The development of ALS related 
disabilities for both groups were assessed by using a neurological scoring system of both 
hindlimbs twice a week commencing from approximately 40 days of age in conjunction with 
the assessment of body weight. As described previously the end point was determined by 
assessing the righting reflex.  
The scoring criteria and survival analysis are described in full details in Chapter 2. 
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5.2.1. Assessment of Body Weight   
Results for the assessment of body weight are presented in Figures 33 and 34, and 
they indicate that there are distinct differences between the sexes. Male animals are generally 
heavier in terms of total body weight in comparison to their female littermates. However, 
despite the differences in body weight both graphs demonstrate that all animals followed the 
same pattern throughout their lifespan. As the animals grew their overall body weight 
gradually increased until all animals reached the maximum weight by approximately 100 
days for females, 90 and 98 days for SOD1G93A and double transgenic males respectively. 
After this point all the animals experienced a dramatic and continuous decrease in their body 
weight until they reached the humane end point.  
In addition, Figure 33, which represents data for the assessment of body weight in 
females demonstrates that there are no major differences in overall body weight between the 
different genotypes. This however is not true in the case of SOD1G93A and double transgenic 
males (Figure 34). As shown by the graph, there are clear differences in body weight, where 
the double transgenic animals weigh approximately 21 grams very early in their lifespan in 
comparison to their SOD1G93A littermates whose earliest mean group weight is recorded to be 
approximately 23 grams. The graph clearly displays that the distinct differences in overall 
body weight consistently continued throughout the animals life until the curves reached a 
peak, from which point the curves merged very closely, indicating that the body weight was 
highly similar between both genotypes from this point onwards until the animals of both 
groups reached the end stage.  
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Figure 33. Longitudinal assessment of body weight in female SOD1G93A and double 
transgenic (SOD1G93A/DAOWT) littermates. 
Mean group body weight plotted for SOD1G93A and double transgenic (SOD1G93A/DAOWT) female 
mice over time from approximately 40 days of age until all the animals within a group reached the 
end stage and the study was terminated (n = 14 SOD1G93A mice and 12 double transgenics). As mice 
within groups died at different ages, in order to avoid decomposition of the mean at later stages, the 
final weights of all mice were carried forward when calculating group mean values, until the date at 
which the last mouse in that particular genotype group died. Error bars represent standard error of the 
mean (SEM). 
SOD1G93A females are presented in purple, and the double transgenic (SOD1G93A/DAOWT) littermates 
are displayed in red.     
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Figure 34. Longitudinal assessment of body weight in male SOD1G93A and double 
transgenic (SOD1G93A/DAOWT) littermates. 
Mean group body weight plotted for SOD1G93A and double transgenic (SOD1G93A/DAOWT) male mice 
over time from approximately 40 days of age until all the animals within a group died and the study 
was terminated (n = 14 SOD1G93A mice and 19 double transgenics). As mice within groups died at 
different ages, in order to avoid decomposition of the mean at later stages, the final weights of all 
mice were carried forward when calculating group mean values, until the date at which the last mouse 
within that particular genotype group died. Error bars represent standard error of the mean (SEM). 
SOD1G93A males are presented in blue, and the double transgenic (SOD1G93A/DAOWT) littermates are 
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5.2.2. Assessment of Neurological Scores 
The development of ALS related neurological symptoms were carefully examined on 
a twice a week basis in all animals in a blinded fashion. Each individual animal was carefully 
assessed and scored for both its hindlimbs in accordance to the scoring criteria established by 
ALSTDI and analysed in a large study by Scott and colleagues in 2008 (Scott et al., 2008).  
As described previously the scoring system indicates that the score of ‘0’ is 
considered as normal and it is defined as a full extension of hind legs away from the lateral 
midline when the animal is suspended by its tail, score ‘1’ is awarded upon collapse of 
hindlegs towards the lateral midline due to muscle weakness or trembling of hindlegs during 
tail suspension. Score ‘2’ is associated with toe curling or dragging any part of the foot, 
animals are given a score ‘3’ when rigid paralysis or minimal joint movement is observed in 
the hindlegs, and the animal is regarded to have reached the end stage when it is unable to 
right itself within 20 seconds of being placed on its side, at which point score ‘4’ are awarded 
and the animal was terminated (Scott et al., 2008). 
One male and two females were discovered dead in their cages during this study, 
detailed postmortem examination revealed that the animals did not suffer from internal 
abnormalities or injuries and no physical signs of fighting wounds, bleeding, or skin 
abnormalities were found on their bodies that may have resulted in their premature death. As 
the mice had not shown a typical disease progression, the death of these animals was 
therefore recorded as “non-ALS deaths” and they were treated as “censored” in the Kaplan-
Meier analyses and excluded from the weight and combined neurological score plots. 
Overall assessment of the neurological score for both females and males are presented 
in Figures 35 and 36 respectively. Both graphs show that animals of both genotypes appeared 
normal early in their lifespan (denoted by score 0) and the ALS related abnormalities 
developed at approximately 70 and 90 days of age in males and females respectively. From 
	   210 
this point onwards, the symptoms of the ALS related disabilities became more and more 
apparent and consistently worsened until the animals reached the end stage. The data also 
demonstrates that animals bearing the SOD1G93A transgene only developed the neurological 
scores at a moderately accelerated pace when compared to their double transgenic littermates 
(SOD1G93A/DAOWT), this is particularly visible in the males (Figure 36).  
More detailed analysis of the neurological score data sets were carried out by means 
of summary measurements as described in detail in Chapter 2. Materials and Methods, 
subsection 2.2.1.8. These summary measure are presented in Figures 37-40.  
Results collected for the onset of neurological symptoms, defined as the point in time 
at which the animal reached the score of 2 in both hindlimbs (displayed by toe curling or 
dragging any part of the foot) are demonstrated in Figure 37. As shown in the top panel, the 
double transgenic animals had a significantly later onset of neurological symptoms in both 
males and females (median of 123 vs. 138 days) in comparison to their SOD1G93A littermates 
whose median onset of neurological scores was noted to be at approximately 112 (males) and 
124 (females) days. The bottom panel demonstrates that the double transgenic males and 
females approached the score 2 significantly later in comparison to their SOD1G93A 
littermates (median of 123 vs. 112 days in males (P = 0.0326), and 138 vs. 124 days in 
females (P = 0.0397)). In addition, the onset of the neurological symptoms amongst both 
sexes bearing the double transgenes was significantly different (P = 0.0196, Table 10B), 
females were found to develop the neurological scores at a later stage of their lifespan in 
comparison to their male littermates. Similar patterns were observed in animals expressing 
the SOD1G93A transgene, the differences however did not reach significance in this particular 
genotype group.    
Analyses of the disease onset, described as the point in time that the animal was at its 
highest weight, are displayed in Figure 38 for both males and females. The Figure 
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demonstrates that the disease had a later onset in double transgenic males in comparison to 
their SOD1G93A littermates, although the differences did not reach significance (median 
values of 98 vs. 90 days, P = 0.0826). The onset of the disease amongst females however was 
not different, as both genotypes had highly similar median disease onset (100 days). Females 
expressing the SOD1G93A transgene however had a significantly later onset in comparison to 
their male littermates (median values of 100 vs. 90 days, P = 0.0205). No significant 
difference was detected amongst the double transgenic littermates.    
 Disease progression is summarized as the period of time between the disease onset 
and the end stage, results of which are presented in Figure 39. Both male and female mice 
expressing the double transgenes (SOD1G93A/DAOWT) had a slower progression of the disease 
in comparison to their SOD1G93A littermates. The median rate of disease progression in 
double transgenic females was determined to be approximately 54 days as opposed to 48 days 
recorded for the female SOD1G93A littermates. Similar effects were seen in the males, where 
the disease progression was significantly slower in the double transgenic males compared to 
their SOD1G93A littermates (median value of 51 vs. 40 days, P = 0.0144). No major 
differences were detected in terms of disease progression between the two sexes of the same 
genotype (Figure 39, Table 10A and B).  
Survival is defined as the period of time between birth and the humane end point 
(assessed by the righting reflex) when the animal is euthanized, graphs demonstrating the 
survival of the animals recruited in this part of the experiment are presented in Figure 40. 
These Figures reveal that there are significant differences in terms of survival time between 
the different genotypes. The median survival for double transgenic males was significantly 
longer than that of the SOD1G93A littermates (151 vs. 130 days respectively, P = 0.0010). 
Similarly survival in double transgenic females was significantly longer in comparison to 
their SOD1G93A littermates (157 vs. 136 days respectively, P = 0.0085). Further comparisons 
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of the survival data demonstrate that the SOD1G93A females lived significantly longer in 
comparison to their SOD1G93A male littermates (136 vs. 130 days, P = 0.0169). However, no 
major differences were noted in terms of survival amongst the sexes in the double transgenic 
animals. Overall the survival data indicates that double transgenic animals 
(SOD1G93A/DAOWT) lived significantly longer in both sexes in comparison to their SOD1G93A 
littermates. 
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Figure 35. Longitudinal assessment of neurological scores in female SOD1G93A and double 
transgenic (SOD1G93A/DAOWT) littermates. 
Mean group combined neurological score plotted for SOD1G93A and double transgenic 
(SOD1G93A/DAOWT) female mice over time from approximately 40 days of age until all the animals 
within a group died and the study was terminated (n = 14 SOD1G93A mice and 12 double transgenics). 
A combined neurological score was calculated for each mouse at each time point through summation 
of the neurological scores recorded for its left and right hindlimbs. Error bars represent standard error 
of the mean (SEM).  
SOD1G93A females are presented in purple, and the double transgenic (SOD1G93A/DAOWT) littermates 
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Figure 36. Longitudinal assessment of neurological scores in male SOD1G93A and double 
transgenic (SOD1G93A/DAOWT) littermates. 
Mean group combined neurological score plotted for SOD1G93A and double transgenic 
(SOD1G93A/DAOWT) male mice over time from approximately 40 days of age until all the animals 
within a group died and the study was terminated (n = 14 SOD1G93A mice and 19 double transgenics). 
A combined neurological score was calculated for each mouse at each time point through summation 
of the neurological scores recorded for its left and right hindlimbs. Error bars represent standard error 
of the mean (SEM).  
SOD1G93A males are presented in blue, and the double transgenic (SOD1G93A/DAOWT) littermates are 
displayed in green.	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Kaplan-Meier plot demonstrating the time taken for the animals to reach the score of 2, otherwise 
referred to as the onset of the neurological symptoms, in both SOD1G93A and double transgenic 
(SOD1G93A/DAOWT) male and female littermates (n ≥ 12 mice per experimental group - females: n = 
14 SOD1G93A mice and 12 double transgenics; males: n = 14 SOD1G93A mice and 19 double 
transgenics). The graph on the top panel represents the data for both SOD1G93A and double transgenic 
male and female littermates.	  
The graph in the bottom left presents data for both SOD1G93A versus the double transgenic male mice 
(blue and green respectively). The Log-rank test analysis indicates that there are significant 
differences in onset of neurological symptoms amongst males (P = 0.0326, threshold of significance 
was set at P ≤ 0.05).   
The graph in the bottom right presents data for female mice bearing the SOD1G93A versus the double 
transgenes (purple and red respectively). The log-rank test analysis indicates that there are significant 
differences in onset of neurological symptoms between the SOD1G93A and the double transgenic 
females (P = 0.0397, threshold of significance was set at P ≤ 0.05). Results for statistical analyses 
performed on the above data set are presented in Table 10B. 
  
Figure 37. Onset of neurological symptoms in SOD1G93A and double transgenic 
(SOD1G93A/DAOWT) mice in both male and female littermates. 
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Kaplan-Meier plot demonstrating the disease onset, defined as the point in time that the animal was at 
its maximum weight, in both SOD1G93A and double transgenic  (SOD1G93A/DAOWT) male and female 
littermates (n ≥ 12 mice per experimental group - females: n = 14 SOD1G93A mice and 12 double 
transgenics; males: n = 14 SOD1G93A mice and 19 double transgenics).  
Results for statistical analyses performed on the above data set are presented in Table 10B, where the 
threshold of significance was set at P ≤ 0.05.	  
Graph presents data for both male (blue) and female (purple) SOD1G93A mice as well as male (green) 
and female (red) double transgenic mice.	  
	  
	   	  
Figure 38. Disease onset in SOD1G93A and double transgenic  (SOD1G93A/DAOWT) mice in 
both male and female littermates. 
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Kaplan-Meier plot demonstrating the disease progression, defined as the period of time between the 
peak weight and the end stage, calculated by subtracting the age at death from the age at onset (peak 
weight). The graph on the top panel represents the data from both SOD1G93A and double transgenic 
male and female littermates (n ≥ 12 mice per experimental group - females: n = 14 SOD1G93A mice 
and 12 double transgenics; males: n = 14 SOD1G93A mice and 19 double transgenics). 	  
The graph at the bottom left presents data for both SOD1G93A and double transgenic male mice (blue 
and green respectively). The log-rank test analysis indicates that there are significant differences in 
terms of disease progression amongst males (P = 0.0144, threshold of significance was set at P ≤ 
0.05).  
The graph at the bottom right presents data for female mice bearing the SOD1G93A and double 
transgenes (purple and red respectively). The log-rank test analysis indicates that there are no 
significant differences in disease progression between the SOD1G93A and the double transgenic 
females (P = 0.0737, threshold of significance was set at P ≤ 0.05). Results for statistical analyses 
performed on the above data set are presented in Table 10B. 
Figure 39. Disease progression in SOD1G93A and double transgenic mice 
(SOD1G93A/DAOWT) in both male and female littermates. 
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Kaplan-Meier plot demonstrating survival, determined as the time taken for the animal to reach the 
humane end point, in both SOD1G93A and double transgenic male and female littermates. The graph on 
the top panel represents the data from both SOD1G93A and double transgenic male and female 
littermates (n ≥ 12 mice per experimental group - females: n = 14 SOD1G93A mice and 12 double 
transgenics; males: n = 14 SOD1G93A mice and 19 double transgenics). 	  
The graph at the bottom left presents data for both SOD1G93A and double transgenic male mice (blue 
and green respectively). The log-rank test analysis indicates that the differences in survival between 
the two genotypes are highly significant (P = 0.0010, threshold of significance was set at P ≤ 0.05).  
The graph at the bottom right presents data for female mice bearing the SOD1G93A and double 
transgenes (purple and red respectively). The log-rank test analysis indicates that there are significant 
differences in terms of survival between the SOD1G93A and the double transgenic females (P = 0.0085, 
threshold of significance was set at P ≤ 0.05). Results for statistical analyses performed on the above 
data set are presented in Table 10B. 
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Figure 40. Survival of SOD1G93A and double transgenic mice (SOD1G93A/DAOWT) in both 
male and female littermates. 
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Males Females Males Females 
Onset of Neurological Symptoms 112 124 123 138 
Disease Onset 90 100 98 100 
Disease Progression 40 48 51 54 
Survival  130 136 151 157 
 
(B) Log-rank Test (P Value) 




Females Males Females 
Onset of Neurological Symptoms 0.0595 0.0196* 0.0326* 0.0397* 
Disease Onset 0.0205* 0.3811 0.0826 0.7892 
Disease Progression 0.7932 0.8976 0.0144* 0.0737 
Survival  0.0169* 0.3323 0.0010*** 0.0085** 
Table 10. Kaplan-Meier time to event analyses for SOD1G93A and double transgenic 
(SOD1G93A/DAOWT) in both males and females. 
(A) Median values obtained from Kaplan-Meier analysis for the time taken for mice to reach a score 
of 2 in both hindlimbs (onset of neurological scores), age at maximum weight (disease onset), disease 
progression and time taken for animals to reach the humane end point determined by its inability to 
right itself within 20 seconds of being placed on its side (survival) for both males and female 
littermates of either genotype. 
(B) The log-rank test assesses the null hypothesis that the Kaplan-Meier curves for all groups are 
identical (i.e. the overexpression of the DAOWT transgene did not change the time taken to reach the 
event being analysed). Thus, low P-values indicate that differences between genotype groups did not 
occur due to chance. Log-rank analysis indicates that there were significant differences between the 
double transgenic (DT) and their SOD1G93A littermates in both males and females in terms of onset of 
neurological symptoms, similar results were obtained when DT males and females were compared. 
Disease onset was only significant between SOD1G93A males and females, and progression was only 
significant between DT males and their SOD1G93A littermates. Significant differences are also present 
in survival between DT and SOD1G93A littermates in both males and females, as well as amongst 
SOD1G93A males and females. Significant differences are indicated in bold and by asterisk in table (B), 
underlined values indicate occasions where the P value was highly close to reach significance. 
Threshold of significance was set at P ≤ 0.05.  
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5.2.3. Assessment of SOD1G93A Transgene Copy Number 
It is well documented that a high copy number SOD1G93A mouse carries 
approximately 23-25 copies of the mutant SOD1G93A transgene (Gurney et al., 1994, Gurney, 
1997). As described previously, low copy number SOD1G93A animals can emerge while 
breeding high copy number SOD1G93A animals due to intra locus recombination events 
during meiosis (Gurney, 1997), consequently resulting in delayed disease onset and 
prolonged lifespan. Given the nature of our study and by taking into account the fact that our 
double transgenic males and females experienced slower disease progression and a longer 
survival in comparison to their SOD1G93A littermates, we therefore deemed it was crucial to 
monitor all our double transgenic animals (SOD1G93A/DOAWT) for variation in SOD1G93A 
transgene copy number. This analysis therefore ensured that the effect we observed in our 
survival study was due to overexpression of the wild type form of DAO protein and not any 
other factor. We also assessed any SOD1G93A animal whose survival time appeared to be 
unusual compared to the other mice of the same sex within this particular group.  
In addition, since the 3 animals that experienced premature death were due to be used as 
censored in our survival analysis, we decided it was necessary to also assess the SOD1G93A 
transgene copy number variation in these animals.     
Hence, the potential variation in SOD1G93A transgene copy number was assessed for 6 
female and 4 male mice within the SOD1G93A genotype group as they displayed a survival 
time that appeared to be an outlier in comparison to their littermates of the same sex and 
genotype. Although in some cases the survival times of the SOD1G93A transgenic animals in 
question only differed slightly from those of their peers, in order to ensure the validity of the 
results it was essential to assess the copy number variation in these animals with respect to 
the rest of their group. We also monitored the potential variation in SOD1G93A transgene copy 
number in the entire double transgenic population (n = 19 males and n = 14 females). The 
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control animals for the assessment of copy number variation in the double transgenic groups 
were selected from the SOD1G93A transgenic animals of the same sex.  
As described in full details in Chapter 2. Materials and Methods, subsection 2.2.1.9 
and 2.2.1.10, the ∆CT values (ΔCT = mouse Il-2 CT – human SOD1G93A CT) obtained for the 
outlying animals were compared to those obtained for control mice. The control animals were 
selected on the basis that they displayed a survival time closest to the median survival (130 
days for males and 136 days for females, as displayed in Table 10A). Therefore, any mice 
whose ∆CT value differed by more than 2 standard deviations from the average ∆CT value of 
the control mice was considered an outlier and hence was excluded from the final analyses 
(Alexander et al., 2004, Kaneb, 2012).  
Detailed analysis of the outlying animals for both SOD1G93A and double transgenic 
genotypes are demonstrated in Tables 11-14. These data confirm that none of double 
transgenic males and the SOD1G93A females experienced a change in transgene copy number. 
However, 2 double transgenic females and 2 male mice expressing the SOD1G93A transgene 
experienced a change in SOD1G93A transgene copy number and were therefore excluded from 
the analyses. Table 13 indicates that the two SOD1G93A males excluded from the study 
displayed a survival time of 156 and 158 days which were significantly outside the range of 
median survival, as determined for their peers (130 days, displayed in Table 10A). Table 12 
on the other hand demonstrates that the two double transgenic females who experienced a 
change in SOD1G93A transgene copy number lived up to the age of 147 and 167.  
The survival times of the control and outlying animals that were monitored for the 
potential change in SOD1G93A transgene copy number are summarized in Tables 11-14. 
It is noteworthy that the number of controls was the reflection of space available on 
the plate.   
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Assessments of copy numbers variation were performed for six females (B) whose survival time 
appeared to be outlying compared to the controls (A), defined as the animals of the same sex within 
their genotype group. ∆CT values obtained for the outlying animals (B) were compared to those ∆CT 
values obtained for the seven females control mice (A) whose survival was closest to the median 
survival determined for females control mice (Table 10A). Hence, any animal in table (B) whose final 
∆CT value differed by more than 2 standard deviations from the mean ∆CT calculated for the control 
mice (A) was to be excluded, none of the animals however met this criteria. The mean and the 
standard deviation of the ∆CT values obtained for control mice as well as the survival and ∆CT values 
obtained for the outlying animals for which copy number variation was assessed are summarised in 
tables A and B respectively. The median survival is presented in Table 10A, where it was determined 
to be 136 days for control females.	  
 





ΔCT Average STDEV STDEVx2 
SOD1G93A 
Females 
2F 136 6.42 
6.33 0.22 0.44 
4F 136 6.42 
9F 138 6.25 
29F 135 6.22 
43F 130 6.73 
50F 134 6.03 
64F 132 6.24 
(B) Outliers  Animal ID  
Age at 
Death 
ΔCT Control ΔCT – 
Sample ΔCT 




8F 156 6.22	   0.11 No 
16F 151 6.36	   -0.03 No 
17F 152 6.39	   -0.06 No 
27F 159 6.40	   -0.07 No 
35F 151 6.18	   0.15 No 
40F 155 6.23	   0.10 No 
Table 11. Assessment of copy numbers variation in females carrying the SOD1G93A transgene. 
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(A) SOD1G93A 
Controls	    Animal ID 	  
Age at 















2F 136 6.42 
6.21 0.16 0.31 
4F 136 6.01 
8F 156 6.28 
9F 138 6.01 
16F 151 6.45 
17F 152 6.23 
27F 159 6.23 
35F 151 6.18 
40F 155 6.12 
To confirm the validity of the results assessments of copy numbers variation were performed for the 
entire population of the double transgenic females (n = 14) (table B). The ∆CT values obtained for the 
double transgenic animals (B) were compared to those ∆CT values obtained for the subset of nine 
SOD1G93A female control mice (A) whose either been assessed for variation in SOD1G93A transgene 
copy number or whose survival was closest to the median survival determined for female control mice 
(Table 10A). Hence, any animal in Table (B) whose final ∆CT value differed by more than 2 standard 
deviations from the mean ∆CT calculated for the control mice (A) was to be excluded, two of the 
double transgenic females met this criteria and were therefore excluded from the final analysis. The 
mean and the standard deviation of the ∆CT values obtained for control mice as well as the survival 
and ∆CT values obtained for the double transgenic animals for which copy number variation was 
assessed are summarised in Tables A and B respectively. The median survival is presented in Table 
10A, where it was determined to be 136 days for control females. 
(B) DT 
Animals	    Animal ID 	  
Age at 
Death	   ΔCT	  























1F 133 6.14 0.07 No 
5F 169 6.14 0.07 No 
10F 147 6.63 -0.42 Yes 
12F 144 6.01 0.21 No 
14F 137 6.24 -0.03 No 
15F 153 6.22 -0.01 No 
30F 166 6.35 -0.14 No 
31F 172 6.06 0.15 No 
32F 143 6.14 0.07 No 
38F 130 6.41 -0.20 No 
41F 167 6.70 -0.49 Yes 
48F 161 6.07 0.14 No 
57F 135 6.06 0.15 No 
59F 165 6.32 -0.11 No 
Table 12. Assessment of copy numbers variation in double transgenic females carrying the 
double transgenes (SOD1G93A/DAOWT). 
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Assessments of copy numbers variation were performed for four males (B) whose survival time 
appeared to be outlying compared to the controls (A), defined as the animals of the same sex within 
their genotype group. ∆CT values obtained for the outlying animals (B) were compared to those ∆CT 
values obtained for the seven males control mice (A) whose survival was closest to the median 
survival determined for males control mice (Table 10A). Hence, any animal in table (B) whose final 
∆CT value differed by more than 2 standard deviations from the mean ∆CT calculated for the control 
mice (A) was to be excluded, two of the SOD1G93A males met this criteria and were therefore 
excluded from the final analysis. The mean and the standard deviation of the ∆CT values obtained for 
control mice as well as the survival and ∆CT values obtained for the outlying animals for which copy 
number variation was assessed are summarised in tables A and B respectively. The median survival is 
presented in Table 10A, where it was determined to be 130 days for control males. 
(A) Controls	   Animal ID	   Age at 
Death	   ΔCT	   Average	   STDEV	   STDEVx2	  
SOD1G93A 
Males	  
6M	   132	   6.08	  
6.15	   0.12	   0.24	  
7M	   133	   6.33	  
11M	   123	   6.19	  
19M	   128	   6.05	  
26M	   127	   6.07	  
59M	   123	   6.24	  
61M	   131	   6.25	  
(B) Outliers  Animal ID  
Age at 
Death 
ΔCT Control ΔCT – 
Sample ΔCT 




27M 143 6.02	   0.13 No 
37M 139 6.34	   -0.19 No 
38M 156 6.43	   -0.28 Yes 
47M 158 5.78	   0.37 Yes 
Table 13. Assessment of copy numbers variation in males carrying the SOD1G93A transgene. 
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To confirm the validity of the results assessments of copy numbers variation were performed for the 
entire population of the double transgenic males (n = 19) (table B). ∆CT values obtained for the 
double transgenic animals (B) were compared to those ∆CT values obtained for the subset of nine 
SOD1G93A male control mice (A) whose either been assessed for variation in SOD1G93A transgene copy 
number or whose survival was closest to the median survival determined for females control mice 
(Table 10A). Hence, any animal in table (B) whose final ∆CT value differed by more than 2 standard 
deviations from the mean ∆CT calculated for the control mice (A) was to be excluded, none of the 
double transgenic males however met this criteria. The survival, mean and the standard deviation of 
the ∆CT values obtained for control mice as well as the survival and ∆CT values obtained for the 
double transgenic animals for which copy number variation was assessed are summarised in Tables A 
and B respectively. The median survival is presented in Table 10A, where it was determined to be 130 
days for control males.	  
(A) SOD1G93A 
Controls	    Animal ID 	  
Age at 













 6M 132 6.51 
6.18 0.21 0.42 
7M 134 6.01 
19M 128 6.12 
26M 127 6.17 
37M 139 5.99 
51M 130 6.26 
56M 134 6.51 
59M 123 6.04 
61M 131 6.00 
(B) DT 
Animals	   Animal ID	  
Age at 
Death	   ΔCT	  





















2M 151 6.53 -0.35 No 
14M 116 6.41 -0.23 No 
18M 156 6.50 -0.32 No 
23M 159 5.89 0.29 No 
24M 127 6.00 0.18 No 
28M 145 6.34 -0.16 No 
31M 138 6.09 0.09 No 
35M 163 6.30 -0.12 No 
42M 135 6.18 0.00 No 
44M 167 6.36 -0.18 No 
45M 130 6.21 -0.03 No 
46M 139 6.41 -0.23 No 
50M 186 6.14 0.04 No 
55M 102 6.49 -0.31 No 
57M 151 6.41 -0.23 No	  
58M 138 6.01 0.17 No	  
66M 154 6.09 0.09 No	  
67M 155 6.41 -0.23 No	  
68M 164 6.05 0.13 No	  
Table 14. Assessment of copy numbers variation in males carrying the double transgenes 
(SOD1G93A/DAOWT). 
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5.3. Discussion  
In this study we aimed to test the hypothesis that overexpression of the wild type form 
of DAO protein (DAOWT) would interfere with the onset of ALS associated phenotypes and 
delay disease onset, slow disease progression and prolong survival in both male and female 
double transgenic mice in comparison to their SOD1G93A littermates. This hypothesis was 
made based on the grounds that NMDA-mediated neurotoxicity has been shown to be a 
hallmark of neurodegenerative disorders (Shleper et al., 2005, Inoue et al., 2008, Mustafa et 
al., 2010, Hardingham and Bading, 2010), levels of an NMDAR co-agonist, D-serine, has 
been shown to be elevated in the spinal cord of ALS patients and SOD1G93A mouse model 
(Sasabe et al., 2007), and it has also been demonstrated that degradation of D-serine by DAO 
enzyme is beneficial in terms of reducing NMDA neurotransmission (Mothet et al., 2000). In 
addition, the previous discovery of the R199W mutation in the DAO gene and its association 
with ALS (Mitchell et al., 2010) further supports the potentially beneficial role of DAO in 
this fatal neurodegenerative disorder.  
Hence, we investigated the possible effects induced by overexpression of the wild 
type form of DAO protein (DAOWT) in the presence of the SOD1G93A mutation, and aimed to 
closely monitor and study disease onset, progression and survival. This was done through a 
large cohort, blinded survival study involving the SOD1G93A mouse model of ALS versus 
their double transgenic littermates (SOD1G93A /DAOWT). Disease onset and its progression 
were therefore analysed by twice weekly monitoring of weight and neurological scores, while 
survival was determined as the age at which the animal was unable to right itself within 20 
seconds of being placed on its side. 
Our analysis of the SOD1G93A and their double transgenic littermates 
(SOD1G93A/DAOWT) demonstrate that animals of both genotypes followed the same pattern in 
terms of overall body weight throughout their lifespan. The graph illustrating the body weight 
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assessment for females indicates that there are no major differences amongst the genotypes 
(Figure 33). Similar observations were made upon comparison of the non-transgenic wild 
type and DAOWT female littermates (Chapter 3. Animal Models, subsection 3.2.3.3, Figure 
23). However, there are distinct genotype-specific differences in body weight amongst males 
as displayed in Figure 34. This Figure clearly demonstrates that the initial body weights for 
the double transgenic males are considerably lower in comparison to their SOD1G93A 
littermates, and this seems to be a consistent pattern until the animals reached the maximum 
weight, from which point onwards both genotypes display highly similar body weight. In 
addition, comparing this graph to that of the non-transgenic wild type versus the DAOWT 
littermates (Chapter 3. Animal Models, subsection 3.2.3.3, Figure 24), further highlights that 
in the absence of SOD1G93A mutation, DAOWT animals display highly similar body weights to 
their non-transgenic wild type littermates. 
Given that no weight differences were observed between the SOD1G93A and the 
SOD1G93A/DAOWT (double transgenic) female littermates (Figure 33), and since the weight 
differences only appeared in the males upon overexpression of the DAOWT protein in the 
double transgenics, it is reasonable to speculate that the weight differences observed here are 
related to sex hormones.  
DAO enzyme has been shown to induce oxidative stress through generation of 
hydrogen peroxide (H2O2) (Fang et al., 2002, Fang et al., 2008, El Sayed et al., 2012). In 
addition, it has been demonstrated that the whole body production of reactive oxygen species 
is higher in healthy young men in comparison to the aged matched women (Ide et al., 2002). 
It has also been established that oxidative stress results in reduced muscle protein synthesis 
(Powers et al., 2012), leading to smaller muscle mass and given that skeletal muscle 
contributes to the majority of the overall body weight, smaller muscle mass would results in a 
lower body weight. Based on these reports and by taking into account the high levels of 
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oxidative stress associated with ALS (Shaw et al., 1995, Fitzmaurice et al., 1996, Ferrante et 
al., 1997, Shibata et al., 2001), we speculate that overexpression of the DAOWT protein 
further contributes towards the already high levels of oxidative stress at the cellular level. The 
levels are further promoted in the presence of testosterone in the male animals and due to the 
absence of efficient machinery under these intense physiological conditions, to reduce or 
control the generated oxidative stress, efficient protein synthesis is inhibited which in turn 
leads to smaller muscle mass in these animals. However the double transgenic males are still 
heavier than aged matched females, thus showing that oxidative stress effect does not over 
ride the testosterone related difference in body mass between the two sexes. The hypothesis 
for the difference between the SOD1G93A and double transgenic males however requires 
confirmation through further experimentation, where the hormonal profile could be 
investigated in the presence of the double transgenes by castrating the males.   
Studying the graphs presenting the neurological symptoms indicate that males and 
females behaved differently in term of onset of neurological symptoms, disease onset and 
survival (Figures 37, 38 and 40 respectively). Comparison of the different genotypes within 
the same sex on the other hand also demonstrates some differences.  
These graphs show that overexpression of the DAOWT protein in the double 
transgenic females significantly delayed the onset of neurological symptoms in these animals 
by 14 days in comparison to their SOD1G93A littermates (P = 0.0397). A similar pattern is 
visible between the double transgenic males and their SOD1G93A littermates, where the onset 
of neurological symptoms was significantly delayed by 11 days (approximately 10%, P = 
0.0326) in the presence of the DAOWT transgene (Figure 37). Interestingly, the graph clearly 
demonstrates that there has been a shift in terms of onset of neurological symptoms in the 
double transgenic males, as the curve displays highly similar patterns to that of the SOD1G93A 
female littermates. Comparison of males and females carrying the same transgene on the 
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other hand indicates that the females in both genotype groups had a later onset of 
neurological symptoms in comparison to their male littermates of the same genotype. While 
the differences between the double transgenic males and females are highly significant (P = 
0.0196), this particular summary measurement did not reach significance in the SOD1G93A 
genotype group (P = 0.0595).  
To our surprise despite the presence of the DAOWT transgene, onset of the disease was 
unaffected amongst females, where the median age for disease onset in both double 
transgenic and SOD1G93A animals was at 100 days of age (P = 0.7892). The onset of the 
disease amongst the males however was slightly different with the double transgenics 
displaying a delayed onset by 8 days in comparison to their SOD1G93A littermates (P = 
0.0826). Comparison of the same genotype across the sexes however differed by 
approximately 10 days, where SOD1G93A females had a significantly later onset (P = 0.0205).  
As expected, disease progressed at a slower pace in the presence of the DAOWT 
transgene. Disease progression rate was reduced by approximately 27% in male mice 
overexpressing the DAOWT protein (Figure 39) in comparison to their SOD1G93A littermates 
(P = 0.0144). Similarly a slow progression rate was also observed in the double transgenic 
females (approximately 12%) in comparison to their SOD1G93A littermates, however the 
differences did not reach significance in this particular measurement group (P = 0.0737). 
Interestingly, the graph indicates that disease progression in the double transgenic males was 
almost the same as that of the double transgenic females. 
Survival curves presented in Figure 40, demonstrate distinct differences between the 
various genotypes. Both male and female mice who overexpress the DAOWT protein display a 
significantly longer survival in comparison to their SOD1G93A littermates (P = 0.0010 and P = 
0.0085 respectively). The curves indicate that the median lifespan of the double transgenic 
animals were prolonged by 21 days in both males and females. Interestingly however, while 
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the difference in survival was once again significant amongst the different sexes bearing the 
SOD1G93A transgene (P = 0.0169), survival amongst the double transgenic animals did not 
reach significance across the sexes (P = 0.3323). As with the previous summary 
measurements it is notable that the curve presenting survival for the double transgenic males 
has shifted forward, displaying a highly similar survival rate to that of the double transgenic 
females which is approximately 16% and 15% (respectively) longer in comparison to their 
SOD1G93A littermates of the same sex.  
Data obtained from this survival study therefore indicate that overexpression of the 
wild type DAO protein (DAOWT) may play a significant role in survival by interfering with 
the rate at which the disease progress.  
Various studies have demonstrated the involvement of DAO protein in the NMDAR 
physiological pathway. Papouin and co-workers (2012) aimed to investigate the individual 
functions of D-serine and glycine in brain, by treating slices from adult rat’s hippocampal 
brain with DAO, and a recombinant glycine oxidase (GO) obtained from Bacillus subtilis 
(which acts towards removal of endogenous glycine). Data from this experiment 
demonstrated that synaptic NMDAR response is reduced by almost 60% in the presence of 
the DAO enzyme, confirming that D-serine is the primary coagonist at the synaptic 
NMDARs. The authors further investigated the NMDA-induced neurotoxicity in the rat 
hippocampal slices upon removal of glycine or D-serine, where they observed that treatment 
with the DAO protein induced intense protective effects in terms of NMDA-induced cell 
death, whereas GO treatment did not induce any protective affects towards neurotoxicity 
(Papouin et al., 2012). In line with this finding various other studies showed that exogenous 
DAO protein reduces NMDAR function both in vitro and in vivo (Mothet et al., 2000, 
Stevens et al., 2003, Katsuki et al., 2004, Yang et al., 2005, Hama et al., 2006, Ren et al., 
2006, Gustafson et al., 2007). Studying the mouse strain lacking DAO activity (ddY/DAO−) 
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on the other hand, revealed an increase in NMDAR activity in the cerebellum in the absence 
of DAO protein (Almond et al., 2006). Hence, the DAO enzyme has the ability to regulate 
NMDAR function via degradation of D-serine, and its hypofunction or malfunction may in 
turn contribute to hyperfunctioning of the NMDA receptors and its consequent involvement 
in ALS. Interestingly Sasabe and colleagues demonstrated that DAO enzyme plays a 
fundamental role in motor neuron degeneration through regulation of D-serine. The authors 
reported that loss of DAO activity results in motor neuron degeneration in mice lacking the 
enzyme, and that DAO inactivity is a common feature in the SOD1G93A mouse model (Sasabe 
et al., 2012).  
All the above findings are therefore in line with our data indicating that 
overexpression of the DAO enzyme at the cellular level may provide strong protective 
properties against neurotoxicity and possibly prevent or delay neuronal cell death. Thus, the 
presence of DAO at high concentrations at the cellular level plays a beneficial role by 
slowing down disease progression and prolonging survival in ALS. 
The differences observed in disease progression amongst the double transgenic 
animals and their SOD1G93A littermates in both males and females could be an indication of 
reduced excitotoxicity. It is possible that the presence of the wild type DAO protein at high 
levels at the cellular level resulted in a more rapid degradation of D-serine at the site of 
NMDA receptor. Thus regulating the NMDA receptor activity by controlling the subsequent 
binding of the neurotransmitter glutamate and reducing neurotoxicity. This will in turn 
contribute to the longer survival of the neurons in the area and the consequent slower disease 
progression, a hypothesis that requires further investigations. These results therefore offer 
hope for development of a potentially beneficial therapeutic agent based on increased DAO 
activity that will result in slower disease progression and longer survival in ALS patients.	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6.0 IGF-I Study  
  
	   233 
6.1. Introduction  
The Igf-I gene is highly conserved in mammals, it is relatively large in size (over 
70kb), and is located on chromosome 10 in mice. The single-copy Igf-I gene consists of six 
exons, and encodes an IGF-I protein which is subjected to alternative splicing in mammals, 
giving rise to various isoforms (Shimatsu and Rotwein, 1987).  
Numerous lines of evidence indicate that IGF-I has high potential as a therapeutic 
agent, as reviewed by Boillée and Cleveland (Boillée and Cleveland, 2004). This was 
demonstrated by multiple in vitro and in vivo studies involving delivery of IGF-I, where it has 
been shown to boost motor neuron survival in culture (Ang et al., 1992, Hughes et al., 1993), 
prevent natural death of motor neuron cells in the chick embryo (Neff et al., 1993), prevent 
death of motor neurons upon axotomy in neonatal rodents (Hughes et al., 1993), and induce 
nerve regeneration upon damage/injury by increasing axonal sprouting and stimulating 
muscle innervation (Caroni and Grandes, 1990). In addition, IGF-I has been established as a 
survival mechanism for Schwann cells and oligodendrocytes (Gavrilovic et al., 1995, Ye et 
al., 1995), and has been identified as a strong inducer of the production of myelin using both 
in vivo and in vitro models (Carson et al., 1993, Beck et al., 1995).  
Other studies have also demonstrated that IGF-I has high potentials as a therapeutic 
agent in animal models of ALS (Hantai et al., 1995, Narai et al., 2005, Nagano et al., 2005a, 
Chian et al., 2009). Administration of this neurotrophic factor systematically to human 
patients suffering from ALS in clinical trials however did not yield any beneficial results and 
in some cases led to unsatisfactory outcomes such as adverse side effects (Lai et al., 1997, 
Borasio et al., 1998, Nagano et al., 2005b, Sorenson et al., 2008). Other approaches including 
gene therapy techniques, which offer a more controlled and localized delivery of the target 
gene and have shown extensive success in animal models of ALS, may reduce these side 
effects. Numerous investigations have yielded valuable results using adeno-associated viral 
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(AAV) vectors to deliver IGF-I to various sites such as the spinal cord or hindlimb muscles in 
animal models. These studies demonstrated that delivery of the IGF-I resulted in increased 
muscle mass, muscle hypertrophy, and where ALS animal models were used expression of 
IGF-I resulted in increased motor neuron survival, delayed disease onset and progression, 
prolonged survival, preserved the morphology of motor neurons and decreased gliosis 
(Kaspar et al., 2003, Barton, 2006b, Lepore et al., 2007, Dodge et al., 2008, Franz et al., 
2009, Dodge et al., 2010). These results further confirmed the potential of IGF-I as a 
therapeutic drug, making this particular neurotrophic factor a very attractive agent for the 
treatment of various disorders including ALS. 
Based on the above discoveries, the following chapter has been focused on IGF-I and 
its possible therapeutic properties in ALS, which was initially designed based on the results 
of a relatively recent in vivo study by Riddoch-Contreras and colleagues (Riddoch-Contreras 
et al., 2009). Given that different IGF-I isoforms perform differently at the molecular level 
depending on the site where they are released (as demonstrated by various studies such as 
Riddoch-Contreras (2009)), our objective for this part of the investigation was to use gene 
therapy techniques, delivering two different isoforms of Igf-I to a murine model of ALS (high 
copy number SOD1G93A), using a highly efficient non-viral delivery technique, in vivo 
electroporation. We therefore aimed to clone the two Igf-I isoforms identified in mouse, 
namely Igf-IA and MGF, and upon confirmation of their expression both in vitro and in vivo, 
investigate the effect of each Igf-I isoform on ALS-like phenotypes as well as survival, and to 
further identify the isoform with the most efficient effect in terms of survival and 
improvement of ALS-like clinical signs.  
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6.2. Results 
Given the beneficial properties of IGF-I protein highlighted in a range of in vivo and 
in vitro studies and in the light of the results from a recent investigation by Riddoch-
Contreras and co-workers (2009), we aimed to test the ability of the two murine Igf-I 
isoforms to improve clinical signs and survival in a well-known model of ALS, namely the 
high copy number SOD1G93A mouse.  
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6.2.1. Murine Igf-I Gene  
Alternative splicing at the carboxyl-terminus of the mature polypeptide chain gives 
rise to various IGF-I isoforms, known as E-peptides that share 50% homology at the amino 
acid level (Lund, 1998, Barton, 2006a). Three different E-peptides have been identified in 
human and non-human primates namely IGF-IA, IGF-IB, IGF-IC. Cattle, sheep, dogs, and 
rodents however are known to express only two different types of E-peptides referred to as 
IGF-IA and IGF-IB (Bell et al., 1986, Roberts et al., 1987, Shimatsu and Rotwein, 1987, 
Chew et al., 1995, Lund, 1998, Wallis, 2009). Human IGF-IB isoform is unique to primates 
and therefore absent in rodents, whereas IGF-IA is highly identical in mammals. Human IGF-
IC and rodent IGF-IB are highly identical and also known as mechano growth factor (MGF, 
Barton, 2006a). The latter shall be referred to as MGF hereafter. 
All IGF-I isoforms bear an identical sequence for the 70 amino acids long mature 
IGF-I protein and a variable E-peptide (Rotwein et al., 1986). In rodents the Igf-IA isoform is 
encoded by exons 1, 3, 4, and 6. Inclusion of the 52 nucleotides long exon 5 of the Igf-I gene 
causes a frame shift and premature termination in exon 6 consequently leading to generation 
of the MGF (Igf-IB) transcript, which only occurs in up to 10% of the transcripts (Bell et al., 
1986, Roberts et al., 1987, Barton, 2006a, Pfeffer et al., 2009, Wallis, 2009).   
For this part of the investigation our primary goal was to first identify the two murine 
classes of the Igf-I gene, Igf-IA and MGF (GenBank mRNA accession number AY878192 
and AY878193, respectively) (Barton et al., 2010). Exons for each transcript were then 
identified and annotated using the Ensemble database (transcript ID: 
ENSMUST00000095360 for Igf-IA and ENSMUST00000105300 for MGF). Messenger 
RNA (mRNA) sequences for both isoforms with the annotated exons, start and stop codons 
as well as the protein sequence generated by the mRNA transcripts are all presented in 
subsections 6.2.1.1-2 of this Chapter. 
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Considering the fact that these isoforms both bear exons 1 and 6 and only differ by the 
presence or absence of exon 5, we designed one set of primers that recognised both isoforms 
as displayed in subsection 6.2.1.3. The initial step was then amplification of the murine Igf-I 
gene from mouse muscle tissue using normal TA muscle from wild type female mice 
(C57BL6×CBA/Ca). Samples were crushed in the presence of liquid nitrogen followed by 
RNA extraction and generation of cDNA as described in detail in Chapter 2. Material and 
Methods, subsection 2.2.10. The Igf-I isoforms were then amplified using standard PCR and 
the resultant products were separated on a 3% agarose gel (full details in Chapter 2. Materials 
and Methods, subsection 2.2.13). Separation of the murine Igf-I isoforms generated from 
normal TA muscle are presented in Figure 41, where the arrow signifies the Igf-IA isoform. 
The image also displays a second band with a very faint nature but larger size, sitting on the 
top of the Igf-IA isoform, assumed to be MGF at the time of the experiment. However, while 
Igf-IA was successfully amplified various attempts at isolation and purification of the second 
larger band were unsuccessful.  
In order to successfully clone MGF we attempted to increase the endogenous MGF 
levels by creating a temporary muscle injury with a myotoxic agent, BaCl2 (full details in 
subsection 2.2.7.1). Following BaCl2 induced injury we observed a distinct increase in levels 
of the MGF isoform in the injured muscle as displayed in Figure 42, indicated by the red 
arrow. Comparison of the Figure on the right panel obtained from the injured muscle to that 
of the normal muscle on the left indicates that in the presence of injury a third 
product/isoform is formed, which appeared slightly larger in size at approximately 780 base 
pairs (bp). The Figure also demonstrates that MGF expression was extremely faint to almost 
undetectable levels in the normal muscle in comparison to that of the injured muscle. The 
third and largest band on the top also displayed highly similar features to that of the MGF 
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isoform, where it appeared extremely faint in normal muscle but its expression increased in 
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6.2.1.1 Mus Musculus Insulin-like Growth Factor 1, Isoform Ea (Igf-IA)  
The Igf-IA gene transcript (NCBI mRNA accession number AY878192) consists of 
exons 1, 3, 4, and 6, it is 713bp in size as displayed below. In the following sequence exons 
are colour coded, the untranslated regions of the gene (UTRs) are indicated in purple font and 
the coding regions are shown in black font.  
 1 attgctctaa catctcccat ctctctggat ttctttttcg cctcattatccctgcccacc 
 
       61 aattcatttc cagactttgt acttcagaag cgatggggaa aatcagcagc cttccaactc 
 
      121 aattatttaa gatctgcctc tgtgacttct tgaagataaa gatacacatc atgtcgtctt 
 
      181 cacacctctt ctacctggcg ctctgcttgc tcaccttcac cagctccacc acagctggac 
 
      241 cagagaccct ttgcggggct gagctggtgg atgctcttca gttcgtgtgt ggaccgaggg 
 
      301 gcttttactt caacaagccc acaggctatg gctccagcat tcggagggca cctcagacag 
 
      361 gcattgtgga tgagtgttgc ttccggagct gtgatctgag gagactggag atgtactgtg 
 
      421 ccccactgaa gcctacaaaa gcagcccgct ctatccgtgc ccagcgccac actgacatgc 
 
      481 ccaagactca gaaggaagta catttgaaga acacaagtag aggaagtgca ggaaacaaga 
 
      541 cctacagaat gtaggaggag cctcccacgg agcagaaaat gccacatcac cgcaggatcc 
 
      601 tttgctgctt gagcaacctg caaaacatcg aaacacctac caaataacaa taataagtcc 
 
      661 aataacatta caaagatggg catttccccc aatgaaatat acaagtaaac att 
Colour Codes 
Purple Sequences: UTRs  Red: Start/Stop Codon   
Green: Exon 1    Blue: Exon 3    
Yellow: Exon 4   Grey: Exon 6    
Black Sequences: Coding sequence 
IGF-IA Protein Sequence 
The above gene transcript is translated into a 153 amino acids long polypeptide chain 
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6.2.1.2 Mus Musculus Insulin-like Growth Factor 1, Isoform Eb (MGF)  
The MGF gene transcript (NCBI mRNA accession number AY878193) consists of 
exons 1, 3, 4, 5, and 6, its 765bp in size as displayed below. In the following sequence exons 
are colour coded, the untranslated regions of the gene (UTRs) are indicated in purple and the 
coding regions are shown in black font.  
1 attgctctaa catctcccat ctctctggat ttctttttcg cctcattatc cctgcccacc 
 
      61 aattcatttc cagactttgt acttcagaag cgatggggaa aatcagcagc cttccaactc 
 
      121 aattatttaa gatctgcctc tgtgacttct tgaagataaa gatacacatc atgtcgtctt 
 
      181 cacacctctt ctacctggcg ctctgcttgc tcaccttcac cagctccacc acagctggac 
 
      241 cagagaccct ttgcggggct gagctggtgg atgctcttca gttcgtgtgt ggaccgaggg 
 
      301 gcttttactt caacaagccc acaggctatg gctccagcat tcggagggca cctcagacag 
 
      361 gcattgtgga tgagtgttgc ttccggagct gtgatctgag gagactggag atgtactgtg 
 
      421 ccccactgaa gcctacaaaa gcagcccgct ctatccgtgc ccagcgccac actgacatgc 
 
      481 ccaagactca gaagtccccg tccctatcga caaacaagaa aacgaagctg caaaggagaa 
 
      541 ggaaaggaag tacatttgaa gaacacaagt agaggaagtg caggaaacaa gacctacaga 
 
      601 atgtaggagg agcctcccac ggagcaggaa atgccacatc accgcaggat cctttgctgc 
 
      661 ttgagcaacc tgcaaaacat cgaaacacct accaaataac aataataagt ccaataacat 
 
      721 tacaaagatg ggcatttccc ccaatgaaat atacaagtaa acatt 
Colour Codes 
Purple Sequences: UTRs  Red: Start/Stop Codon   
Green: Exon 1   Blue: Exon 3    
Yellow: Exon 4   Pink: Exon 5 
Grey: Exon 6   Black Sequences: Coding sequence 
MGF Protein Sequence 
The above gene transcript is translated into a 159 amino acids long polypeptide chain 
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6.2.1.3 Igf-I Primers  
Based on the sequences obtained for each isoform and bearing in mind the only 
difference between the two isoforms is due to the presence or absence of exon 5, we designed 
one set of primers recognising the UTR segment at the 5’and 3’ end of both transcripts, using 
the CLC Main Workbench software.    
IGF1 Forward primer:       GCTCTAACATCTCCCATCTCTCTGG  
IGF-1 Reverse primer:  GGGAAATGCCCATCTTTGTAATG   
The MGF mRNA sequence is displayed below and was used as a template, where all 
the exons, start and stop codons have been highlighted in different colours as displayed 
previously and the UTR binding sites for the sense and anti-sense primers are also annotated 
by different font colours. The red sequence represents the forward primer, the blue sequence 
represents the reverse primer, and the purple sequence represents the UTRs. The arrows after 
the primer sequences indicate the direction of the primers expansion in accordance to the 
reference sequence in the PCR process.  
   5’-gctctaa catctcccat ctctctgg-3’ 	  
5’ - 1 attgctctaa catctcccat ctctctggat ttctttttcg cctcattatc cctgcccacc 
 
      61 aattcatttc cagactttgt acttcagaag cgatggggaa aatcagcagc cttccaactc 
 
	  	  	  	  	  	  	  	  	  	  	  	  121 aattatttaa gatctgcctc tgtgacttct tgaagataaa gatacacatc atgtcgtctt 
 
      181 cacacctctt ctacctggcg ctctgcttgc tcaccttcac cagctccacc acagctggac 
 
      241 cagagaccct ttgcggggct gagctggtgg atgctcttca gttcgtgtgt ggaccgaggg 
 
      301 gcttttactt caacaagccc acaggctatg gctccagcat tcggagggca cctcagacag 
 
      361 gcattgtgga tgagtgttgc ttccggagct gtgatctgag gagactggag atgtactgtg 
 
      421 ccccactgaa gcctacaaaa gcagcccgct ctatccgtgc ccagcgccac actgacatgc 
 
      481 ccaagactca gaagtccccg tccctatcga caaacaagaa aacgaagctg caaaggagaa 
	  
      541 ggaaaggaag tacatttgaa gaacacaagt agaggaagtg caggaaacaa gacctacaga 
 
      601 atgtaggagg agcctcccac ggagcaggaa atgccacatc accgcaggat cctttgctgc 
 
      661 ttgagcaacc tgcaaaacat cgaaacacct accaaataac aataataagt ccaataacat 
              3’-gta 
      721 tacaaagatg ggcatttccc ccaatgaaat atacaagtaa acatt – 3’ 
          atgtttctac ccgtaaaggg-5’        
	   242 
Amplification of cDNA generated from TA muscle extracted from female mice (C57BL6×CBA/Ca). 
The PCR process yielded two different products, a slightly larger product approximately 780bp in size 
and a slightly smaller product approximately 713bp in size, which was determined to be Igf-IA 
isoform as annotated by the arrow. Bands were amplified using standard PCR, and they were 
separated overnight (over a period of approximately 16 hours) via agarose gel electrophoresis where a 
highly concentrated agarose gel (3%) was used for separation of the products.	  
Igf-IA  
  Figure 41. Murine Igf-IA isoform, amplified from mouse TA muscle. 
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Re-amplification of cDNA generated from TA muscle extracted from female mice 
(C57BL6×CBA/Ca). Left panel indicates that MGF levels were up-regulated by means of myotoxic 
injury caused by BaCl2. The process yielded 3 distinct products with sizes of approximately 780bp, 
765bp and 713bp (from the top respectively). The isoforms were amplified using standard PCR and 
they were separated overnight (over a period of approximately 16 hours) via agarose gel 







Injured Muscle  Normal Muscle  
  ~ 780bp 
MGF 
Figure 42. Expression of the murine MGF isoform in normal and injured TA muscle. 
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6.2.2. Igf-I Cloning 
We sub-cloned the amplified and purified Igf-I fragments (as described in the Chapter 
2. Materials and Methods, subsection 2.2.7.2) into a TOPO TA cloning vector (Invitrogen, 
map of which is provided in Figure 43), a linearized vector equipped with 3’ deoxythymidine 
T residues overhangs. The chimeric plasmid was then transformed into the 10-beta 
Competent E. coli cells as described in the Chapter 2. Materials and Methods (subsection 
2.2.7.2) followed by an overnight incubation at 37°C. In order to monitor the success of the 
ligation and the consequent transformation process upon overnight incubation, colonies were 
screened for the presence of the Igf-I transgene via a PCR screening technique (full details 
presented in the Chapter 2. Materials and Methods, subsection 2.2.11), where approximately 
60 colonies were screened. As demonstrated in Figure 44, strong bands displaying the desired 
molecular size were formed (approximately 765bp in this case) in the presence of the 
transgene of interest (MGF in this case) indicating a successful ligation of the TOPO/insert 
and transformation of the competent cells. Very faint bands are also visible in some of the 
lanes, which were excluded from the study as it was assumed they are either a false positive, 
or from a smaller size colony. To ensure the validity of our results only strong bands were 
regarded as positively transformed colonies and were subjected to sequencing and upon 
confirmation of the sequencing process indicating the presence of the gene of interest (either 
Igf-IA or MGF), we proceed by transferring the insert into a pCAGGs expression vector.    
Hence, the TOPO/insert chimeric vector was digested in the presence of EcoRI 
restriction enzyme. As displayed in Figure 45, upon digestion two bands of different sizes 
were formed, where the largest band was the vector (approximately 3.917kb in size) and the 
band with the smaller size was the insert (approximately 787bp in the case of MGF as 
displayed in the Figure, the insert size for Igf-IA transgene was 735bp).  
	   245 
We selected the pCAGGs plasmid as our expression vector, which consisted of the 
cytomegalovirus immediate early enhancer-β-actin hybrid (CAG) promoter (Niwa et al., 
1991). Thus, in a parallel digestion reaction, the pCAGGs plasmid was also digested with 
EcoRI restriction enzyme and the phosphate groups were removed from the 5’ end of the 
plasmid vector in the presence of Antarctic phosphatase enzyme to avoid self-ligation of the 
plasmid.     
The fragment of interest was consequently purified and inserted into the pCAGGs 
expression vector, map of which is provided in Figure 46, full details of the ligation process 
are presented in the Chapter 2. Materials and Methods, subsection 2.2.7.3. The ligation 
reaction was set up in two different ratios, 1:1 where both vector and the insert were present 
in equimolar concentrations and 1:2 where the concentration of the insert was twice as much 
as that of the pCAGGs vector. Ligation was followed by transformation of 10-beta 
Competent E. coli cells with the plasmid, overnight incubation, and a mini prep (full details 
available in Chapter 2. Materials and Methods, subsection 2.2.7.3). The latter involved 
picking a single colony from plates where cells were transformed with various ligation ratios, 
and the success of the ligation as well as the transformation process were then analysed 
through EcoRI restriction digestion and visualised on a 1% agarose gel as displayed in Figure 
47. The Figure demonstrates that the ligation process was successful for three out of the nine 
collected clones, two of which belonged to the plates with the ratio of 1:1 and one was picked 
from the plate with the 1:2 ratio. The large bands were approximately 4.793Kb in size and 
were therefore identified as the plasmid backbone. The smaller bands at the bottom on the 
other hand were approximately 787bp in size and were therefore identified as the MGF insert, 
in the case of Igf-IA however the estimated size of the insert was approximately 735bp. Lanes 
with one band only, therefor represent unsuccessful ligation in the rest of the collected clones 
as the band in these lanes display highly similar size to that of the plasmid backbone.  
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The resultant chimeric pCAGGs plasmid therefore contained one of the two Igf-I 
isoforms, either MGF or Igf-IA, and upon confirmation through sequencing (performed by 
GATC Biotech) the final products were subjected to mass scale production (i.e. Giga prep). 
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Figure demonstrating the structure of TOPO TA cloning vector, 3.9kb in size and consisting of T7 
promoter, f1 and pUC origin, Ampicillin and Kanamycin resistance gene and various restriction sites 
including EcoRI. The insertion site for the PCR product is highlighted in black within the sequence in 
the top panel. 
 







LacZ! fragment: bases 1-547
M13 reverse priming site: bases 205-221
Multiple cloning site: bases 234-357
T7 promoter/priming site: bases 364-383
M13 Forward (-20) priming site: bases 391-406
f1 origin: bases 548-985
Kanamycin resistance ORF: bases 1319-2113
Ampicillin resistance ORF: bases 2131-2991
pUC origin: bases 3136-3809
CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
T7 Promoter M13 Forward (-20) Primer

















lacZ! ATG Kpn I Sac I Spe IBamH IHind III
EcoR IEcoR IBstX I
BstX IEcoR V
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
AGT GAG TCG TAT TAC AAT TCA CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA AAC
TCA CTC AGC ATA ATG TTA AGT GAC CGG CAG CAA AAT GTT GCA GCA CTG ACC CTT TTG
PCR ProductGTA ACG GCC GCC AGT GTG CTG GAA TTC GCC CTT           AAG GGC GAA TTC TGCCAT TGC CGG CGG TCA CAC GAC CTT AAG CGG GAA           TTC CCG CTT AAG ACG
Figure 43. Map of TOPO TA cloning vector. 








PCR screening technique carried out on numerous colonies following transformation with TOPO 
TA/MGF, monitoring the success of the transformation process by amplifying the MGF transgene. 
The presence of the bands are an indication of the presence of gene of interest. Only strong bands 
were purified and their identity was confirmed through sequencing. The very first lane represents the 
1Kb ladder.   
750bp 
Figure 44.	  The PCR screening process, screening for MGF transgene. 
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TOPO TA/MGF vector digestion with EcoRI following confirmation of the presence of MGF 
transgene via sequencing. Where the ligation/transformation process were successful restriction digest 





Figure 45. TOPO TA/MGF vector digestion with EcoRI following sequencing 
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Map of pCAGGs expression vector (4,801kb in size), in the presence of the insert. Consisting of the 
cytomegalovirus immediate early (CMV-IE) enhancer, chicken β-actin hybrid (CAG) promoter, rabbit 











Figure 46. Map of pCAGGs Expression vector. 
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pCAGGs/MGF plasmid digestion with EcoRI to determine the success of the ligation and 
transformation process. The ligation process for each clone was carried out in two different ratios 
(1:1, equimolar concentration of vector and insert were present in the ligation reaction mix and 1:2, 
the concentration of the insert in the solution was twice that of the vector). Of the nine clones picked 
only three were successfully ligated. Restriction digest generated two different size fragments for two 
of the samples with the 1:1 ratio and one sample with the 1:2 ratio, with the largest product being 
approximately 4.793kb and the smallest product being approximately 787bp in size.  	  
Figure 47.	  pCAGGs/MGF vector digestion with EcoRI. 
1:1 1:2 
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6.2.3. IGF-I Antibody 
The ‘Mouse IGF-I, Antigen Affinity-purified Polyclonal Goat IgG’ (R&D Systems) 
was used for detection of IGF-I protein. We determined an optimal concentration for our pure 
protein positive control ‘recombinant murine IGF-I’ via a dot blot analysis. We therefore 
analysed various concentrations of the pure protein ranging from 10ng to 0.25pg as indicated 
in Figure 48, and selected the suitable dilution that would emit a reasonably strong signal at 
the selected antibody dilution. The Figure indicates that concentrations between 1ng to 
0.25pg in the second column on the right hand side of the strip did not produce any detectable 
signal at the presented time. Higher concentrations however, ranging from 10ng to 2.5ng in 
the first column on the left hand side of the strip generated strong to mild signals respectively 
as the pure protein decreased in concentration. Thus, the selected concentration for the 
‘recombinant murine IGF-I’ pure protein was determined to be 6ng as indicated by the red 
box in Figure 48. 
Upon confirming the optimum concentration of the pure protein, the ability of the 
selected antibody to detect the two murine IGF-I isoforms, namely IGF-IA and MGF, in vivo 
was then examined in injured murine muscle where TA muscles were subjected to BaCl2 
induced local muscle injury as describe previously in Chapter 2. Materials and Methods, 
subsection 2.2.7.1. IGF-I was detected post injury via western blot analysis at various time 
intervals, namely 2, 4, 6, and 8 days as displayed in Figure 49. In a parallel experiment we 
also collected muscles from untreated animals of the same age and sex for comparison 
purposes and ran them alongside the treated muscles. The Figure demonstrates that post 
injury three different types of IGF-I molecules are detected that vary in their molecular 
weight, ranging from approximately 17kDa to 6.5kDa. The heaviest group of bands at the top 
(annotated by the blue arrow) were estimated to weigh approximately 17kDa, the slightly less 
heavier bands in the middle (highlighted by the black arrow) were approximately 14kDa. The 
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group of bands at the bottom of the Figure (flagged up by the green arrow) were aligned with 
the IGF-I pure protein positive control and were therefore estimated to have highly similar 
molecular weight to that of the pure protein positive control (approximately 6.5kDa). Based 
on its very small molecular weight the latter groups of bands were therefore determined to be 
the processed form of IGF-I. Comparison of this panel to that of the untreated muscles on the 
left indicates that although very faint, some bands that are highly similar in weight to that of 
the MGF isoform are detected in lanes presenting untreated muscles on days 4, 6, and 8. In 
addition, two bands resembling a similar weight to that of the IGF-IA has also been detected 
in untreated muscles on days 6 and 8.  
However it is noteworthy that considering the aim of this part of the investigation was 
to solely test the ability of the antibody to detect IGF-I, no protein assay was done for these 
western blots, and we therefore cannot comment on the variability in the intensity of the 
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Recombinant murine IGF-I (estimated to have the molecular weight of 7.6kDa) was tested at 11 
different concentrations. From the top on the left panel of each strip 10ng, 8ng, 6ng, 4ng and 2.5ng 
and from the top on the right panel of each strip 1000pg, 500pg, 250pg, 25pg, 2.5pg and 0.25pg. 6ng 
concentration (red box) was determined to be the optimum concentration. 
	  
2	  Minutes	  
Figure 48. Dot blot demonstrating various concentrations of the recombinant murine IGF-I 
pure protein at various exposure intervals.   
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Western blot analysis displaying the expression of two murine IGF-I isoforms namely MGF (blue 
arrow, ~17kDa) and IGF-IA (black arrow, ~14kDa) as well as the processed form of IGF-I (green 
arrow, ~6.5kDa) at various time intervals post BaCl2 induced injury including days 2, 4, 6, and 8. 
Murine IGF-I expression is also demonstrated at the same time intervals in untreated animals of the 
same age and sex in the left panel (n = 2 per experimental group).      
The band in the first column is the recombinant murine IGF-I pure protein (~6.5kDa) that was 
































Figure 49. Western blot analysis demonstrating the expression of IGF-I protein in the 
presence and absence of BaCl2 induced local muscle injury. 
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6.2.4. The in vitro Studies 
Following cloning, the expression of the pCAGGs/Igf-I chimeric plasmid was tested 
in vitro, using two different cell lines namely the mouse Neuroblastoma (Neuro2A) and 
differentiated immortomouse myoblasts (H2K 2B4) (Muses et al., 2011) cell lines.  
For all in vitro experiments we used 5 different groups consisting of 3 control groups 
namely, untreated cells, pCAGGs only and pmaxGFP and 2 experimental groups namely 
pCAGGs/Igf-IA and pCAGGs/MGF chimera plasmids. 	  
Considering that Neuro2A cell line is easily transfected and we have a long record of 
regular use of this particular cell line in our laboratory, we initially assessed the expression of 
our plasmids in these cells using the lipofectemine transfection technique (described in detail 
in Chapter 2. Materials and Methods, subsection 2.2.8). The efficiency of the transfection 
technique was assessed 24 hour post-transfection, as presented in Figure 50. Comparison of 
the fluorescent picture in the right panel to that of the same area on the left hand side clearly 
indicates that a large proportion of the cells were successfully transfected with pmaxGFP. 
However, since our goal for this part of the experiment was to only assess the success of the 
transfection protocol we did not quantify the percentage of the transfected cells. Following 
successful transfection we proceed by assessing the in vitro expression of our genes of 
interest in the Neuro2A cell line via a western blot analysis, results of which are presented in 
Figure 51. For this part of the experiment we monitored both media and cell lysate from each 
experimental group for the expression of IGF-I isoforms, as displayed in Figure 51. The 
Figure clearly demonstrates that none of the IGF-I isoforms were detected in the cell lysate or 
media collected from the untreated and pCAGGs treated cells. However, 3 protein products 
of various molecular weights are present in cell lysate where the cells have been transfected 
with the pCAGGs/Igf-IA chimeric plasmid. While the two heavier products had an unknown 
origin, the smaller product (red box) was estimated to weigh 14kDa and was therefore 
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assumed to be IGF-IA isoform. Similarly two different size products were also present in the 
column representing the cell lysate from pCAGGs/MGF chimeric plasmid, and as before 
while the heavier protein band had an unknown origin the smaller protein (blue box) with the 
approximate molecular weight of 17kDA was identified as the MGF isoform.  
Following this unexpected results/observations we monitored the expression of our 
plasmids in the differentiated immortomouse (H2K 2B4) cell line (Muses et al., 2011), as our 
long term plan for this part of the investigation was to inject our chimeric plasmids into 
mouse muscle and hence the differentiated H2K 2B4 cell line provided us with an in vitro 
model closely resembling characteristics of the in vivo model to be used.  
Cells were subjected to transfection via the nucleofection technique as described in 
detail in Chapter 2. Materials and Methods, subsection 2.2.8. As with the Neuro2A cells, 
transfection efficiency was assessed 24 hours post-transfection in early differentiating 
myoblasts via the GFP transfected control group, demonstrated in Figure 52. As the Figure 
indicates, comparison of the fluorescent picture on the left to that of the bright field on the 
right hand side captured from the same area of the plate indicates that a large proportion of 
the cells were transfected. However as described previously we did not proceed with 
calculating the percentage of transfection efficiency as our goal was solely to confirm the 
success of the transfection experiment.  
As described in the Chapter 2. Materials and Methods, both cells and media from one 
complete set of experimental groups were collected 3 days post-transfection including 
untreated, pCAGGs only, pCAGGs/Igf-IA and pCAGGs/MGF. The collected samples were 
subjected to western blot analysis with the aim of monitoring the expression of the IGF-I 
isoforms under the influence of the pCAGGs promoter/enhancer in this particular cell line, 
results of which are presented in Figures 53.  
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Analyzing this Figure, where western blot investigation was carried out 3 days post-
transfection on differentiated H2K 2B4 cells demonstrate that IGF-I protein was not detected 
in either the cell lysate or the media of the control samples. The Figure further displays that 3 
faint bands were detected in the column representing cell lysate from pCAGGs/Igf-IA. While 
once again the two heavier bands had an unknown origin, the approximate molecular weight 
of the smallest band (red box) was estimated to be 14kDa and it was therefore assumed to be 
the IGF-IA protein. The adjacent column however where the media from the same 
experimental group was loaded appeared blank which indicates that no IGF-I protein was 
present in the media. Studying the next two sets of columns on the right hand side, displaying 
the cell lysate and media from pCAGGs/MGF highlights the presence of two bands in the cell 
lysate, the darker of which was at the expected molecular weight for MGF (17kDa, blue box) 
and the final column representing media appeared blank.  
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Neuro2A cells 24 hours post-transfection. Figure on the left represents cells expressing GFP 
(pmaxGFP plasmid), the right hand Figure demonstrates the bright field picture captured from the 
same area.  
















Figure 50. Neuro2A cells transfected with GFP in the presence of lipofectemine reagents. 
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Western blot analysis displaying the expression of the cloned murine IGF-I isoforms, IGF-IA and 
MGF, under the influence of pCAGGs promoter/enhancer in Neuro2A cell line. 	  
Four different experimental groups were analysed, from the left, untreated cells, pCAGGs plasmid 
with no insert, pCAGGs plasmid with Igf-IA insert and pCAGGs plasmid with MGF insert, both cell 
lysate and media for each experimental group were ran in parallel to each other. Two different size 
bands appeared in the presence of the Igf-IA insert in the pCAGGs/Igf-IA cell lysate, with the lightest 
band bearing the approximate molecular weight of 14kDa identified as IGF-IA (red boxed). Two 
bands of different sizes were also detected in cell lysate from pCAGGs/MGF, where the lower 
molecular weight band with the approximate molecular weight of 17kDa was determined to be MGF 
(blue box).  	  
The band in the first column on the left is a recombinant murine IGF-I pure protein with the 
approximate molecular weight of 6.5kDa that was commercially available and was used as a positive 


























Figure 51. Western blot analysis demonstrating the expression of the two IGF-I isoforms in 
both cell lysate and media of Neuro2A cell line 24 hours post-transfection.  









H2K 2B4 cells 24 hours after transfection. Figure on the left represents cells expressing GFP 
(pmaxGFP plasmid), the right hand Figure demonstrates the bright field picture captured from the 
same area.  
Scale bar represents 1000µm.  
Figure 52. H2K 2B4 cells transfected with GFP via nucleofection technique. 
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Western blot analysis displaying the expression of the cloned murine Igf-I isoforms, Igf-IA and MGF, 
under the influence of pCAGGs promoter in differentiated H2K 2B4 cell line.  
Four different experimental groups were analysed, from the left, untreated cells, pCAGGs plasmid 
with no insert, pCAGGs plasmid with Igf-IA insert and pCAGGs plasmid with MGF insert, both cell 
lysate and media for each experimental group were ran in parallel to each other. Three different size 
bands appeared in the presence of the insert in the cell lysates from pCAGGs/Igf-IA, with the lowest 
band (red box) identified as IGF-IA isoform with the approximate molecular weight of 14kDa. A 
band of 17kDa was detected in the cell lysate collected from the pCAGGs/MGF treated experimental 
group.   	  
The band in the first column on the left is a recombinant murine IGF-I pure protein with the 
approximate molecular weight of 6.5kDa that was commercially available and was used as a positive 





























Figure 53. Western blot analysis demonstrating the expression of the two IGF-I isoforms in 
both cell lysate and media of differentiated H2K 2B4 cell line 3 days post-transfection.   
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6.2.5. The in vivo Study  
As demonstrated in the previous subsection, as well as our products of interest, some 
unexpected protein products also appeared in the cell lysates transfected with the chimeric 
pCAGGs/Igf-IA and pCAGGs/MGF plasmids in vitro. Thus, to assess the expression of our 
plasmids further we introduced our chimeric plasmids in vivo. In a small pilot study (n = 3, 
per experimental group), wild type male mice (C57BL10×CBA/Ca) were injected with 
plasmids into three muscle groups namely TA, quadriceps (quad) and gastrocnemius (gastro) 
where the plasmid was delivered into the muscle via electroporation (full details available in 
Chapter 2. Materials and Methods, subsection 2.2.9). Three different experimental groups 
were set up and each group was injected with one of the following constructs pCAGGs/Igf-
IA, pCAGGs/MGF and pCAGGs plasmid with no insert, the latter acted as a control to 
monitor for any possible effects that may arise from the presence of the foreign DNA. The 
plasmid was allowed to express for 2 weeks upon which the treated muscles were collected 
and subjected to western blot analysis as shown in Figure 54. As the Figure demonstrates 
none of the IGF-I isoforms were detected in the presence of the pCAGGs plasmid with no 
insert, the lanes representing the three sets of muscles injected with pCAGGs/Igf-IA vector 
however display two very faint bands in lanes for the TA and gastrocnemius muscles with the 
approximate molecular weight of 14kDa (annotated by the red boxes), whereas no product 
was detected in the lane representing the quadriceps muscle for this particular experimental 
group. The adjacent set of samples representing the muscle sets injected with pCAGGs/MGF 
chimeric plasmid also display similar results (blue box), the bands in these lanes however 
appear slightly heavier in size in comparison to those of the pCAGGs/Igf-IA (approximately 
17kDa). Further analysis of Figure 54 indicates that the intensity of the bands present in the 
set of muscles treated with pCAGGs/MGF are considerably higher in comparison to those 
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muscles injected with pCAGGs/Igf-IA, this is particularly noticeable in the quadriceps 
muscle.     
To check for equal protein loading we monitored the expression of an endogenous 
protein with a relatively constant expression namely beta-tubulin, displayed in Figure 55. 
This Figure indicates that except for two muscles, TA-pCAGGs and gastrocnemius-
pCAGGs/MGF, where the band for the former group appeared more intense and the band 
obtained for the latter had a lower intensity in comparison to the rest of the samples, a fairly 
consistent protein loading was noted across the rest of the samples. Due to space limitation on 
this gel, only two of the treated muscles with pCAGGs plasmid were loaded as control and 
the gastrocnemius-pCAGGs muscle was ran in a parallel gel, which yielded the same results, 
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Western blot analysis displaying the expression of the cloned murine Igf-I isoforms, Igf-IA and MGF, 
under the influence of pCAGGs promoter/enhancer in wild type male mice (C57BL10×CBA/Ca). 
Three different muscle types were injected with one of the following plasmid vectors, pCAGGs with 
no insert, pCAGGs/Igf-IA and pCAGGs/MGF (n = 3 per experimental group). A set of bands with the 
approximate molecular weight of 14kDa were detected in only two muscle types namely TA and 
gastrocnemius in the presence of pCAGGs/Igf-IA.  
A set of bands were also detected in the presence of pCAGGs/MGF which were slightly heavier with 
the approximate weight of 17kDa.  
The band in the first column on the left is a recombinant murine IGF-I pure protein with the 
approximate molecular weight of 6.5kDa obtained that was commercially available and was used as a 
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Figure 54. Western blot analysis demonstrating the expression of the two IGF-I isoforms 
in vivo 2 weeks post-electroporation.  
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Endogenous beta-tubulin was used as a loading control to monitor the consistency of sample loading 
in the IGF-I pilot study. 	  
Except for TA-pCAGGs samples where the band is more intense and the gastrocnemius-
pCAGGs/MGF where the detected band was less intense, a fairly consistent set of bands was detected 









Quad  TA 
pCAGGs/Igf-IA 
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pCAGGs/MGF 
Quad  Gastro TA 
Figure 55. Analysis of beta-tubulin loading control. 
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6.3. Discussion 
This experiment was designed based on the findings of Riddoch-Contreras and 
colleagues in 2009, where they demonstrated delivery of naked plasmid via direct injection 
into skeletal muscle tissues of SOD1G93A ALS mouse model increased motor unit number, 
motor neuron survival and significantly improved muscle strength compared to untreated 
SOD1G93A mice (Riddoch-Contreras et al., 2009).  
With these findings in mind and considering the fact that amongst in vivo gene 
transfer techniques direct injection of chimeric plasmids bearing the gene of interest into 
muscle tissue is a particularly economical, safe and simple technique; we aimed to investigate 
the effect of two murine Igf-I isoforms in high copy number SOD1G93A mouse model. This 
was done by employing an even more efficient gene delivery methodology, in vivo plasmid 
electrotransfer. For this purpose we initiated our study by identifying, purifying and 
amplifying Igf-I isoforms from wild type mouse TA muscles. Upon identification of murine 
Igf-I isoforms, their corresponding exons and the consequent protein sequence using 
GenBank, Ensemble and UniProt databases, a set of primers were designed and the Igf-I 
isoforms were subjected to amplification as displayed in Figure 41. As the Figure 
demonstrates the two resultant bands differ distinctively in nature, where the lower band that 
was approximately 713bp appeared extremely strong in comparison to the top band which 
appeared very faint and diffused. Following sequencing the lower band was confirmed to be 
the Igf-IA isoform.  
Mounting evidence indicates that MGF is up-regulated in response to exercise, 
mechanical overload and injury (Yang et al., 1996, McKoy et al., 1999, Hameed et al., 2003). 
Following injury, MGF expression is increased and reaches its peak at day 4 from which 
point onwards its levels continuously decrease. However Igf-IA levels are also up-regulated 
upon injury but they do not reach a peak until day 11, and it continues to express thereafter 
	   268 
for 24 days whilst declining in levels (Hill and Goldspink, 2003). Thus, local muscle injury 
was induced using BaCl2, a myotoxic agent which resulted in high MGF yield as displayed in 
Figure 42. As the Figure demonstrates three bands were formed as a result of BaCl2 induced 
muscle injury, and sequencing confirmed that the middle band of 765bp was indeed MGF. 
Comparison of two Figures obtained from normal and injured muscle further indicates that 
the previous unsuccessful attempts towards amplifying and purifying this particular isoform 
were possibly due to its naturally low levels under normal conditions as its expression were 
almost undetected in normal muscle as displayed in Figure 42.   
The Figure also demonstrates that stimulation of the muscle by the myotoxic agent 
(BaCl2) not only led to up-regulation of the MGF isoform, but resulted in expression of a 
third isoform. The newly discovered isoform appeared to be the largest of all three 
(approximately 780bp in size) and to our knowledge has not been reported previously in any 
of the literature and its nature is therefore currently unknown. Unfortunately attempts to clone 
this isoform were unsuccessful.  
Following successful amplification and purification of our isoforms of interest, they were 
sub-cloned into a TOPO TA cloning vector. Since the Taq DNA polymerase enzyme 
employed in the PCR reaction mix has a nontemplate-dependent terminal transferase activity, 
it acts by adding a single deoxyadenosine (A) residue to the 3’ end of the PCR products 
creating an overhang at each end of the amplified product. The linearized TOPO TA cloning 
vector equipped with 3’ deoxythymidine (T) residue overhangs therefore provided 
complimentary base pairs for the newly generated isoform/insert. In the presence of the 
Vaccinia virus topoisomerase I enzyme, the ligation of our amplified PCR fragment (insert) 
and the TOPO TA vector was facilitated through binding of the compatible ends. The 
efficiency of the TOPO TA/insert ligation and the transformation process were tested through 
a PCR screening technique and as presented in Figure 44, where only strong bands were 
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taken into account and were regarded as successfully transformed colonies. The selected 
colonies were then subjected to EcoRI digestion, cleaving off the insert (with the molecular 
sizes of 787bp in the case of MGF and 735bp in the case of Igf-IA) in preparation for 
inserting it into an expression vector as displayed in Figure 45.      
The pCAGGs vector was selected as the expression vector which is equipped with 
chicken β-actin hybrid (CAG) promoter that facilitates its universal expression in vivo in all 
tissue types and cytomegalovirus immediate early (CMV-IE) enhancer which promotes 
increased expression levels of the construct. We selected the named vector since our ultimate 
goal involved the expression of the cloned gene in muscle tissue, and the pCAGGs 
expression vector is known to be particularly active in muscle (Miyazaki and Aihara, 2002), 
and in our experience provides a fairly long-term and constant expression. Thus, the fragment 
of interest was cloned into a pCAGGs expression vector, and the success of the ligation and 
transformation process was assessed through an EcoRI digestion as presented in Figure 47. 
Any sample with two bands was determined as a chimeric plasmid with the heavier band 
representing the vector and the smaller band representing the insert. Both pCAGGs/Igf-IA 
and pCAGGs/MGF plasmids were assessed for their true identities and any possible 
mutations via sequencing which in turn confirmed that both our constructs were an exact 
match to that of the reference sequences.      
In order to ensure that the expression of the Igf-I isoforms, we first analysed our 
constructs in a series of in vitro studies monitoring two different cell lines, namely Neuro2A 
and differentiated H2K 2B4. The former was used since they are easy to transfect and we 
have a long history of using this particular cell line in our laboratory. However following an 
unexpected results obtained from the Neuro2A cell line we employed the latter cell line to 
assess the expression of Igf-I isoforms in a muscle cell line induced to differentiate thus 
giving us an advance insight on how the isoforms are likely to behave in vivo. Five different 
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experimental groups were selected including 3 control groups, pmaxGFP treated, untreated 
and pCAGGs only, and two experimental groups, pCAGGs/Igf-IA and pCAGGs/MGF. The 
control groups were selected carefully to ensure that the results obtained from these set of 
experiments were due to the expression of our protein of interest. Therefore, the use of 
pmaxGFP control group provided us with a positive control and allowed us to assess 
successful transfection in each experimental setting before proceeding any further with the 
western blot analysis. The untreated group was used as a negative control to monitor for 
optimal cell growth conditions, to facilitate a comparison in the absence and presence of the 
transfection agents. The pCAGGs only control group involved transfecting cells with the 
plasmid backbone only (i.e. no insert), which consequently allowed us to monitor for any 
possible problems related to the presence of the foreign DNA.    
Overall analysis of the results obtained from the in vitro studies indicates that all cells 
were successfully transfected with the desired constructs. Comparing the untreated and 
pCAGGs only control groups to those of the experimental groups in Figures 51 and 53 
indicates that both chimeric plasmids, show the expression of a specific IGF-I isoform 
depending on the type of the specific insert they enclosed.  
In addition, two nonspecific bands appeared in columns representing cell lysate from 
pCAGGs/Igf-IA experimental group in both Neuro2A and H2K 2B4 transfected cells (Figures 
51 and 53 respectively). Considering that the unknown bands only appeared in the in vitro 
experiments and they disappeared when the chimeric plasmids were expressed in vivo (Figure 
54), by taking into account the time frame allocated for completion of this thesis and due to 
the fact that we were unable to complete the course of the planned IGF-I studies, we decided 
that exploring these unknown protein products was beyond the scope of this thesis. While 
identifying the nature of these bands was not pursued any further the bands generated in the 
cell lysate of the pCAGG/Igf-IA could be the differential glycosylated forms of the IGF-IA 
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protein as two N-linked glycosylation regions has been reported to be present in the rodent 
Ea-peptide (Bach et al., 1990, Wilson et al., 2001). Interestingly similar results were observed 
by Hede and colleagues (2012), where the authors concluded that the nonspecific bands are 
likely to be the glycosylated IGF-IA proteins (Hede et al., 2012). Unlike our results their 
investigation did not yield any nonspecific band for the MGF isoform and currently there are 
no record of glycosylation site in this particular protein. However, considering that the 
nonspecific band only appeared in the Neuro2a cells lysate transfected with pCAGG/MGF, it 
is reasonable to speculate that this may be due to the fact that different cells provide different 
processing for various proteins and thus the unknown protein product maybe a glycosylated 
form of MGF that is specific to Neuro2a cells and not other cell types. This hypothesis can be 
further tested by pre-treating the proteins with ‘Peptide-N-Glycosidase F’ enzyme to cleave 
off the possible sugar groups followed by a western blot analysis, where disappearance of the 
unknown bands will be an indication of the presence of glycosylation.  
Thus, by comparing the Figures (51 and 53) to that of the neurotoxin treated muscles 
in Figure 49, we determined that the bands with the molecular weight of 14kDa and 17kDa 
were indeed the deglycosidated forms of IGF-IA and MGF isoforms respectively. Further 
comparison of these Figures to that of the neurotoxin treated muscles in Figure 49 highlights 
the absence of the processed form of IGF-I molecule in the transfected cell lines. The absence 
of this particular molecule in this set of experiments could be due to its very low 
concentrations in the samples and the consequent inability of the antibody to detect it.  
Following successful expression of our pCAGGs/Igf-I plasmids in vitro, we proceed 
by assessing the expression of our chimeric plasmids in vivo by injecting three groups of 
muscles in wild type animals namely TA, quadriceps and gastrocnemius, presented in Figure 
54. Except for quadriceps-pCAGGs/Igf-IA, the expression of the isoform of interest was 
achieved under the influence of the CAGG promoter in all other muscle types whereas no 
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product was detected in the absence of the inserts in lanes presenting muscles injected with 
pCAGGs plasmid only.  
This Figure displays that the bands generated from expression of the pCAGGs/Igf-IA 
are very faint in comparison to those produced from pCAGGs/MGF plasmid, considering the 
equal loading for the groups in question as presented in Figure 55. The differences in the 
intensity of the bands between the TA and gastrocnemius muscles may be due to inefficient 
injections. This may have occurred during the injection phase of the experiment (where 
muscles were injected blindly with the appropriate plasmids prior to electroporation process). 
Hence the consequent leaking out into the periphery resulted in unequal amounts of plasmid 
amongst the comparable muscle tissues and across experimental groups, consequently 
leading to unequal expression levels. The absence of an IGF-IA protein product in the 
quadriceps muscle however may be due to a failure to inject the muscle. Since the injection 
procedure was carried out blindly, it is possible that the subcutaneous fat was target by the 
needle instead of the desired muscle, consequently resulting in the absence of expression in 
the muscle tissue.   
Whilst the ultimate goal of this part of the investigation was to assess and monitor the 
effects of Igf-I isoforms in the mouse model of ALS in term of disease progression and 
survival, due to the shortage of time it was not possible to complete this study.  
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7.0 Final Discussion, 
Future Directions  
& Conclusion  
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7.1. Final Discussion 
The inability of Riluzole to treat ALS, its incapability to improve disease symptoms, 
its limited effects on prolonging survival (average life extension of 2-3 months), and the 
urgent need for an effective treatment or therapy for ALS has been the concern of numerous 
investigations. Considering the vast number of successful preclinical studies and their poor 
translation into patients has led us to take a new approach into the field and encouraged us to 
design this investigation.  
The overall aim of this thesis was to design and study novel therapeutic strategies in a 
series of carefully monitored survival studies with the long-term vision of developing an 
efficient treatment for ALS using the most studied model of the disease, the high copy 
number SOD1G93A mouse.  
Following the discovery of the R199W mutation in the DAO gene and its link to an 
ALS phenotype (Mitchell et al., 2010), two new lines of transgenic animals were created 
prior to this investigation in a collaboration between the Wells and de Belleroche groups, 
namely DAOR199W and DAOWT.  
Therefore in the first experimental Chapter we aimed to introduce these two unique 
transgenic lines and draw a comparison between our models and the well-known mouse 
model of ALS, the high copy number SOD1G93A mouse. This Chapter highlighted that 
although the ubiquitous overexpression of DAOWT protein was not achieved in all organs, we 
successfully overexpressed the DAOWT in the spinal cord of this particular transgenic line. It 
was also demonstrated that overexpression of the wild type DAO protein is not toxic and 
animals appear normal and are able to live a healthy life. In addition, we demonstrated that 
the high copy number SOD1G93A mouse model expresses severe pathology at the cellular 
level which results in an aggressive phenotype and ultimately death, similar to that of the 
human patients. We also showed that our mutant line (DAOR199W) displays some cellular 
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pathologies including significant loss of motor neurons (19.7%) at approximately 15 months 
of age, but these changes are not enough to trigger any obvious phenotype at the physical 
level.  
Lack of disease associated phenotypes is one major drawback of transgenic animals. 
McGoldrick and colleagues (2013) recently reviewed the latest lines of ALS transgenics and 
pointed out that development of disease phenotypes in SOD1 mouse models and TDP-43-
ALS transgenic rodents is highly dependent on the level of transgene expression and the 
promoter used (McGoldrick et al., 2013). The expression of our transgene was under the 
influence of the CAGG promoter (beta-actin promoter with the CMV enhancer), which 
should promote ubiquitous expression of the transgene but this can be modified by the 
insertion site of the transgene and that may influence the subsequent pathology. As with the 
DAOWT transgenic line ubiquitous expression of the DAOR199W was not achieved, however a 
reasonable expression level was achieved in organs that did express the mutant transgene and 
thus location of the insertion site did not appear to be a major problem in this particular 
transgenic line. Another factor that may be responsible for the lack of severe physical 
phenotype like those of the high copy number SOD1G93A model may be the presence of the 
endogenous DAO protein as our mutant animals were generated on the non-transgenic wild 
type background and were therefore heterozygous for the faulty allele. These theories need to 
be subjected to further investigations in any future experiments.  
The possible effects of the DAOR199W mutation and its contribution towards ALS in 
humans was then investigated in Chapter 4, in a cross between DAOR199W and high copy 
number SOD1G93A animal models. We hypothesized that the mutual presence of the faulty 
DAOR199W transgene and the SOD1G93A mutant alleles might result in a more aggressive 
phenotype in double transgenic animals (DAOR199W/SOD1G93A) associated with earlier 
disease onset, accelerated disease progression and shorter lifespan in comparison to their 
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SOD1G93A littermates. However we did not observe any change in any of the phenotypes in 
our double transgenic groups. From this observation we then hypothesized that two factors 
may have interfered with the absence of a more severe ALS-like phenotype:  
1) The pathogenesis triggered by the SOD1G93A gene is extremely aggressive and thus 
any possible pathogenic effect induced by the presence of the DAOR199W mutation may 
be masked by the presence of SOD1G93A transgene.  
2) The presence of the endogenous DAO protein may have partly played a role in 
normalizing the potentially harmful effects of R199W mutation.  
In Chapter 5, we tested the possible therapeutic properties of wild type DAO protein 
in ALS. This was done by overexpression of the wild type form of DAO protein in the high 
copy number SOD1G93A mouse model of ALS. We hypothesized that the presence of high 
levels of DAO protein at the cellular level in the double transgenic animals 
(SOD1G93A/DAOWT) would lead to delayed disease onset, slow disease progression and 
prolonged survival. As expected our data produced extremely encouraging results, 
demonstrating that in the presence of high levels of DAO protein, while disease onset is 
unaffected both male and female double transgenics display a slower disease progression in 
comparison to their SOD1G93A littermates. The mean progression of the disease was 27% and 
12% slower in double transgenic males and females respectively although this improvement 
fell beneath our threshold for significance in females. We observed a highly significant 
difference in survival, where both our male and female double transgenics lived 21 days 
longer in comparison to their SOD1G93A littermates, and we observed an overall 16% and 
15% increase in survival respectively in males and females.      
Considering the potential D-serine induced excitotoxicity at the NMDAR 
glutamatergic terminal in ALS, the ability of the DAO protein to degrade D-serine to 
pyruvate, the involvement of the DAOR199W mutation in ALS, and our exciting new findings 
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led us to hypothesize that the presence of high levels of DAO protein at the cellular level 
results in more rapid breakdown of D-serine and may provide the receptor with more 
controlled signalling, reduced excitotoxicity, and delay or prevent motor neuron death, 
consequently leading to slow disease progression and prolonged survival.  
Currently the only licensed drug available for the treatment of ALS is Riluzole. A 
number of studies demonstrated that it prolonged survival in SOD1G93A mouse model, and so 
it was taken into clinical trials and upon producing minor positive results it was approved for 
the treatment of ALS patients (Bellingham, 2011). In 2008, Scott and co-workers 
demonstrated that the preclinical studies that demonstrated positive results from 
administration of Riluzole were poorly designed and did not control for variables such as 
gender, number of animals per treatment groups and the mutant SOD1G93A transgene copy 
number changes. In the same study they showed that a carefully designed preclinical 
investigation is not only crucial for evaluation of any compound used in the SOD1G93A ALS 
animal models with the possibility of being taken into clinical trials but reported no 
significant effect of Riluzole in a large cohort survival study (Scott et al., 2008).   
In addition, since the discovery of Riluzole many other studies aimed to test and 
possibly introduce new drugs for the treatment of ALS. Some of these drugs were selected to 
particularly target the glutamate induced excitotoxicity pathway. Ceftriaxone is an antibiotic 
that as well as providing prevention on glutamate neurotoxicity, also has anti-apoptotic 
properties, testing this compound in a population of 20 SOD1G93A mice showed it prolonged 
survival, delayed neuronal loss and muscle weakness (Rothstein et al., 2005). Memantine is 
another compound that reduces excessive NMDAR activity (excitotoxicity) by blocking the 
receptor and it was shown to increase survival in SOD1G93A mice (Wang and Zhang, 2005, 
Joo et al., 2007). Treating the SOD1G93A mouse model (n = 3 per sex, per experimental 
group) with a combination of lithium (an anti-inflammatory compound) and valproic acid 
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(VPA) (excitotoxicity preventative agent) was shown to be highly effective and produced 
positive outcomes such as delayed onset of symptoms, prolonged lifespan and decreased 
neurological scores deficit (Feng et al., 2008). Another group recently published the result of 
a survival study where they administered melatonin, a naturally occurring pineal hormone, to 
SOD1G93A ALS model. As well as preventing excitotoxicity, this compound also has anti-
oxidative stress, anti-apoptotic and anti-inflammatory properties and its administration 
resulted in significant delays in disease onset, neurological deterioration and increased 
survival (Zhang et al., 2013).  
Although these studies generated promising results, none of them followed the 
guidelines generated by Scott and colleagues (2008) and had a number of problems including 
small group sizes, lack of information on the sex of the animals employed or employment of 
one sex only, no information on balancing the experimental groups for age and litter, and 
insufficient information on monitoring the possible variations in SOD1G93A transgene copy 
numbers. Thus, lack of control for any of these parameters has the potential to generate false 
positive data and makes the final outcome questionable. In addition, we have previously 
reported that employing both sexes in preclinical studies is of utmost importance as some 
treatments may affect one sex more severely than the other. We demonstrated that metformin 
had an adverse effect on the SOD1G93A female mice in terms of onset of neurological 
symptoms and disease progression whereas the male littermates were unaffected (Kaneb et 
al., 2011). This study therefore indicates that failure to include both sexes in preclinical 
studies may result in misleading information regarding the behaviour of the treatment in 
question in different sexes, and thus may limit the development and use of a potential drug to 
one sex only.        
Considering that we carefully monitored for the above variables and followed the 
guidelines by Scott et al (2008) as per protocol and given that we have successfully 
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established and published results generated from two large cohort survival studies prior to 
this thesis, we are confident that the results generated from this investigation are accurate and 
reliable. Our results have opened a new chapter in the field of ALS drug discoveries, as we 
have shown that overexpression of the wild type form of DAO protein at the cellular level 
does not exert any effect on disease onset but instead slows disease progression and 
significantly prolongs survival. This increased survival, 21 days in both males and females 
(16% in males and 15% in females), is equivalent to approximately 6-7 years in human. This 
finding is relevant for translation into clinical trials as patients are frequently diagnosed after 
disease onset and therefore a potential treatment with particular effects on disease progression 
and survival is very attractive in the current field of ALS therapeutic studies. To our 
knowledge such significant increase in survival has not been reported commonly in the 
literature considering that more than 1000 drugs and therapies have been tested in the 
SOD1G93A model.  
Harraz and colleagues (2008) reported a significant increase of 50% in survival of 
SOD1G93A mouse upon treatment with apocynin (an anti-oxidant, administered in drinking 
water at the dose of 300mg/kg at 14 days of age). However, while both males (n = 11) and 
females (n = 10) were tested, the authors do not report balancing for age, weight and litter. 
There are also lack of information on monitoring for the possible changes in SOD1G93A 
transgene copy number, and a variable end point was employed (either the inability of the 
animal to right itself within 20 seconds or 20% weight loss in a 1 week period) (Harraz et al., 
2008). Another study showed a 20% increase in survival of SOD1G93A animals (n = 20 males 
only) upon treatment with L-arginine, a semi-essential amino acid with anti-glutamatergic 
properties, administered in drinking water at 30 days of age. While a large ‘n’ number was 
employed, the investigators did not balance for age, weight and litter amongst experimental 
groups, only studied one sex (males), and the possible changes in the SOD1G93A transgene 
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copy numbers were not monitored (Lee et al., 2009). Some other studies with similar designs 
reported similar increases in lifespan in SOD1G93A mouse model including 34% upon 
administration of lithium (Fornai et al., 2008), WHI-P131 treatment led to 49% boost in 
survival (Trieu et al., 2000), and treating with morphine increased survival by 30% (Chritin et 
al., 2006). Furthermore, only one study led by Ralph and coworkers (2005), reported 
approximately 80% increase in survival and over 100% delay in onset of ALS-like symptoms 
upon silencing the mutant SOD1 gene in the SOD1G93A mouse model by intramuscular 
delivery of EIAV (equine infectious anemia virus) vector encoding shRNA (short hairpin 
RNA) at 7 days of age (Ralph et al., 2005). Although this finding is highly valuable and the 
authors carefully monitored for the SOD1G93A transgene copy number changes. As before we 
noted that the experiment was conducted on a small group of animals (n = 6), the sex of the 
animals employed are not specified, and no evidence is given indicating that the experimental 
groups were balanced for age and litter.   
Moreover, other therapeutic approaches also demonstrated some positive results 
towards extending survival in SOD1G93A mouse model. In a similar approach to that 
presented in this thesis (generating new line of double transgenic animals), Taes and 
colleagues (2013) focused on the role of histon deacetylase 6 protein (Hdac6), a crucial 
protein involved in degradation of misfolded proteins that play a part in the mechanism of 
neurodegeneration. By crossbreeding the Hdac6 knockout mice to SOD1G93A transgenics they 
demonstrated 60% increase in survival of double transgenic animals (n = 29 males only) 
(Taes et al., 2013). However the authors did not provide evidence for monitoring for 
SOD1G93A transgene copy number, and they focused on one sex only.   
Based on these findings it is therefore reasonable to argue that the results of our study 
are reliable and potentially DAO can be targeted as a therapeutic agent for the treatment of 
ALS. It is however noteworthy that ubiquitous overexpression of the wild type DAO protein 
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in human patients may not be ideal, as DAO overexpression has been reported in the brain of 
schizophrenic patients (Kapoor et al., 2006, Burnet et al., 2008), and its dysregulation has 
been demonstrated in brain tissue from individuals suffering from bipolar disorder, 
schizophrenia, or major depressive disorders (Madeira et al., 2008). Thus, to take our findings 
further and develop DAO as a therapeutic agent we propose that it is feasible to focus on 
compounds that are associated with cellular up-regulation of wild type DAO protein in the 
spinal cord only. This is discussed further in the future studies subsection (7.2.1).  
   In addition to the aims of this thesis, in the second part of the study (Chapter 6) we 
proposed to investigate the effect of Igf-I isoforms on ALS. Although we successfully 
managed to extract and clone the two known murine Igf-I isoforms from mouse muscle and 
confirmed their expression both in vitro and in vivo, due to time constraints we were unable 
to complete this work and therefore did not reach the stage of administering the cloned 
isoforms into the SOD1G93A mouse model to investigate its potential beneficial effects on 
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7.2. Future Directions 
Based on our novel scientific discoveries throughout the duration of this thesis, the 
following experiments are proposed as a follow up of the findings of this study.  
7.2.1 The DAO Studies 
Currently the only licenced drug for the treatment of ALS is Riluzole, which acts by 
preventing excitotoxicity and appears to offer an increased lifespan of several months.  
Our unique discoveries throughout the duration of this thesis raise hope for a new 
potential therapeutic. The demonstration that overexpression of DAO increases survival time 
in the double transgenic mice compared to the SOD1G93A transgenic mice identifies a strong 
candidate target for the development of drugs to either up-regulate DAO expression or target 
other elements of the pathway downstream of DAO. Thus we propose the following 
experiments to confirm the beneficial effects of overexpressing DAO and are hoping to take 
this further to test a variety of compounds ranging from those that increase DAO expression 
(such as D-amino-acid oxidase activator (DAOA) and D-alanine), NMDA receptor antagonist 
(including memantine) as well as those that block D-serine binding to the NMDA receptor 
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7.2.1.1. In vivo Electrophysiology 
At 120 days of age, under deep anesthesia both male and female mice with the 
following genotype (non-transgenic wild type (WT), SOD1G93A, DAOWT, DAOWT/ 
SOD1G93A; n = 8 per sex, per group) could be subjected to electrophysiology. By stimulating 
the sciatic nerve innervating the TA and extensor digitorum longus (EDL) muscles, we could 
measure the maximum and specific force of these two muscles, the number of motor units, 
and analyse the fatigue test. 
This study would allow us to test the hypothesis that the increased survival time in the 
double transgenic mice (DAOWT/SOD1G93A) compared to the SOD1G93A transgenic mice is 
due to preservation of motor neurons and associated motor units. 
 
7.2.1.2. Immunohistochemistry 
Following electrophysiology, as described in Chapter 2. Materials and Methods, 
subsections 2.2.3-4, animals could be perfused through the left ventricle of the heart with 
phosphate buffered saline (PBS) followed by 4% paraformaldehyde in PBS. Their spinal 
cords could be prepared for staining where we could investigate if any functional motor unit 
preservation seen in the TA and EDL muscles translates to the number of motor neuron cell 
bodies seen in the sciatic motor pool of the lumbar spinal cord via Nissl stain and ChAT 
immunostaining. We could also assess the distribution of ubiquitinated protein aggregates by 
immunohistochemistry in the spinal cord of these animals. 
This investigation would allow us to study the hypothesis that the increased survival 
time in the double transgenic mice (DAOWT/SOD1G93A) compared to the SOD1G93A 
transgenic mice is associated with reduced markers of disease pathogenesis such as the 
presence of ubiquitinated protein aggregates. 
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7.2.1.3. Assessment of D-Serine Levels  
In order to demonstrate that the neuro-protective effect of overexpression of DAOWT 
in the SOD1G93A mouse is due to the reduction of D-serine in the spinal cord, we propose to 
assess the levels of D-serine in the spinal cords of all four genotypes (WT, SOD1G93A, 
DAOWT, DAOWT/SOD1G93A), at 90 and 120 days of age (n = 6 per sex, per genotype). This 
could be done using micro-2D High-Performance Liquid Chromatography (HPLC) as 
described by Miyoshi and colleagues (Miyoshi et al., 2009). 
 
7.2.1.4. In vitro & in vivo Studies 
Upon investigating the cellular mechanisms behind the beneficial effects of DAOWT 
overexpression on survival, we could assess a variety of compounds that may result in 
overexpression of the DAO protein in vitro. For this purpose, primary motor neurons could 
be isolated from spinal cord of SOD1G93A mouse and non-transgenic wild type littermates. 
Cells could be exposed to multiple doses of various compounds associated with inhibiting 
NMDAR signalling and/or expression of DAO protein. NMDAR antagonists, such as ACEA-
1021 (Woodward et al., 1995), memantine (de Carvalho et al., 2010) and GV150526 (Lees et 
al., 2001), drugs for enhancing the DAO activity could include DAOA (a DAO activator 
protein) (Chumakov et al., 2002), D-alanine (a substrate for DAO protein) (Takahashi et al., 
2012), as well as supplementing DAO protein itself.  
Those compounds with the most beneficial effects in terms of motor neurons survival 
as well as the most effective doses employed could be introduced into high copy number 
SOD1G93A animal model. In a large-scale survival study animals could be administered with 
the drug of interest from 90 days of age (upon disease onset) and the ALS-like phenotypes 
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including disease progression and survival could be monitored as described throughout this 
thesis in a blinded fashion.  
Should any of the proposed drugs yield any beneficial effects, in a separate study, we 
could investigate the formation of ubiquitinated aggregates and motor neurons survival in a 
time dependent manner in the lumber region of the spinal cord via immunohistochemistry as 
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7.2.1.5 Improvements  
 If more time were available the following amendments and improvements could have 
been considered:   
• The possible effects of R199W mutations could have been investigated in another 
animal model of SOD1 with a slower disease progression, such as the heterozygous 
SOD1G85R whose disease onset is at 12 months. This might have allowed enough time 
for any possible pathogenic effect of the mutant DAO protein to develop that may 
have contributed towards disease progression.   
• The differences observed in the number of motor neurons at the lumber region of the 
spinal cord in the DAOR199W animals requires further investigations in a time course 
manner. An early time point would reveal the age at which degenerations initiated, 
and a later time point would indicate whether the changes in motor neuron numbers 
are progressive.      
• Assessing the enzymatic activity of the DAO protein as well as levels of D-serine in 
the spinal cord of both our transgenic lines and their non-transgenic wild type 
littermates would have produced a set of data that may have been useful for our final 
analysis.  
• Considering that our DAOR199W transgenics were generated on a wild type 
background, they bear the endogenous DAO protein. Although it was shown that the 
DAOR199W is pathogenic in vitro despite the presence of the endogenous DAO protein 
(Mitchell et al., 2010), it is possible that the presence of the endogenous protein 
masked any obvious phenotypes in these animals. It would therefore be ideal to 
generate a second line of mutant DAOR199W transgenic animals on the ddY/DAO− 
background that lacks the endogenous DAO protein, to ensure the absence of 
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endogenous DAO protein and certainty of the final results as well gaining a more in 
depth insight onto the behaviour of the R199W mutation.  
• Various studies highlighted that the promoter employed for expression of the 
transgene when generating the transgenic animals may play a part in expression of the 
phenotype. The expression of our transgene of interest was under the influence of the 
ubiquitous CAGG promoter, it may therefore be interesting to explore other 
promoters (such as ‘mouse prion promoter’, that is used to express transgenes in the 














	   288 
7.2.2. The IGF-I Studies 
 All the following studies should be carried out in a blinded manner as described 
throughout this thesis, to ensure the reliability of the final data. 
7.2.2.1. IGF-I Treatment  
The two cloned Igf-I isoforms, Igf-IA and MGF, could be delivered into the high copy 
number SOD1G93A mouse model of ALS.  
A large scale study could be carried out where each of the 2 plasmid vectors encoding 
one of the two Igf-I isoforms (Igf-IA or MGF) would be delivered into SOD1G93A transgenic 
mice at disease onset (90 days of age), using the plasmid electrotransfer techniques (n = 12 
per group, per sex) as described in Chapter 2. Materials and Methods section. This age has 
been selected as patients are frequently diagnosed after the onset of the disease, and therefore 
the need for a therapy with beneficial post diagnosis effects is currently a priority in the field 
of ALS therapeutics.   
As described previously the onset and progression of the disease as well as the 
possible beneficial outcomes of the treatment would be monitored blindly by means of 
neurological scoring and weight loss in all treatment groups in comparison to their non-
transgenic wild type littermates.  
Thus, this study would allow us to identify the best isoform in terms of survival and 
improvement of symptoms, providing an insight on the effect of two different Igf-I isoforms 
on ALS phenotype using an efficient gene therapy technique.  
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7.2.2.2. Time-Course Study & IGF-I Treatment 
This part of the experiment could be carried out in a very similar manner to that 
described in the previous section. However, our aim for this part would be to investigate and 
monitor the effect of both Igf-I isoforms (Igf-IA and MGF) administered at various stages of 
the disease. For this purpose we would use electrotransfer delivery of plasmid vectors 
encoding one of the two Igf-I isoforms into a high copy number SOD1G93A model of ALS (n 
= 12, for each experimental group, in both male and female). The IGF-I treatment groups 
would receive treatment at one of 4 different time-points (28 days, 47 days, 70 days, and 110 
days) to monitor the efficiency of the treatment on survival at different stages of the disease. 
As described previously the onset and progression of the disease as well as survival would be 
monitored blindly by means of neurological scoring and weight loss until mice reach the 
humane end point (Scott et al., 2008).  
7.2.2.3. Time Dependent Effect of IGF-I Treatment 
This study would be carried out in a very similar manner to that described in the 
previous section. Our objective for this part however, would be to establish the possible long-
term effects of Igf-I delivery. Hence, animals would receive plasmid vectors encoding one of 
the two Igf-I isoforms or empty control vectors at 70 days of age (n = 12, for each 
experimental group, in both male and female), when there is a significant denervation of 
neuromuscular junctions. The participating groups would then be euthanized at different ages 
including 90 days, 100 days and 120 days; and each group will be analyzed by means of 
electrophysiological and immunohistochemical techniques.  
This study would therefore allow us to evaluate and investigate the effect of Igf-I 
treatment on survival and disease progression, and determines the efficiency of IGF-I 
treatment as ALS progress.  
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7.3. Conclusion  
NMDAR has been shown to be highly abundant in the CNS and thus under normal 
conditions the low levels of co-agonist D-serine prevents overstimulation and the consequent 
excitotoxicity. However, under intense physiological conditions high concentration of D-
serine and the capability of the D-serine to increase receptor binding affinity for glutamate 
and the subsequent mediated excitotoxicity enables this molecule to promote motor neuron 
death even when there are no changes in glutamate levels within the cellular environment 
(Crow et al., 2012). For this reason D-serine may indeed be the primary cause of excitotoxic 
cell death in ALS, and maintaining a normal physiological levels of this potentially harmful 
D-amino acid needs to be the ground for further exploration in future investigations.  
Based on the collective evidence, it has therefore been hypothesised that DAO (an 
enzyme responsible for degradation of D-serine) could play a role in modulation of D-serine 
availability at the synapse and consequently influence the physiological function of NMDAR 
function (Verrall et al., 2010). Taken together the published data and the findings presented 
here allow us to speculate that DAO may serve as a good candidate for developing a therapy 
for ALS.  
Throughout the duration of this investigation we clearly demonstrated that mutant 
DAOR199W protein did not contribute towards ALS-like phenotypes in SOD1G93A mouse. 
However, the presence of high concentrations of the wild type DAO protein at the cellular 
level, not only prolonged survival and slowed disease progression but eliminated the 
significant sex difference effects that has been observed in all studies involving the SOD1G93A 
animal model including our own. As both male and female double transgenic animals 
displayed highly similar survival and disease progression rate, this discovery opens new 
therapeutic avenues, enabling researchers to target both sexes equally and develop a 
potentially therapeutic agent that enforces beneficial effects on both sexes.  
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Appendix I. DAOWT Fold Change (raw data) 
Figure 1. Graphs displaying the intensity of the bands for each individual sample used in 
the western blot analysis demonstrated in figure 19.  
The intensity of each band produced by the western blot analysis was measured by ImageJ64 
software. The DAOWT protein fold change was calculated with respect to the endogenous protein beta-
tubulin that was used as the internal control (the obtained values and the calculations are presented on 



























Table 1. Values generated from the measurement of band intensity for each sample using 






Table 2. Values generated from the measurement of band intensity for endogenous beta-








Table 3. Values generated for each sample (Table 1) was normalized against beta-tubulin 








Table 4. Calculation of the approximate fold change in DAOWT protein in the transgenic 
animals.  
The average values for each group of samples was calculate from the normalized values in 
Table 3. The average value for the DAOWT group was then divided by the average value 
obtained for the non-transgenic wild type control group, generating the approximate DAOWT 
protein fold change.  
  
 Samples  



















Genotype Average STDEV 
DAOWT 0.043 0.019 
Non-transgenic 0.005 0.005 
Fold Change 8.6  
 Lane no. Samples / Beta-tubulin 
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Appendix II. Permission to use Figure 1 
Figure 1. Phenotypic characteristics of SOD1G93A mouse model versus the non-transgenic 
wild type, Chapter 3. Animal Models, subsection 3.2.1, page. 115; was adopted from Turner 
and Talbot (2008).  
 
The following information and guidelines are available on the Elsevier publisher’s website 
regarding seeking permission for use of figures (http://www.elsevier.com/journal-
authors/permission-seeking-guidelines-for-elsevier-authors): 
Permission Seeking Guidelines 
“When the material is not subject to copyright protection: 
• Copyright protects only original (i.e. creative) material.  
• Copyright protects only the particular form of expression of a work, and not the 
ideas or facts contained in it. So, for example, a fact in an individual article would 
not be protected, although if it were arranged in a table in a particularly unusual way, 
the table would be protected.”  
As stated above, given the nature of the material used here (pictures demonstrating the 
phenotype of SOD1G93A mouse model versus a wild type mouse), permission is not 
required for this particular type of Figure. The publisher clearly states that facts (i.e. the 
phenotype developed by these commercially available mouse model due to ALS disease) 
are NOT copyright protected and therefore do not require permissions.   
